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ABSTRACT
The medicinal plants, Vitellaria paradoxa, Neorautanenia mitis, Hydnora abyssinica and Senna
surattensis, are used by Nigerian traditional medical practioners (TMP) to treat the symptoms of
diarrhea in animals and humans. This study aims to validate claims of the traditional use of these
plants in the treatment of diarrhea and provide a scientific basis for further studies. The crude
aqueous extracts of these plants were evaluated for their antidiarrheal activity in a castor oil (CO)
induced diarrhea model and in the gastrointestinal transit of charcoal model in albino rats, their
acute toxicities were also determined in albino rats. There was no mortality recorded in the rats
at the dose 2000 mg/kg, therefore the LD50 in rats was considered higher than 2000 mg/kg for all
the extracts. In the CO induced diarrhea model, the highest percentage inhibition of defecation
was observed in the test groups treated with the extracts of H. abyssinica (82%) followed by S.
surattensis (81%), N. mitis (66%), and V. paradoxa (32%). The H. abyssinica extract also
decreased the intestinal transit of charcoal meal significantly compared to the other extracts. The
antidiarrheal activities of the crude extracts give credence to their traditional use. Further studies
on N. mitis led to the isolation of one new and 19 known natural product compounds, eight of
these were isolated for the first time from N. mitis. These compounds were screened for CFTR
(Cystic Fibrosis Transmembrane Conductance Regulator) inhibitory activity and four of these
compounds inhibited cAMP-induced Cl− secretion across T84 cell monolayers; dolineone (10),
neodulin (2), pachyrrhizine (6) and neotenone (7) with IC50 values of 0.81, 2.42, 2.87 and 4.66
µM, respectively. Compound 7 also showed reduction in defecation by 65% in CO induced
diarrhea, while compound 2 showed pronounced relaxation of jejunum contraction in a
concentration dependent manner, giving a complete relaxation at 194.7 µM in the isolated rabbit
jejunum model. The accessment of the antidiarrheal potential of N. mitis and its phytochemical

xxiv

constituents on three independent models shows its anti-secretory activity and therefore
consistent with its antidiarrheal activity as acclaimed by TMPs. Other biological assays carried
out on the constituents of N. mitis showed that rautandiol B (20) had significant inhibitory
activities against two strains of Plasmodium falciparum showing a high safety ratio (SR) and
significant IC50 values of 0.75±0.12 µM (SR - 108) and 0.61±0.2 µM (SR - 133) on the TM4/8.2
and

K1CB1

strains,

respectively.

While

(-)-2-isopentenyl-3-hydroxy-8-9-methylene

dioxypterocarpan (11) showed the highest inhibitory activity against T. brucei rhodesiense with
an IC50 value 4.87 ± 0.49 µM (SR > 5.83). All the crude extracts from N. mitis showed inhibitory
activities against α-amylase (AA) and α-glucosidase (AG), with the most active phytochemical
components;

rautandiol

A

(19), and

dolineon

(10), having

modest activities

against

AG with IC50 values of 0.28 mM and 0.66 mM, respectively. Studies on H. abyssinica led to the
isolation of catechin (26) which showed reduction of defecation in CO induced diarrhea by 59%,
catechin may contribute to the same activity shown by the crude aqueous extract (KAQ) of H.
abyssinica and thereby giving credence to its traditional use as an antidiarrheal remedy. Catechin
also showed modest activity against AG with IC50 values of 0.36 mM. The phytochemical
studies on S. surattensis revealed the presence of 1,4,5,7-tetrahydroxy-9H-xanthan-9-one (34)
and catechin (26). Compound 34 showed inhibitory activity against CFTR with an IC50 value of
~3.05 μM, while 26 reduced defecation by inhibiting of CO induced diarrhea. These inhibitory
activities on two independent models give credence to the traditional use of S. surattensis leaves
in the treatment of diarrhea. The crude extracts from S. surattensis gave significant inhibitory
activity against AA and AG, and catechin, isolated from these extracts, is thought to contribute to
this activity.
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CHAPTER 1
Introduction and literature review
1.1 Introduction
Medicinal plants have played a major role as a source of medicines to humans and animals from
ancient times and they are still very useful today.1 Centuries ago, healing practices depended
largely on medicines from plants until the discovery of synthetic/orthodox drugs which happened
in Western countries about a century ago. Because these drugs were quantifiable, stable, specific
and relatively easy to use, this resulted in a decline in the use of medicines from plants,
especially in the Western countries. However, the use of medicines from plants continued in
underdeveloped and developing countries despite the challenge of safety, efficacy,
standardization, unreliable evidence and continuous changes in production practices.2
Today, the use of medicines from plants is thriving in many industrialised and non-industrialised
countries. It is clear that a large population of people across the world utilize the Unani medicine,
Ayurvedic medicine, Kampo medicine, and traditional Chinese medicine (TCM) from Middle
East and South Asia, India, Japan and China, respectively.3-5 In Africa, a large population of the
people in rural communities depend on the use of traditional practices including the use of
medicinal plants for their primary health care needs and that of their animals. Medicinal plants
are used exclusively, or in combination with modern medicines, and in some communities they
remain the most affordable option and, sometimes, the only known and effective option.6-9
The renewed interest in plant–based medicines could be attributed to the high cost of
synthetic/orthodox medicines especially in low income countries and also the significant side
effects associated with their usage. Furthermore, the rate of new drug discovery is currently not
matching the rate of emergence of drug resistance poised by constantly evolving infectious
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microorganisms, and this in a way portrays synthetic/orthodox medicine as ineffective,
consequently plant derived medicines are thought to be safer, cheaper and more efficacious.
Similarly the suggestion that chronic and complex disease conditions may respond to complex
plant medicines that contain many small molecular weight compounds with various biological
modes of action is worthy of consideration.9-14
In the past few decades, there has been increased demand for herbal drugs in the Western
countries, this can be seen in reports showing an increase in the use of herbal medication by the
members of the Consumers Association in the United Kingdom, from one in seven in 1985 to
one in four in 1991.15 In the United States, 1997 figures showed that 67.6% of the population had
used alternative and complementary medicine at least once in their lifetime.16 While in South
Australia, data collected from 3,027 people revealed that, about one in two (52.1 %) had used at
least a form of herbal product in the year 2000 and these respondents admitted they visited at
least one herbal practitioner during that year.17
Apart from the health benefits derived from the use of plant-base medicines, the economic
impact is also impressive. In South Africa, traditional complementary and alternative medicines
contributed about R 2.9 billion (US $2.2 million) to the economy, while in Australia the national
cost of herbal medicines and practitioner consultations has been placed at approximately AUD
2.3 billion annually with at least 2.8 million Traditional Chinese Medicine consultations every
year, generating an annual turnover of AUD 84 million in the health economy.7,17-18
Owing to these benefits, it is necessary to continue screening programs that search for lead
compounds from medicinal plant materials that are beneficial to humans and animals. The World
Health Organisation (WHO) estimates that of the 250,000 plant species, only about 2% have
been thoroughly screened for their chemical components (phytochemicals) with potential
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medicinal use. Since native plant habitats are destroyed almost daily, many medicinally valuable
plants will be gone before they are investigated.19 In most developing countries, the indigenous
knowledge system and practices within a given community are passed down orally from
generation to generation. As such knowledge systems are not documented and they stand the risk
of being lost within a generation due to either urban-rural migration, preference for orthodox
drugs or complete loss of interest in traditional practices by younger people in the community. 20
It is important therefore to collaborate with the custodians of herbal practice, also known as the
Traditional Medicine (TM) Practitioners, for proper documentation and scientific screening of
the medicinal plants they claim to be active against diseases.
For this study, the medicinal plants; Neorautanenia mitis, Hydnora abyssinica, Senna surattensis
and Vitellaria paradoxa were selected following a recommendation by a Nigerian TM
practitioner who claims they are very effective in the management of diarrhea symptoms in both
humans and animals.21 V. paradoxa was also reported as effective for the management of
diarrhea symptoms in animals and humans among livestock farmers.22
1.1.0 Aims
The aims of this study were to screen the extracts and constituents of the selected plants for their
anti-diarrheal activities in a castor oil (CO) induced diarrhea model, and a gasterointestinal
motility test. The extracts and pure phytochemicals were to be tested as inhibitors of Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR), a Cl- channel, and the calciumactivated Cl- channel (TMEM16A). These are validated targets in the discovery of antisecretory
compounds. Further tests include the cholera toxin (CT) challenge in a mouse model and the
isolated organ/tissue test on rabbit jejunum. Other biological assays include; anti-bacterial/antifungal screening, and α-amylase (AA), α-glucosidase (AG), Trypanosoma brucei rhodesiense,
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Mycobacterium tuberculosis and Plasmodium falciparum inhibitory activities and to investigate
the compound/compounds responsible for these activities along with their toxic effects
(cytotoxicity).
1.1.1 Objectives
1. To authenticate the selected plants, make extracts from the plant materials and
qualitatively determine the phytochemicals present in the aqueous solvent extracts.
2. To evaluate the antidiarrheal activity of the crude aqueous extracts and to determine their
LD50 values in albino rats.
3. To separate the natural product components/compounds present in the aqueous and
organic plant extracts by column chromatography and PTLC.
4. To elucidate the individual structures of these phytochemicals by NMR spectroscopy, MS
spectrometry, and X-ray crystallography.
5. To evaluate the biological activities of the crude extracts and pure compounds in in-vivo
and in-vitro anti-diarrheal models and in-vitro models for inhibitory activities against
AA, AG, T. brucei rhodesiense, M. tuberculosis and P. falciparum.
6. Results from this work will be shared with the Nigerian herbalists involved, and other
incentives such as co-authorship. This is to help validate the traditional health system
methods and pave way for future active collaborations in the utilization of the traditional
knowledge system and in the discovery of lead compounds with promising potential in
the management of diarrhea and other diseases.
1.2 Literature review
1.2.0 Neorautanenia mitis (A. Rich) Verdc.
N. mitis is a leguminous plant which belongs to the family Fabaceae, it is one among ten other
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species in the genus Neorautanenia. Synonyms include; Dolichos mitis, Dolichos orbicularis
(Baker) Baker f. Dolichos pseudopachyrhizus Harms, Pachyrhizus orbicularis Welw. Ex Baker,
Pueraria hoschstetteri Chiov, Neorautanenia orbicularis, and Neorautanenia pseudopachyrhiza
(Harms) Milne- Redh.23-25
The leaves and roots are known for their medicinal and poisonous uses in many African
countries. It is a perennial, flowering and climbing plant extending up to 1 meter while growing
in rocky soil with deeply lobed leaves (Fig. 1.1). The roots may be small or large up to 10 kg and
usually found at a depth of 1-2 meters in the ground (Fig. 1.2).

Figure 1.1 N. mitis climbing stems and lobed leaves (Picture Source- Yilnya Gosomji)

Mostly spread across South, East, Central and West Africa, in Nigeria, it is found in the Central
region and is commonly known as Doyan kupasa, Karamin karara, Abargora (Nigeria), Lidupa,
(Tanzania) and Igitembatenibe or Amakubwe (Rwanda).26-30 The medicinal uses and previous
phytochemical studies on this plant are discussed in Chapter 3 of this thesis.

Figure 1.2 Small and large roots of N. mitis (Picture Source- Yilnya Gosomji)
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1.2.1 Hydnora abyssinica A. Braun
H. abyssinica is a subterranean holoparasitic plant from the family Hydnoraceae, the genus
Hydnora consist of eight species including; H. dregeana, H. africana, H. triceps, H. visseri, H.
sinandevu, H. esculenta, H. angolensis and H. abyssinica. This plant has been described as the
strangest in the world due to its rare appearance and peculiarity.31
H. abyssinica is also known as H. africana Sensu Eyles, H. johannis Becc. and H. solmsiana
Dinter and is commonly called Kurshim and Kaushen kasa in the Ngas and Hausa languages
(Nigeria), respectively. It is endemic to many African countries including; Somalia, South
Africa, Sudan, Angola, Namibia, Ethiopia and Kenya. Recently its occurrence was reported in
Nigeria growing in the woodland of acacia with Acacia hockii as the main plant host. Not many
botanists have encountered this species and therefore it is rare to find a deposited specimen in a
herbarium. However it is very common among TM practitioners and medicinal plant vendors in
local markets where it is traded frequently for its medicinal use. Unlike other plants, it lacks
chlorophyll and consists of only roots and flowers.32-33
The flowers are solitary, with a dome shape appearing above the ground like a tube with the
fleshy calyx lobes that separates after a little while to reveal the hollow structure of the fruit tube,
(Fig. 1.3 and 1.4). The flowers are attached to a massive pilot root system, while the fruits are
subterranean and brown34-35 (Fig. 1.5 and 1.6).

Figure 1.3 Flowers and roots of H. abyssinica
Figure 1.4 Opened flower of H. abyssinica
(Picture Source- Yilnya Gosomji)
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Figure 1.5 Fruits of H. abyssinica attached to roots
Figure 1.6 Roots of H. abyssinica
(Picture Source- Yilnya Gosomji)

The medicinal uses and previous phytochemical studies on this plant are discussed in Chapter 4
of this thesis.
1.2.2 Senna surratensis (Burm. f.) H. Irwin and Barneby
Senna surratensis is a member of the Fabaceae family, commonly known as golden bush, golden
senna or scrambled eggs bush (English). S. surratensis is a small tree or shrub (Fig. 1.7) its
leaves

are

about

18

cm

long

with

6-10

pairs

of

leaflets

(Fig.

1.8).

Figure 1.7 Shrub of S. surratensis
Figure 1.8 Leaves of S. surratensis
(Picture Source- Yilnya Gosomji )

Because it is widely spread across tropical and sub-tropical regions of the world, it has the
following local names; Dorowan Bature (Hausa, Nigeria) Kembang Kuning (Indonesia),
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Gelenggang (Malaysia), Kalamona and Kolomona (Hawaii, USA), Kembang, Koning,
Kemoning and Kuning (Indonesia/Nusa Tenggara), Dok Sake and Sak Heng (Laos), Khilek-Ban,
Songbadan (Thailand) and Huang Huai Jue Ming (Chinese). It also has the following synonyms;
Cassia glauca Lam., Cassia surattensis Burm.f., Psilorhegma suffruticosa (Roth) Britton &
Rose, Cassia suffruticosa Roth, Senna speciosa Roxb., and Cassia fastigiata Vahl.25,36
It has been referred to as an agricultural and environmental weed with a history of being
introduced to new areas outside its native environment. For example, in Nigeria it was
introduced and it has made its way into the wild and has spread across the bush lands and is
sighted on roadsides and in pastures and wastelands. It is used as food, pasture shade, and for
medicinal purposes.30,36 The medicinal uses and previous phytochemical studies on this plant are
discussed in Chapter 5 of this thesis.
1.2.3 Vitellaria paradoxa C.F. Gaertn
This popular plant is commonly called the shea butter tree, it is from the family Sapotaceae
known as the only species in the genus Vitellaria and its common synonym is Butyrospermum
paradoxum (Geartn. f.) Hepper. It is a small to medium sized fruit bearing tree (Fig. 1.9) which
is indigenous to Africa. The leaves are arranged spirally in dense clusters at the tips of the
branches (Fig. 1.10).

Figure 1.9 V. paradoxa tree
Figure 1.10 V. paradoxa leaves
(Picture Source- Yilnya Gosomji )
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The bark is quite rough with scales that are corky square or rectangular in shape, it can either be
black, grey or reddish in colour, and it produces a white latex when cut (Fig. 1.11 and 1.12). This
plant grows naturally in the wild and is commonly sighted in many Africa countries including
Mali, Nigeria, Burkinafaso, Cameroun, Togo, Ghana, Guinea, Uganda, Sudan, Senegal, and Cote
d Ívoire. Because it is wide spread in Nigeria, different tribes in the country identify it with a
local name as follows: Kareje (Fulfulde), Kadanya (Hausa), Okwuma (Igbo), Ikini (Taroh) and
Mmameng (Cham).37

Figure 1.11 V. paradoxa bark
Figure 1.12 V. paradoxa cut bark with white latex
(Picture Source- Yilnya Gosomji )

The fruits from V. paradoxa serve as food to humans, livestock and wild animals for their
nutritional values, and they are also used in traditional medicine because of their medicinal
properties. The oil from the seeds, also referred to as shea butter, is used as a moisturizer for hair
and skin, and also for smoothening dry skin. Other skin conditions, including chapped lips, acne,
wrinkles, burns, arthritis, scars, rheumatism and stretch marks, have been treated with shea
butter.38-39
1.2.4 The use of medicinal plants in the treatment of diarrhea
The continuous search for new approaches in the management of diarrhea and the development
of new specific drugs for the treatment of diarrhea is very important, and medicinal plants are
reported as effective means of treating and managing the symptoms of diarrhea among rural
9

dwellers, TM practitioners and livestock farmers.22,30 Therefore the WHO suggested that herbal
formulations could be effective in the treatment of diarrhea and other related disease
conditions.39
For many centuries, the sap (dragon’s blood) form the bark of Croton lechleri (Fig. 1.13) has
been used by indigenous people of Ecuador and Peru to cure diarrhea. The sap contains
crofelmer, the active compound in FulyzaqTM which is currently used in the management of HIV
related diarrhea, and it is also under clinical trials for secretory diarrhea of various etiologies.40

Figure 1.13 Bark of Croton lechleri with sap or dragon’s blood
(Picture souruce- por natikka http://www.arteyfotografia.com.ar/4429/fotos/54367/)

In Mexico, some plants including; Chiranthodendron pentadactylo, Decachaeta incompta,
Helianthemum glomeratum, Salvia polystachya and Rubus coriifolius have been studied
extensively and compounds from these plants have shown significant amoebicidal and
giardicidal activities. These activities show evidence-based support for the use of these plants
traditionally in the management of diarrhea caused by giardiasis and ameobiasis.41
The people living in the rural communities in Plateau state Nigeria use a number of medicinal
plants that are effective in the treatment of diarrhea symptoms for themselves and their
livestock. Similarly a number of plants in Bangladesh were also attested to be useful in the
treatment of diarrhea.22,42 Extracts from Khaya senegalensis, Croton macrostachyus,
Momordica charantia, Myrtus communis, Desmodium puchellum, and Anogeissus leiocarpus
10

were found to reduce castor oil induced diarrhea, GIT motility or enteropooling in
experimental mice/rat models.43-48 Also, extracts from the stem bark of Vitellaria paradoxa
inhibited the growth of some enteric bacteria implicated in diarrhea.49 The
pharmacological activity of natural antidiarrheal activity of 91 medicinal plant extracts
were shown to either inhibit induced diarrhea, reduce intestinal motility, inhibit
gasterointestinal tract (GIT) secretion or inhibit diarrhea causative agents such as E. coli
and Shigella spp.50 A number of traditional Chinese herbal medicines including, Rhodiola
kirilowii are useful in the treatment of secretory diarrhea and the compounds responsible
for this activity were identified as flavonoids.51 The complexity of diarrhea is due mainly to
its multi causative factors, and over the years plants have been used to treat diarrhea with
its complexities, therefore, plants have significant potential in reducing the morbidity and
mortality that is caused by diarrhea.
The phytochemicals largely responsible for the antidiarrheal activity displayed by plants extracts
include alkaloids, flavonoids, tannins and other phytochemicals.50
1.2.5 Alkaloids
Alkaloids are naturally occurring organic nitrogen containing bases with low molecular weight,
found in animals, plants, fungi and bacteria. They are often biosynthesised from amino acids and
are also known to be biologically active. Basically, they possess a proton-accepting nitrogen
atom and sometimes one or more proton donating-amine hydrogen atoms which form hydrogen
bonds with proteins, enzymes and receptors. They also have functional groups including
phenolic hydroxy groups making them exceptionally bioactive. Alkaloids are classified basically
into 3 groups namely; true alkaloids, proalkaloids and pseudoalkaloids.52-53 For more than a
century, alkaloids have been useful as therapeutic agents for several disease conditions in
11

humans and animals. They have shown some interesting biological properties such as;
anticholinergic, diuretic, emetic, antiviral, antitumor, sympathomimetic, analgesic, muscle
relaxant, antihypertensive, anti-depressant, antiulcer, antimicrobial and anti-inflammatory
activities.54 A number of alkaloids have also shown antidiarrheal activity through diverse
mechanisms of action due to their anti-inflammatory and muscle relaxant properties and their
ability to reduce fluid secretion into the GIT (Fig. 1.14). Alkaloids with anti-inflammatory
activity have been isolated from medicinal plants or herbal prepartions used in Eastern traditional
medicine, these studies have lead to the identification of several alkaloids including
the isoquinoline berberine (I) which is known for its intestinal pharmacological activity, and its
major source is the Berberis sp.55 Berberine showed effectiveness in the management of colitis
by decreasing colonic inflammation in Crohn’s disease and in ulcerative colitis experimental
models by inhibiting the release of cytokines. These activities are promising for the development
of therapies for inflammatory diseases such as inflammatory bowel disease (IBD) and irritable
bowel syndrome.56 Nicotine (II) a prominent alkaloid from Nicotiana tabacum (tobacco) is also
known for its smooth muscle relaxant properties and its potential role in the management of IBD,
due to its anti-inflammatory activity on the intestine in both experimental and clinical trials.57-63
The anti-inflammatory and muscle relaxant properties of alkaloids are thought to be helpful in
the management of diarrhea, these effects contribute largely in aiding the retention and
reabsorption of fluids and electrolytes from the GIT, thereby reducing the consequent
dehydration.53,64 The phytochemical investigation of the seeds Murraya koenigii led to the
isolation of three carbazole alkaloids, namely, kurryam (III), koenimbine (IV) and keonine (V),
these alkaloids were evaluated against antidiarrheal models in winster rats, including; castor oil
(CO) induced diarrhea, gasterointestinal motility test and PGE2 (Prostaglandin E2) enterpooling.
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The alkaloids kurryam (III) and koenimbine (IV) showed significant dose dependent
antidiarrheal activities in each of these models, when compared to the standard drugs.

Figure 1.14 Alkaloids with antidiarrheal activity

The effects of these alkaloids on CO induced diarrhea, GIT motility and PGE 2 enterpooling
could be exerted through their anti-inflammatory and smooth muscle relaxant properties. This
study justified the use of Murraya koenigii traditionally in the management of diarrhea.65 The
black pepper Piper nigrum is known for its usefulness in the traditional formulation against
diarrhea. Piperine (VI) was isolated from black pepper as the compound responsible for this
activity. It showed inhibitory activity against CO induced diarrhea and enteropooling; these
effects are thought to be mediated through its ability to inhibit the release of prostaglandins.
Piperine has also shown anti-infalmmatory activity, and this property is helpful in antidiarrheal
therapy.66-67
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1.2.6 Flavonoids
Flavonoids are a group of phytochemicals with low molecular weights that are secondary
metabolites with often polyphenolic structures. They often have a 15-carbon skeleton comprising
two benzene rings and a three carbon linker. They are widely spread in the plant kingdom and
found in several plants parts such as fruits, vegetables, fruits, roots, flowers, bark and leaves. The
synthesis of flavonoids in plants aids in growth and defence mechanisms.68-69 Flavonoids are
classified into several groups including; flavones, flavanones, isoflavanones, anthocyanins and
chalcones.70 Flavonoids are known for their wide range of health benefiting effects, they are
utilized in the medicinal, pharmaceutical, nutraceutical and cosmetic industries as essential
bioactive components, and they have shown anti-inflammatory, antimicrobial, antifungal,
antidiaheal, antioxidative, anticarcinogenic, antidiabetic and antimutagenic effects and
antidiarrheal activities.69,71-74 The anti-inflammatory, antimicrobial and antifungal effects are key
components in the treatment of gastrointestinal diseases like diarrhea and some flavonoids have
shown antidiarrheal activity through these effects (Fig. 1.15). Isoliquiritigenin (VII), a chalcone,
showed significant inhibitory activity against CO induced diarrhea in rats. This activity is
thought to be achieved through its dual effects on the GIT motility as well as fluid and
electrolyte transport across the intestinal musosa, leading to decrease GIT motility and increased
reabsorption of fluids and electrolytes from the GIT.75 Hesperidin (VIII), apigenin (IX), luteolin
(X) and quercertin (XI) have shown anti-inflammatory and analgestic effects. Flavonoids are
generally known for their ability to modulate key enzyme functions,76 and enzyme systems
critical to the generation of anti-inflammatory process especially tyrosine and serine-threonine
protein kinases may be affected by flavonoids. Some flavonoids are also potent inhibitors of
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prostaglandin release and this is thought to be important in the management of diarrhea arising
from inflammation of the intestinal mucosa.77-78 Other flavonoids such as, crisimaritin (XII),

Figure 1.15 Flavonoids with antidiarrheal activity

epicatechin (XIII), and geranin A (XIV) were isolated from plants used in the treatment of
diarrhea from Mexican flora. Those showed activity against two important enteric protozoa,
namely; Entamoeba hystolytica and Giardia lamblia.41 Epicatechin (XIII) also showed
inhibitory activity against the CFTR Cl- channel, this dual activity can be of great importance in
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the development of broad spectrum antidiarrheal therapies.51 A number of flavonoids have also
shown antibacterial activity against a range of diarrhea causing bacteria (Fig. 1.15).
Catechins have been extensively researched for their antibacterial activities and have shown
activity against Vibrio cholera and Shigella spp. Their activity is through inactivation of cholera
toxin in V. cholera.79 Quercetin and apigenin have inhibited DNA gyrase in Escherichia coli
leading to the inhibition of its DNA synthesis.80 Naringenin (XV) has also showed significant
inhibitory activity against methicilline resistant Staphylococcus aureus and Streptococci spp.
This action is mediated through the alteration of the bacterial cell membranes, causing the
reduction of fluidity of the outer and inner layers of the membranes.81
1.2.7 Tannins
Tannins are complex structured polyphenolic phytochemicals with high molecular weights and
bioactive properties. They are very polar in nature and therefore very difficult to crystallize
thereby making their isolation and structure elucidation very difficult.82
Tannins are majorly classified as condense or hydrolysable, the condense tannins are one of the
largest groups found all over the plant kingdom. They are also referred to as proanthocyanidins
and are further classified as type-A and type-B, they are oligomers of flavan-3-ol. Studies have
revealed that tannins have anti-convulsant, anti-tumor, anti-inflammatory antioxidative,
antibacterial, anti-aging, anti-hyperglycaemia and anti-cholesterase bioactivities and this implied
their possible use in the modification of disease processes like; cancer, diabetes, stroke,
Parkinson, Alzheimers, and cardiovascular disease. They are also useful in the management of
GIT disorders such as IBD, diarrhea, hemorroids, and dysentery.83-84 The antidiarrheal activity
displayed by tannins has been attributed to their ability to decrease intestinal transit, reduce
secretion into the GIT and also balance the fluid transport across the mucosal membranes.
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Crofelmer (XVI) is an example of oligometric proanthocyanidins found to be effective in the
management of diarrhea through its Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR) inhibitory activity, where it regulates fluids and electrolyte secretion.40,85 The rhubarb
tannin extract (RTE) contains a number of tannins found in nature including; gallic acid (XVII),
procyanidin-B1 (XVIII), procyanidin-B2 (XIX), epigallocatechin gallate (XX) (Fig.1.16), and
epicatechin (XIII) (Fig.1.15).

Figure 1.16 Tannins with antidiarrheal activity

These tannins are known for their antidiarrheal activities. The evaluation of RTE on aquaporins
(AQPs) 2 and 3 expression in in-vivo (mice) and in-vitro (HT-29 cells) models, led to the
inhibition of AQP 2 and 3 expression induced by magnesium sulphate (MgSO4) in both models.
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AQPs 2 and 3 are localized in the colon and they play a vital role in regulating transepithelial
fluid balance. The ability of RTE to suppress the expression of AQPs 2 and 3 led to the decrease
faecal output in diarrheic mice, further histological findings on the colon showed decrease in
inflammation caused by MgSO4 in mice treated with RTE. Therefore, the anti-inflammatory
properties of RTE also contributed in its antidiarrheal activity.86 Epigallocatechin gallate (XX)
has also been identified as a CFTR Cl- channel inhibitor.51
1.2.8 Other phytochemicals with antidiarrheal activity
Some phytochemicals as listed on Fig 1.17 have shown antidiarrheal activity, with diverse modes
of action. Dehydroleucodine (XXI) was isolated from Artemisia douglasiana Besser. It is a
sesquiterpene lactone, and its antidiarrheal activity is shown through the inhibition of GIT
motility and inhibition of enteropooling. While, neoandrographolide (XXII) and andrographolide
(XXIII) were isolated from Andrographis paniculata, they are known diterpenoids with many
biological activities including; antisecretory, anti-inflammatory and potential anti-neoplastic
properties. Their ability to reduce inflammation and secretion in the GIT is the means by which
they inhibit diarrhea.50
The compound α-terpineol (XXIV) is a monoterpene volatile alcohol, found in essential oils
from many plants including, Psidium guajava L. (Guava) which is used in the treatment of
diarrhea, Rosemarinus officinalis L. (Rosemary) and Punica granatum L. (Pomegranate). It has
shown its antidiarrheal activity through inhibiton of; CO induced diarrhea, inflammatory diarrhea
induced by prostaglandins and secretory diarhea induced by cholera toxin in experimental
models. These activities have resulted in the reduction of GIT motility through anticholinergic
action, thereby reducing intestinal fluid secretion and accumulation in the GIT, and also the
reabsorption of fluid from the GIT. It is also thought to block channels and transporters through
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intercellurlar action.87-90 The fungal metabolites, arthropsolide A (XXV), and zearalenone
(XXVI) have been shown to be CFTR inhibitors and thus have potential as therapeutic target to
treat secretory diarrhea.91-92

Figure 1.17 Other phytochemicals with antidiarrheal activity

Sulphated polysaccharide extracted from seaweed Gracilaria cervicornis, has shown significant
inhibitory activity against acute and secretory diarrhea in CO induced diarrhea and cholera toxin
induced diarrhea models, respectively.93 The red angico gum (XXVII), a biopolymer extracted
from the trunk exudates of Anadenanthera colubrina var. cebil (Griseb.) also showed significant
inhibition of diarrhea by reducing enteropooling, enhanced Na+/K+-ATPase activity and reduced
intestinal motility. Through Enzyme-Linked Immunosorbent Assay (ELISA), it has
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demonstrated its ability to interact with monosialotetrahexosylganglioside (GM1) receptors and
can also reduce E. coli induced diarrhea in an in-vivo model.94
1.2.9 Diarrhea
Diarrhea is a global problem and also a common symptom in many other diseases. It is defined
as an increased volume, fluidity or frequency of faecal discharge compared with the normal stool
and is characterised by abdominal pain. When diarrhea persists, it can result in dehydration due
to the loss of electrolytes, and this can be fatal without intervention. Diarrhea can be caused by a
range of microorganisms from viral, bacterial, parasitic, fungal to protozoan infections. Other
causes could result from drug side effects and other physiological disorders. 95-96 In developing
countries, the periodic outbreaks of severe secretory diarrhea caused by Vibrio cholerae and
rotavirus, results in high morbidity and mortality especially in children under the age of 5 years.
There has been an improvement in diarrhea case management with the mortality rate going down
by 20.8% between 2005 - 2015.69 It is currently rated as the eighth cause of death across all ages
and the fifth among children under the age of 5 years, causing more than 1.6 million deaths
globally. In Nigeria alone, 331.3 per 100,000 children died in 2016 due to diarrhea.97 Although
Africa and East Asia account for the highest incidence in severe disease burden, in developed
countries however, diarrhea remains one among the common reasons for hospital consultations,
which leads to discomfort and loss of productivity.89-99
1.2.9.0 Types of diarrhea
Diarrhea can be broadly categorized as acute or chronic based on its duration. Acute diarrhea
lasts for a shorter time of not more than 14 days, while chronic diarrhea last longer than 14 days
and up to four weeks or more.
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1.2.9.1 Acute diarrhea
This can be defined as an abrupt onset of the discharge of watery or bloody stool characterized
by an increase in frequency or volume of stool which leads to loss in nutrients and electrolytes. It
is usually of infectious etiology and mostly self-limiting through a course of 14 days or less. The
symptoms can be mild, moderate or severe with excessive loss of fluid which can be fatal
especially in children under the age of five years. Infectious agents responsible for this condition
include Shigella species, Escherichia coli, Vibrio cholerae, nonavirus, rotavirus, Candida
albicans, Aspergillus fumigatus and Giardia lamblia.99-100
1.2.9.2 Chronic diarrhea
This is characterized by loose stool discharge that occurs at least three times a day and lasts for
up to four weeks or more. This usually has an impact in the quality of life as it comes with
discomfort, it is also disabling and is life threatening. The main causes of this condition may
depend largely on the socioeconomic status of the population, for example in high income
countries, causes are mostly non-infectious including inflammatory bowel syndrome and
malabsorption syndrome and are sometimes due to chronic infections. In low income countries
causes may include chronic mycobacterial, parasitic and fungal infections.99, 101
1.2.9.3.0 Diarrhea case management
The imbalance in fluids and electrolytes as seen in the mechanism of acute diarrhea is
accompanied by increased luminal osmolality, increased intestinal secretion, decreased fluid
absorbtion and altered intestinal motility.102 Basic and effective management of diarrhea should
address the symptoms and the underlying causes. Because diarrheal conditions, especially
secretory or acute diarrhea, can deteriorate within a very short time due to fluid and electrolyte
losses, treatment must be geared towards achieving homeostasis. Therefore treatments have

21

focused on fluid replacement therapy and the use of mucosal protectant and adsorbents, antiinflammatory, antibiotics, antibacterial and moltility modifying drugs.103
1.2.9.3.1 Fluid replacement therapy
Dehydration and hypovolemic shock are the immediate danger caused by diarrrhea due to loss of
fluids and electrolytes. The use of oral and parenteral fluid replacement therapy is crucial
especially in children and elderly patients, and this usually comes as a first line of action. Oral
rehydration salt (ORS) is used to alleviate mild to moderate dehydration, it is easy to use and
widely available and therefore plays a vital role in reducing mortality rate especially in rural
areas. For severe dehydration, appropriate parenteral fluid replacement is safe and it promptly
reverses fluid and electrolyte balance.44,104
1.2.9.3.2 Mucosal protectants and adsorbents
Bismuth subsalicylate is considered in the symptomatic treatment of infectious diarrhea due to its
ability to improve the consistency of the stool and also by effectively binding to harmful viruses,
bacteria and their enterotoxins, however, it is not recommended in patients with chicken pox or
influenza because of the danger of Reye’s syndrome.103 On the other hand, the popular kaolinpectin formulation, containing aluminium silicate and carbohydrate from citrus fruits is thought
to act as an adsorbent and a demulcent, thereby binding viruses and enterotoxins, and also
changing the consistency of the stool. However no clinical studies support this claim, because it
is not shown to shorten diarrhea duration nor reduce fluid/electrolyte loss and dehydration.
Therefore it is used in the same way as activated charcoal and fibre and is not recommended in
children.105
1.2.9.3.3 Anti-inflammatory drugs
The incorporation of anti-inflammatory drugs in the management of diarrhea is very important as
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the loss of fluids and electrolytes occurs due to malabsorption by the inflamed musosal lining of
the GIT, especially in patients with inflammatory bowel disease (IBD). Mesalazine or 5aminosalicylic acid (5-ASA) is used in the treatment of IBD while non-specific loperamide is
used in the treatment of microscopic colitis.106
1.2.9.3.4 Antibiotics
There has been misuse of antibiotics in the management of diarrhea especially in children. A
report shows that despite the fact that rotavirus is the leading cause of diarrhea in children, 85%
of children receive inappropriate treatment with antibiotics.107 However the use of antibiotics in
patients with prolonged diarrhea who are at risk of secondary complications is indicated and
these have been found useful in the treatment of infectious diarrhea caused by Shigella species,
Escherichia coli, Vibrio cholerae, and Clostridium difficile.105
1.2.9.3.5 Antiparasitic drugs
The most important parasites responsible for diarrheal disease are Cryptosporidium and Giardia
causing morbidity and mortality worldwide. Once infected with these parasites, they colonize in
the epithelial lumen of the small intestine causing enteritis which results in diarrhea.
Cryptosporidium is common in children and immunocompromised patients such as those having
HIV disease. In Nigeria 14.8% of diarrheal disease in children is caused by Cryptosporidium.96
So far only nitazoxanide is moderately effective against this parasite. Giardia on the other hand
causes more chronic diarrhea in children and immunocompromised patients and can be treated
with variety of drugs including, metronidazole, paromomycin, and nitazoxanide. A major
concern is that these parasites develop resistance to these current drugs, therefore the
development of newer drugs is crucial.108
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1.2.9.3.6 Motility modifying drugs
Increased GIT motility and fluid secretion are very important factors in diarrheal disease process
resulting in loss of fluids and electrolytes. The anti-cholinergic drugs, loperamide and
diphenoxylate play a significant role in decreasing intestinal motility and aiding fluid absorption
from the GIT by blocking the binding of acetylcholine to its receptors. This action leads to an
increase in stool consistency and a decrease in the loss of fluids and electrolytes; it also reduces
the duration of diarrhea especially in secretory diarrhea.106
1.2.9.3.7 Anti-secretory drugs
One approach that is relevant to this study is the treatment of secretory diarrhea with drugs that
inhibit the intestinal chloride channel also known as the Cystic fibrosis transmembrane
conductance regulator (CFTR) and the calcium-activated Cl- channel- TMEM16A. CFTR is a
cAMP-activated chloride channel expressed in the epithelia of the intestine and other organs and
tissues, where it facilitates transepithelial fluid transport.109 When cholera toxin (CT) or heatstable enterotoxin is released following infections by bacteria, it increases the intracellular cAMP
or cGMP levels through the activation of the membrane-localized adenylate cyclase (AC) or
guanylate cyclase (GC). The rise in the levels of intracellular cAMP or cGMP leads to the
phosphorylation of the R domain of CFTR by protein kinase A (PKA) or cGMP-dependent
protein kinase II (cGK II), which in turn leads to the activation of the CFTR chloride channel,
which results in the release of Cl-, into the intestinal lumen through the apical side. The resultant
effect to this action is the passive efflux of Na+ and water into the lumen through the paracellular
transport mechanism. The Cl- influx into the erythrocytes is from the basolateral (blood) side by
the Na+-K+-2Cl cotransporter (NKCC). Also, Na+ is pumped out of the cell by Na+-K+-ATPase
and K+ recycles through basolateral K+ channels.40,109-110 (Fig. 1.18)
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The increase in fluid and electrolyte secretion into the intestine results in increase GIT motility
which leads to secretory diarrhea, and these diarrheas are specifically and effectively managed
by CFTR and TMEM16A inhibitors. In 2012, the US FDA approved the use of crofelmer
(FulyzaqTM) to treat HIV related diarrhea. Crofelmer inhibits the CFTR Cl- channel and
TMEM16A, and it is being considered as a potential treatment for infectious diarrhea of multiple
aetiologies.40,92

Figure 1.18 The transepithelial fluid transport model showing apical and basolateral intestinal sides. Adapted from
Li et al. 2010.110

While this thesis focused on the antidiarrheal properties of the selected plants, including their
ability to inhibit CFTR and TMEM16A, the crude plant extracts and their phytochemical
components will also be tested for their other biological activities.
1.2.10 Other biological activities
Medicinal plants are useful for the cure of many ailments/diseases, and often, one medicinal
plant is said to have multiple uses. Sometimes, different parts of a plant could be used to treat
different conditions, and one part of a plant could be used for the treatment of more than one
condition. Some plants have been used for different purposes in different regions or countries,
for example N. mitis has multiple uses in the same country,30,111 and TM practitioners have made
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claims to this fact.21,112 This is possible since the number and types of phytochemicals in the
plant may vary from the various geographical locations or due to different climates or seasonal
conditions.
Therefore, new bioactivities could be discovered through the random search for bioactive natural
products from medicinal plants. In this study, we searched for new and further proof of existing
bioactivities from our selected plants for which have not been reported. We tested the crude
extracts and pure compounds for their inhibitory activities against α-amylase (AA), αglucosidase (AGO), Trypanosomea brucei, Mycobacterium tuberculosis and Plasmodium
species.
Diabetes type II is a condition in which the capacity of the body to produce enough insulin is
gradually lost. It is a degenerative condition in which the body becomes resistant to the normal
effects of insulin, due mainly to excessive glucose absorption from the gastrointestinal tract
(GIT).113 Also referred to as non-insulin dependent diabetes mellitus (NIDDM), diabetes type II
is the common cause of endocrine system disease which leads to the decrease secretion of insulin
by the B-cells of the pancreatic Langerhans resulting in excessive absorption of glucose, which
causes postprandial hyperglycemia. Currently, glucosidase inhibitors such as acarbose and
miglitol are useful in the management of type II diabetes, but they are reported to produce some
undesirable side effects such as diarrhea, intestinal pain and flatulence.114 Consequently, the
search for new glucosidase inhibitors from plants is indicative, as many medicinal plants are
known to have AA and AG inhibitory activities.113
Africa Trypanosomes including Trypanosoma concolense, T. vivax and T. brucei with subspecies T. brucei gambiese and T. brucei rhodensiense cause trypanosomiasis in humans and
animals, it is also referred to as sleeping sickness. This is a tropical parasitic disease transmitted
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by bites from the tsetse fly (Glossina spp) vector, found in some communities and regions of
sub-Saharan Africa. The hosts affected by this disease are peasant farmers, fishing communities,
animal rearers and hunters, therefore it is considered the disease of the poor and also a neglected
human disease, making investment by the pharmaceutical industries essentially nonexistence.115,116 Despite efforts to curb the disease by independent organizations like WHO, up to
70 million people are at risk of infection and the current treatment suffers set back due to drug
resistance and the lack of more options for orally administered drugs.117 Continuous screening of
compounds for the development of new effective drugs especially from natural sources is
worthwhile.
Tuberculosis (TB) is a very important re-emerging disease caused by bacteria Mycobacterium
tuberculosis, it is one of the oldest diseases and still a pandemic affecting mankind around the
world. The WHO estimated about 10 million people were infected with TB and more than 1.5
million deaths globally in the year 2018.118 TB is preventable and curable, but the increased rate
of multi drug resistance may be responsible for the failed treatments and high numbers of
fatalities. The combination of drugs for treatment with proper supervision is able to prevent the
occurrence of drug resistance, but this is challenged by neglect, limited resources and poverty.119
As supervised care is provided to patients in order to combat drug resistance, screening for lead
compounds with promising activity against this bacterium is vital in the development of newer
drugs that may have effective and different mechanism of action.
Malaria is a disease caused by a protozoan known as the Plasmodium parasite, the most virulent
is Plasmodium falciparum which is transmitted through a bite of the female anopheles
mosquitos. Malaria remains endemic in most tropical countries of Asia, Africa and South
America. A recent report from the WHO shows estimated deaths of 405,000 from 228 million
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infected cases in 2018.120 Like diarrhea, most of these deaths are recorded among children under
the age of five years in Africa. Malaria is both preventable and curable, with many therapies
available including anti-malaria drugs and herbicides against the mosquito vector. The parasite
has proved over the years to be resistant to each new class of drug, which is a major setback in
combating this disease.121 Therefore, the development of new drugs that would target different
mechanisms of action, may be helpful.
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CHAPTER 2
Antidiarrheal activity of the aqueous extracts from the selected medicinal plants
2.0 Introduction
Herbal preparations made from the stem bark of Vitellaria paradoxa, the roots of Neorautanenia
mitis, the leaves of Senna surattensis, and the roots of Hydnora abyssinica are normally used in
the treatment of human and animal diarrhea in Nigeria. The extracts are prepared by drying and
grinding the medicinal plant parts into a powder and the plant powder is then either mixed with a
local drink and given to the patient or it can be soaked in cold water (maceration) and the soluble
portion is decanted and administered orally.21 In these studies, we carried out our experiments
using the aqueous extracts from these plants prepared by maceration to validate their potencies as
antidiarrheal medications. A preliminary qualitative phytochemical screening of the extracts was
carried out to reveal the different classes of phytochemicals present in the extract and to know
which could be responsible for the antidiarrheal activity if any. Within the limit of our search, we
have not found any scientific reports indicating the antidiarrheal activity of the aqueous extracts
of these four plants. We are thus reporting for the first time comparisons of the antidiarrheal
activities of these plants using the antidiarrheal model of CO induced diarrhea and motility test
in albino rats. These models allow for easy experimental replication of diarrhea, as diarrhea
affects both humans and animals alike.30
2.1 Results and discussion
2.1.0 Physical appearance and percentage yields of aqueous extracts from all the plants
The percentage yields and physical appearance of the aqueous extracts of the four plants are
summarized in Table 2.1.
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Table 2.1 Physical appearance and percentage yield of the dried aqueous extracted materials
Extract

Appearance

KAQ
ABAQ
SBAQ
CAQ

Brick red solid
Dark brown solid
Light brown solid
Dark green solid

Amount of dried plant
material (g)
571
1000
1000
285

Amount of dried
extract (g)
64.0
65.2
35.0
17.0

Percentage
yield (%)
11.2
6.5
3.5
6.0

All evaporated extracts gave a solid material, the colour of the dried extract material is the
reflection of the colour appearance of the plant parts that were extracted, except for N. mitis
which was off white to light brown in appearance before the extraction, and the resulting dark
brown colour of the dried extract material could be due to concentrating in the drying process or
to autoxidation. A higher yield of 11.2% was obtained from the extract of H. abyssinica (KAQ)
compared to the yields from N. mitis (ABAQ), V. paradoxa (SBAQ) and S. surratensis (CAQ).
The H. abyssinica and N. mitis aqueous extracts were labelled KAQ and ABAQ coined from
their Hausa names, Kaushe and Abargora, respectively, while that of V. paradoxa, was labelled
as SABQ from shea butter which is the common name for V. paradoxa, and S. surratensis was
labelled CAQ from its other name, Cassia of the genus Senna.
2.1.1 Preliminary phytochemical screening
A qualitative phytochemical content analysis of the aqueous extracts of H. abyssinica (KAQ), N.
mitis (ABAQ), V. paradoxa (SBAQ) and S. surratensis (CAQ) was made using literature
described chemical methods to detect the presence or absence of different metabolites classes in
the extracts. (See Chapter 7 for details) The extracts were found to contain tannins, cardiac
glycosides, steroids and alkaloids. In addition, flavonoids were not detected in KAQ while
saponins were detected in KAQ, ABAQ and CAQ. None of the four extracts contained
anthraquinones (Table 2.2). The biological activities of the medicinal plants are attributed to
their phytochemical constituents. The phytochemicals detected in KAQ include; tannins, cardiac
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glycosides, steroids, alkaloids and saponins, which agreed with the findings of Wintola and
Afolayan.122 Saadabi and Ayoub123 also reported the presence of these phytochemical types, with
the exception of cardiac glycosides and saponins.
Table 2.2 Phytochemical composition of KAQ, ABAQ, SBAQ and CAQ aqueous extracts
Extract
KAQ
ABAQ
SBAQ
CAQ

Tan
+
+
+
+

Cg
+
+
+
+

Phytochemical Composition
Ste
Alk
Fla
+
+
+
+
+
+
+
+
+
+
+

Ant
-

Sap
+
+
+

+ = Detected, - = Not Detected; Tan-Tannins; Cg- Cardiac glycosides; Ste- Steroids; Alk- Alkaloid; Fla- Flavonoid; AntAnthraquinones; Sap- Saponins.

The phytochemicals detected in V. paradoxa (SBAQ), were similar to those reported by ElMahmood et al.124 The various organic solvent (methanol, ethanol, ethyl acetate, hexane and
chloroform) extracts of Cassia species (synonym for Senna) revealed the presence of alkaloids,
flavonoids, saponins and tannins in either the leaf, leaf/flower and/or aerial parts of the plant.125
In our study, the same phytochemicals were found in the aqueous extract. The presence of
alkaloids, tannins, and flavonoids in these four plant extracts is indicative of their antidiarrheal
activity since these phytochemicals are known to exert antidiarrheal effects.43,85
2.1.2 Animal experiments
All the experiments performed on the LD50, CO induced diarrhea, gastrointestinal motility test
models were carried out in albino rats, and they were performed by the author at the National
veterinary Research Institute (NVRI) Vom, Nigeria. These experiments required ethical
clearance and it was issued by the NVRI animal ethical committee (AEC) with the approval
numbers; NVRI/EC/20/010.
2.1.2.0 Median lethal dose (LD50)
There was no mortality observed in any of the rats treated with the limit dose of 2000 mg/kg of
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these plant extracts (Table 2.3). Therefore, the LD50 values of the plant extracts is taken to be
greater than 2000 mg/kg.
Table 2.3 The LD50 of KAQ, ABAQ, CAQ and SBAQ aqueous extracts in albino rats
Extract
KAQ
ABAQ
SBAQ
CAQ

Number of rats
3
3
3
3

Dose (mg/kg)
2000
2000
2000
2000

Mortality
0/3
0/3
0/3
0/3

LD50 (mg/kg)
>2000
>2000
>2000
>2000

The LD50 values of more than 2000 mg/kg for each of the aqueous extracts in this study gave an
indication of their relative safety for experimental purposes, since substances with LD50 of 50500 mg/kg body weight are termed highly toxic, those with LD50 of 500-1000 mg/kg are
moderately toxic, and those with LD50 above 1000 mg/kg are regarded as being of low toxicity
or relatively safe.126
2.1.2.1 Gastrointestinal transit of activated charcoal in rats treated with KAQ, ABAQ,
SBAQ and CAQ extracts
This test is also referred to as the motility test, it measures the ability of the extracts to reduce or
inhibit GIT motility, which is a key factor in the treatment of diarrhea. The rats treated with
KAQ at all dose levels showed a significant decrease in the intestinal transit of activated charcoal
when compared to rats treated with distilled water. The rats treated with the highest dose of the
extract at 400 mg/kg decreased the GIT transit by 44.80 ± 6.58% and this is comparable with the
standard drug (atropine sulphate at 5 mg/kg), which gave a decrease transit of 44.79 ± 4.24%.
This is a clear indication of the antidiarrheal potential of the KAQ. In contrast, administration of
the ABAQ, SBAQ and CAQ extracts did not reduce gastrointestinal transit of activated charcoal
when compared with the control rats treated with distilled water. Expectantly, there was a
significant (p<0.05) decrease of the GIT transit observed in rats treated with the standard drug
atropine sulphate at the dose of 5 mg/kg when compared to the control rats (Table 2.4).

32

Table 2.4 Percentage intestinal transit of charcoal meal in rats treated with KAQ, ABAQ, SBAQ
and CAQ extracts
Treatment
KAQ extract
Water
100 mg/kg
200 mg/kg
400 mg/kg
Atropine 5 mg/kg
ABAQ extract
Water
100 mg/kg
200 mg/kg
400 mg/kg
Atropine 5 mg/kg
SBAQ extract
Water
100 mg/kg
200 mg/kg
400 mg/kg
Atropine 5 mg/kg
CAQ extract
Water
100 mg/kg
200 mg/kg
400 mg/kg
Atropine 5 mg/kg

Total Length of
Intestine (cm)

Distance travelled by
Charcoal meal (cm)

% intestinal
transit

103.28 ± 3.87
114.56 ± 4.07
102.88 ± 4.24
117.44 ± 5.60
123.68 ± 3.00

75.30 ± 1.30
69.66 ± 3.05
63.38 ± 4.00
52.48 ± 8.27
50.26 ± 4.14

73.36 ± 3.26
60.75 ± 0.76*
61.87 ± 3.58*
44.80 ± 6.58*
44.79 ± 4.24*

103.28 ± 3.87
102.28 ± 2.96
110.00 ± 2.59
108.40 ± 3.03
123.68 ± 3.00

75.30 ± 1.30
80.80 ± 6.27
86.84 ± 3.82
82.80 ± 2.44
50.26 ± 4.14

73.36 ± 3.26
78.90 ± 6.71
78.44 ± 2.28
68.19 ± 3.92
40.43 ± 2.32*

104.20 ± 4.12
101.60 ± 4.98
110.00 ± 2.59
108.40 ± 3.03
108.60 ± 2.01

72.20 ± 6.55
76.60 ± 5.03
86.40 ± 3.83
82.80 ± 2.44
57.16 ± 4.42

74.77 ± 4.77
78.16 ± 1.90
78.44 ± 2.28
76.41 ± 1.25
40.43 ± 2.32*

104.20 ± 4.12
93.20 ± 2.78
99.80 ± 4.04
96.80 ± 2.82
108.60 ± 2.0

72.20 ± 6.55
72.20 ± 6.55
77.40 ± 3.36
67.00 ± 2.88
57.16 ± 4.42

74.77 ± 4.77
78.17 ± 3.91
78.40 ± 5.78
69.71 ± 4.75
40.43 ± 2.32*

Values are expressed as mean ± SME (n=5) *=P<0.05 significantly different from distilled water treated group

The tannin content of the KAQ extract may be responsible for its antidiarrheal activity, because
tannins are known to possess astringent properties and they are thought to be useful in the
treatment of GIT internal wounds, urinary tract infection (UTI) and helminthiasis.85
2.1.2.2 Comparison of the effects of KAQ, ABAQ, SBAQ and CAQ extracts on intestinal
transit of activated charcoal in rats
In comparing the dose-for-dose effect of the extracts on the intestinal transit of charcoal, it was
found that the KAQ extract significantly decreased intestinal motility when compared to the
other extracts (Fig. 2.1). This result showed that this extract was the most efficacious of the four
extracts against GIT motility giving insight for further studies in this area. This is also the first
study that compared the effect of these extracts on intestinal motility.
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Figure 2.1 Comparison of intestinal transit of charcoal meal in rats treated with the different aqueous extracts KAQ = Hydnora
abyssinica, ABAQ = Neorautanenia mitis, SBAQ = Vitellaria paradoxa and CAQ = Senna surratensis. a,b = values in the same
cluster are significantly different (P<0.05). Dawurung et al. 2019.30

2.1.2.3 Castor oil induced diarrhea test for the KAQ, ABAQ, SBAQ and CAQ extracts in
albino rats
The castor oil induced diarrhea test reveals the ability of the extracts to reduce or inhibit
defecation or diarrhea triggered by castor oil in the rats. When castor oil is administered orally, it
is broken down to ricinoleic acid which is an irritant to the GIT, this irritation causes
inflammation as a result to the release of prostaglandins and nitric oxide from the mucosa, which
alters the permeability of the intestinal mucosa to fluid and electrolytes.127-129 These changes
causes the retention of Na+ and K+, which leads to the reduction of Na+, K+ -ATPase activity in
the small intestine and colon, leading to hyper-secretion and increased intestinal motility causing
diarrhea.130
The results from this study, shown in Table 2.5, revealed that the KAQ extract significantly
decreased fecal output in rats treated with the extract compared to the control group treated with
distilled water. At the dose level of 400 mg/kg, the fecal output was reduced by 82%, which is
comparable to rats treated with the standard drug loperamide at the dose of 10 mg/kg. This is a
further indication of the antidiarrheal potential of the KAQ extract. Following closely at 400
mg/kg is CAQ, reducing the defecation by 81%, there was also a dose dependent response
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observed at all concentrations of the CAQ extract which resulted in a significant (p<0.05) level
of reduced defecation compared to the rats treated with distilled water. It was also observed that
the fecal output of rats treated with the ABAQ extract was significantly (p<0.05) lower than that
of rats treated with distilled water. There was a marginal increase in the inhibition of fecal output
by 61, 64 and 66% at the doses of 100 mg/kg, 200 mg/kg and 400 mg/kg, respectively. The
groups treated with the SBAQ extract gave a clear dose dependent response and the mean
defecation of these rats was also lower than that of rats treated with distilled water, with the
highest dose administered at 400 mg/kg inhibiting fecal output by 32% while the lowest dose of
100 mg/kg inhibited fecal output by just 13%.
Table 2.5 Percentage inhibition of defecation of rats treated with KAQ, ABAQ, SBAQ and CAQ
extracts
Treatment
KAQ extract
Castor Oil + Water
Castor Oil + 100 mg/kg
Castor Oil + 200 mg/kg
Castor Oil + 400 mg/kg
Castor Oil + Water
(ABAQ) extract
Castor Oil + Water
Castor Oil + 100 mg/kg
Castor Oil + 200 mg/kg
Castor Oil + 400 mg/kg
Castor Oil + Loperamide
SBAQ extract
Castor Oil + Water
Castor Oil + 100 mg/kg
Castor Oil + 200 mg/kg
Castor Oil + 400 mg/kg
Castor Oil + Loperamide
CAQ extract
Castor Oil + Water
Castor Oil + 100 mg/kg
Castor Oil + 200 mg/kg
Castor Oil + 400 mg/kg
Castor Oil + Loperamide

Mean defecation
in 5 hours

% inhibition of
defecation

7.8 ± 1.32
5.2 ± 1.24
4.8 ± 0.58*
1.4 ± 0.15*
0.0 ± 0.00*

28
38
82
100

7.8 ± 1.32
3.0 ± 0.84*
2.8 ± 1.32*
2.6 ± 0.40*
0.0 ± 0.00*

61
64
66
100

6.2 ± 0.68
5.4 ± 2.02
4.6 ± 0.46*
4.2 ± 2.28*
0.0 ±0.00*

13
26
32
100

6.2 ± 0.68
4.4 ± 0.86*
2.4 ± 0.38*
1.2 ± 0.38*
0 0 ± 0.00*

29
61
81
100

Values are expressed as mean ± SME (n=5) *=P<0.05 significantly different from distilled water treated group
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The trend with all extracts was of a higher degree of protection or inhibition of diarrhea at higher
doses of the extracts (Table 2.5). This activity could be as a result of the ability of the extracts to
inhibit the release of prostaglandins and nitric oxide from the mucosa.130
2.1.2.4 Comparison of inhibition of defecation in rats treated with KAQ, ABAQ, SBAQ and
CAQ extracts
When the activity of the extracts where compared dose for dose, there was no significant
difference in the output of unformed faeces at the 100 mg/kg or 200 mg/kg dose levels. While at
the 400 mg/kg dose level, there was a significant (p<0.05) reduction observed in defecation of
rats treated with the CAQ extract when compared with those treated with SBAQ (Fig 2.2). On
comparing the percentage inhibition of defecation of the extracts, it was observed that the highest
inhibition of 82% was in the group of rats treated with 400 mg/kg of KAQ, which was followed
closely by the group treated with 400 mg/kg of CAQ which showed 81% inhibition of
defecation. It also observed that at the lowest dose level (100 mg/kg), ABAQ gave the highest
inhibition of 61% and only marginal increases of 64% and 66% were observed at the higher dose
levels of 200 mg/kg and 400 mg/kg, respectively.

Figure 2.2 Comparison of inhibition of defecation in rats treated with the different aqueous extracts. KAQ = Hydnora
abyssinica,
ABAQ = Neorautanenia mitis, SBAQ = Vitellaria paradoxa and CAQ = Senna surratensis. *=Significantly
different from SBAQ in the same cluster. Dawurung et al. 2019.30
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There was a dose dependent response in the groups treated with SBAQ, however the lowest
percentages of fecal inhibition at all dose levels were observed in the SBAQ treated groups when
compared to the other extracts (Table 2.6). From this comparison, we can deduce that KAQ
showed the highest fecal inhibition or reduction followed by CAQ, ABAQ and SBAQ at the
concentration of 400mg/kg, this information is vital to understand the potential effective doses of
these extracts in the treatment of diarrhea and also to identify the most effective among them.
This information could be vital to TM practitioners in their formulations and standardization, and
it also forms the bedrock of our future work.
Table 2.6 Comparison of inhibition of defecation in rats treated with KAQ, ABAQ, SBAQ and
CAQ extracts
Treatment
100 mg/kg
200 mg/kg
400 mg/kg

Percentage inhibition of defecation in rats treated with the extracts (%)
KAQ
ABAQ
SBAQ
CAQ
28
61
13
29
38
64
26
61
82
66
32
81

The significant (p<0.05) dose dependent reduction in the number of faeces excreted by rats
treated with ABAQ, SBAQ and CAQ extracts when compared to the control rats treated with
distilled water showed their antidiarrheal activity, and this is clearly mediated, in part, by a
mechanism other than the inhibition of GIT motility since these extracts did not inhibit intestinal
motility in the transit of activated charcoal meal test. The extracts of N. mitis, V. paradoxa, and
S. surratensis did not significantly decrease intestinal motility, but significantly inhibited castor
oil induced defecation, this trend is also seen in albino rats treated with the aqueous and ethanol
stem bark extracts of Khaya senegalensis.43 Another study, revealed that the extract of black tea
(Camellia sinensis) also showed increase motility of the upper GIT, and decreased fluid and
electrolyte secretion within the GIT, thereby alleviating diarrhea.131 The presence of tannins,
alkaloids, steroids and flavonoids in these extracts may be responsible for the inhibition of castor
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oil induced diarrhea and decreased intestinal transit. These compounds are thought to decrease
the permeability of the intestinal mucosa to fluid and electrolytes because of their astringent and
anti-inflammatory properties.74,127,132
2.2 Conclusions
In a preliminary qualitative phytochemical analysis, the aqueous extracts from H. abyssinica, N.
mitis, V. paradoxa and S. surratensis revealed the presence of secondary metabolites known to
be useful in the management of diarrhea. The antidiarrheal activity shown by the extracts could
be attributed to the presence of these phytochemicals. The extract from H. abyssinica (KAQ)
showed the highest activity in its ability to decrease intestinal motility and reduce defecation in
castor oil induced diarrhea in albino rats. The extracts from N. mitis, V. paradoxa and S.
surratensis only reduced defecation in the castor oil induced diarrhea in albino rats. This study
gives credence to the traditional use of these plants in the treatment of diarrhea symptoms in
humans and livestock.
From these studies, V. paradoxa produced the least antidiarrheal activity and therefore we
continued our studies on the phytochemical and biological studies of the other three plant
species. The results of these studies are discussed in the following Chapters.
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CHAPTER 3
Phytochemical and biological activity studies of Neorautanenia mitis (A. Rich) Verdc.
(Fabacae)
3.0 Introduction
Livestock owners and Traditional Medicine (TM) practitioners in Nigeria employ the use of
herbal preparations of the rhizome (root) of N. mitis (A. Rich) Verdcourt made by water
maceration, as an effective means of managing the symptoms of diarrhea in both livestock and
humans.21,30 In Chapter 2 and reported in our recent publication,30 we found that the aqueous
extract of N. mitis inhibited defecation in a castor oil induced diarrhea model in albino rats by
66%, showing its potential for use in diarrhea therapy and giving credence to its traditional
medicinal usage. N. mitis is from the family Fabacea, genus Neorautanenia, some species from
this genus including N. amboensis,133 N. edulis134-136 and Pachyrrhiza erosus which is closely
related to the genus,137 have been widely studied for their biological properties. In many African
countries, TM practitioners use N. mitis to treat disease conditions including scabies, syphilis,
rashes, bilharzia, dysmenorrhea, diarrhea and female frigidity. It has also been used as a fish
poison, for malaria control, and for killing bilharzias-carrying fresh water snails, and also known
for its insecticidal and insect repellent properties.26,30,111,133,136,138-139 N. mitis has been studied
phytochemically by many groups due mainly to its potential medicinal properties. Formally
called Neorautanenia pseudopacyrrhiza,140-141 its chemical constituents were first studied in
1963 where three new compounds (7, 10, 12) and one known compound (6) were isolated140
(Fig. 3.1). Studies by Puyvelde, et al., in 1987 led to the isolation of seven compounds (2, 6, 7, 9,
10, 16 and 18), of which four of them (2, 9, 16 and 18) were reported for the first time from N.
mitis (Fig. 3.1). This study also reported that the crude methanol extract of N. mitis inhibited
oviposition of the female tick Rhipicephalus appendiculatus and the compound responsible for
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this activity was identified as 12a-hydroxyrotenone (17)26 (Fig. 3.1). Similar studies revealed
significant larvicidal and mosquitocidal effects of both the crude extracts of N. mitis and the
isolated compounds (2, 6, 7 and 12)28 (Fig. 3.1). The pharmacological activity of N. mitis, by
another group in Nigeria, showed the anti-nocieceptive, anti-inflammatory and anti-cholinergic
activities of the crude aqueous extract.29,111 In their effort to discover new anti-tumour agents,
Sakurai et al., in 2006 isolated two new compounds (19 and 20) and eight known compounds (2,
6, 16, 17, and 18) from N mitis. Some of these compounds (6, 16, and 17) (Fig. 3.1) showed
significant cytotoxic activities against MCF-7 breast cancer and A-549 lung cancer cell lines.27
The most recent study was carried out in 2015 in which the isolated compounds (2, 6, 7 16 and
19), showed significant inhibitory activities against a wide range of bacteria and fungi.142
In this study, we explored the biological activity of the crude extracts and the phytochemicals
from N. mitis with the intention of identifying the compound(s) responsible for the bioactivity.
Their inhibitory activities against the Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR), and the Ca2+-activated Cl- channel (TMEM16A) were examined, since inhibition of
these channels has been linked to inhibition of secretory diarrheas.143 The most active
compounds were tested for their antidiarrheal activities in the rat model experiments described in
Chapter 2. Their α-amylase (AA) and α-glucosidase (AGO) inhibitory activities, and their
biological activities against Trypanosoma brucei, Mycobacterium tuberculosis and Plasmodium
falciparum were evaluated.
3.1 Results and discussion
3.1.0 Organic solvent extraction of the roots of N. mitis
The colour and appearances and percentage yield of the dichloromethane (DCM) and ethanol
extracts from N. mitis are reported in Table 3.1, while that of the water extract (ABAQ) was
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described in Table 2.1. We observed a higher yield of 1.5% from the DCM extract while the
ethanol extract had a lower yield of 1.0%. The DCM crude extract (ABDCM) was selected for
phytochemical analysis based on its TLC profile and the compelling preliminary bioactivity
reported in the Results and Discussion section of this chapter.
Table 3.1 Physical appearance and percentage yield based on dry mass of DCM and ethanol
extracts from Neorautanenia mitis (ABDCM, ABEOH)
Extract
ABDCM

Colour/appearance
Dark brown solid

Dry plant
material (g)
1000

Amount of
extract (g)
15.0

Percentage
yield (%)
1.5

ABEOH

Dark brown solid

975

10.0

1.0

3.1.1 Isolation of compounds from the crude DCM extract of N. mitis
The separation of the phytochemical components from the DCM crude root extract of N. mitis
was achieved through the use of column chromatography (CC) over silica gel or Sephadex LH20, and by preparative thin layer chromatography (PTLC), to give the following compounds;
neoduleen (1),134 neodulin (2),26 an ester of ferulic acid (3),144 ambonane (4),133 stigmasterol
(5),145

pachyrrhizine

(6),26

neotenone

(7),26

a

new

compound

7-methoxy-3-(6-

methoxybenzo[d][1,3]dioxol-5-yl) chroman-4-one (8), 12a-hydroxydolineone (9),26 dolineone
(10),26 (-)-2-isopentenyl-3-hydroxy-8-9-methylenedioxypterocarpan (11),146 nepseudin (12),140
neorautenol (13),134,135 isoneorautenol (14),147,148 (-)-2-hydroxypterocarpin (15),146 rotenone
(16),149-150 12a-hydroxyrotenone (17),26,149 dehydroneotenone (18),26 rautandiol A (19, relative
configuration shown as absolute configuration is not known) and rautandiol B (20)27 (Fig. 3.1).
A new compound 7-methoxy-3-(6-methoxybenzo[d][1,3]dioxol-5-yl) chroman-4-one (8) as a
new natural product, was assigned the (S) configuration based on the signs of the Cotton effects
in the CD spectrum. We also established the configuration of compounds 11 and 20 for the first
time as (6a-R,11a-R) and (6a-R,11a-R, 2'-S), respectively through single crystal X-ray diffraction
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(Fig. 3.2). In this study, the complete NMR spectroscopic data along with proton and carbon
assignments and supporting spectroscopic data for compounds 1, 3, 4, 11, 12, 13 and 15 are
provided for the first time. The configurations of compounds 7 and 12 were tentatively assigned.

Figure 3.1 Compounds isolated from the roots of N. mitis
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as (S) based on the negative signs of their specific rotations. We also provide the full physical
and spectroscopic data of compound 3 which was isolated as a single entity for the first time.
This data is provided in the experimental section of this thesis (Chapter 7) along with tabulated
comparisons of the obtained and literature data, the physical data (Mp and specific rotations)
where appropriate along with the NMR spectroscopic data of all the other known isolated
compounds.

Figure 3.2 Crystal structures of compounds 11 and 20 (CCDC 1973442 and 1972703, respectively)

Our studies also resulted in the isolation of nine compounds from N. mitis for the first time, these
were compounds; 1, 3, 4, 5, 8, 11, 13, 14 and 15.
Compound 8 was isolated as a white solid after purification by PTLC, mp 133-135°C, and [α]22D
-11.2 (c 0.2 CHCl3). Its HRESITOFMS data afforded an [M + H] + ion peak at m/z 329.1025,
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implying a molecular formula of C18H16O6 (calcd for C18H17O6, m/z 329.1025). The

13

C NMR

and DEPT spectra indicated the presence of a total of 18 carbons, eight of which werequaternary,
five aromatic methines, two methylenes, one sp3 methine and two methoxy carbons (Table 3.2).

Compound 8 (7-methoxy-3-(6-methoxybenzo[d][1,3]dioxol-5-yl) chroman-4-one)
Table 3.2 1H NMR and 13C NMR spectroscopic data of compound 8 (CDCl3)a
No
2
3
4
5
6
7
8
4a
8a
1'
2'
3'
4'
5'
6'
2''
OCH32'
OCH37

1

H NMR (500 MHz)
4.57 – 4.45 (m, 2H)
4.25 (dd, J = 11.3, 5.5, 1H)
7.92 (d, J = 8.8, 1H)
6.61 (dd, J = 8.8, 2.0, 1H)
6.44 (d, J = 2.0, 1H)

6.56 (s, 1H)

6.59 (s, 1H)
5.91 (s, 2H)
3.74 (s, 3H)
3.85 (s, 3H)

13

C NMR (125 MHz)
71.3
47.5
191.5
129.4
109.9
165.8
100.7
115.5
163.8
115.6
152.8
95.3
141.3
147.7
109.7
101.3
56.6
56.6

HMBC
C-8a, 1', 3, 4
C-1', 2, 2', 4, 6'
C - 4, 7, 8a
C - 4a, 8
C- 6, 7, 8a

C - 4', 5'

C - 3, 2', 4', 2''
C - 4', 5'
C - 2'
C–7

a

Assignments were made on the basis of COSY, HSQC and HMBC correlations,
chemical shift values are in δ (ppm), and coupling constants (J) are in Hz.

The 13C NMR resonances for the oxygenated aromatic carbons of 8 were at δC 165.8 (C-7), 163.8
(C-8a), 152.8 (C-2'), 147.7 (C-5') and 141.3 (C-4'), while C-4 resonated at δC 191.5. The 1H
NMR spectrum showed aromatic proton resonances at δH 7.92 (d, J = 8.8 Hz, 1H), 6.61 (dd, J =
8.8, 2.1 Hz, 1H), 6.59 (s, 1H), 6.56 (s, 1H), and 6.44 (d, J = 2.0 Hz, 1H) (Table 3.2).
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The HMBC correlations (Table 3.2) allowed the assignment of the aromatic ring protons to the A
and B rings which were consistent with an isoflavonoid skeleton. The methylenedioxy group, δH
5.91 (s, 2H), was attached to C-4' and C-5' on the B ring from its HMBC correlations to these
aromatic carbons, while the 1H NMR resonances at δH 3.85 (s, 3H) and 3.74 (s, 3H) represented
the methoxy groups that were substituted at C-7 and C-2' on the A and B rings, respectively. The
overlapping diastereotopic methylene protons at δH 4.57 - 4.45 (m, 2H) and the methine proton at
δH 4.25 (dd, J = 11.3, 5.5 Hz, 1H) were part of the heterocyclic C ring and were assigned to H-2
and H-3, respectively. Their chemical shifts and splitting patterns were comparable to those of
the corresponding protons of compound 7,26 which was also isolated in this study. Compound 8,
or its isomer was prepared by synthesis; however the authors were not able to distinguish
between the two possible structures. The NMR spectroscopic data of the synthetic compound
was not provided to allow for a comparison151 with compound 8 that we isolated in this study. In
general flavanones having the 2S configuration have a positive Cotton effect at the π to π*
absorption band at 270-290 nm and a negative Cotton effect at the π to π* absorption band at
320-330 nm. The Cotton effect at the shorter wavelength band (270-290 nm) is due to the higher
energy π – π* transition, and the longer wavelength absorption (320-330 nm) is due to the n – π*
transition. 152 In the case of compound 8, the Cotton effects were positive at 303 nm and negative
at 328 nm indicating indicating that the major enantiomer of 8 had the 2S configuration (Fig.
3.3).
3.1.2 Isolation of compounds from the aqueous extract of N. mitis
In Chapter 2 of this thesis, we highlighted that TM practitioners administered the aqueous extract
of the roots of N. mitis orally to treat the symptoms of diarrhea, we also prepared the crude
aqueous extract using the traditional method (water maceration) as described in Chapter 2.
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Figure 3.3 Circular dichroism spectrum of compound 8 (MeOH)

This extract was concentrated in vacuo and further extracted with chloroform and the
components separated by CC to give compounds 2, 6, 7 and 18 with the percentage yields of
0.20%, 0.58%, 1.1% and 0.78%, respectively based on the dry weight of the root. The remaining
aqueous extract was then extracted with n-butanol but no compounds could be isolated, while
evaporation of the aqueous extract only gave a mixture of carbohydrates.
Other compounds isolated previously from the roots of N. mitis which were not isolated in this
study include; 12a-hydroxyerosone (21),27 iseoliptol (22),27 neorautanone (23),28 4methoxyneoduline (24)28 and neoraudiol (25)142 (Fig. 3.4).

Figure 3.4 Compounds previously isolated from the roots of N. mitis but not found in this study

3.1.3 Biological activities of crude extracts and compounds from N. mitis
3.1.3.0 CFTR inhibitory activity
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Compounds in sufficicient quantities including; 2, 6, 7, 10, 11, 15, 16, and 18-20, together with
the crude extracts (ABDCM and ABAQ) were primarily screened at 5 µM and 5 µg/mL
concentration, respectively, for their CFTR inhibitory activities. These studies were performed
by Prof. Chatchai Muanprasat at Mahidol University, Thailand. Compounds 2, 6, 7, 10, 11, 16
and the crude extracts showed significant CFTR inhibitory activities (Table 3.3).
Table 3.3 Primary screening of compounds and crude extracts (ABDCM and ABAQ) of
N. mitis for CFTR inhibitory activity
Compound (5µM)
/Extract (5µg/mL)
2
6
7
10
11
15
16
18
19
20
ABDCM
ABAQ

% CFTR Inhibition
~45%
~60%
~60%
~85%
~75%
Inactive
~80%
Inactive
Inactive
Inactive
~70%
~60%

These studies involved an examination of the inhibitory effects of our isolated compounds at 5
µM and crude extracts at 5 µg/mL, on the short circuit current (ISC) stimulated by forskolin on
T84 cells which results in cAMP-induced chloride (Cl-) secretion from the CFTR Cl- channel
(Fig. 3.5 and 3.6). Compounds 2, 6, 7, and 10 and the aqueous extract (ABAQ) inhibited cAMPinduced chloride secretion in a concentration-dependent manner with significant IC50 values of
2.42 ± 0.26 µM, 2.87 ± 0.78 µM, 4.66 ± 0.43 µM, 0.81 ± 0.19 µM and 2.49 ± 0.43 µg/mL
respectively, (Table 3.4, Fig. 3.5B and Fig. 3.6) compared to the reference compound CFTRinh172 which showed a consistent IC50 of ~5 µM in intact T84 cells.
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Table 3.4 The IC50 values of compounds 2, 6, 7, 10 and the extract ABAQ
Compound

~IC50 (µM)

2

2.42 ± 0.26

6

2.87 ± 0.78

7

4.66 ± 0.43

10

0.81 ± 0.19

ABAQ

2.49 ± 0.43
(µg/mL)

From these results compound 10 showed the highest potency, while compounds 11 and 16
together with the DCM extract (ABDCM) did not give a dose-dependent response; therefore no
further investigations were carried out on them.

A

[compound 2] (μM)

[compound 7] (μM)

[compound 6] (μM)

[compound 10] (μM)

48

B

Figure 3.5 Inhibitory effects of compounds 2, 6, 7 and 10 on cAMP-induced chloride secretion in T84 cells. (A) Dose response
studies of compounds 2, 6, 7 and 10 on cAMP-induced chloride secretion. The representative traces of apical ISC on T84 cells are
shown. (B) Data were fitted to the Hill equation and expressed as means of %forskolin-stimulated ISC ± S.E.M. (n=3). Dawurung
et al. 2020.143

A

B

Figure 3.6 Inhibitory effects of ABAQ on cAMP-induced chloride secretion in T84 cells. (A) Dose response studies of ABAQ
on cAMP-induced chloride secretion. The representative traces of apical ISC on T84 cells is shown. (B) Data were fitted to the
Hill equation and expressed as means of %forskolin-stimulated ISC ± S.E.M. (n=3). Dawurung et al. 2020.143

3.1.3.1 TMEM16A inhibitory activity
TMEM16A is a Ca2+-activated Cl- channel that transports Cl across biological membranes. It
plays an important role the secretion of fluids in epithelia cells and is also active in various
physiological processes. The TMEM16A inhibitory activity of the compounds and crude extracts
were carried out on Calu-3 cells (human airway epithelial cells) using the apical Cl- current (ICl-)
analysis. This is made possible since Calu-3 cells endogenously express high levels of
TMEM16A.153

49

To ensure the functional existence of TMEM16A in Calu-3 cells, the cells were pretreated with
MONNA, a specific TMEM16A inhibitor, the Cl- current induced by Eact, a specific TMEM16A
activator was almost completely diminished (Fig. 3.7).154-155 The inhibitory activities of the
compounds and extracts on TMEM16A were determined at a final concertration of 10 µM and
10 µg/mL, respectively. In the primary screening, ABDCM and ABAQ extracts showed the

Figure 3.7 Validation of TMEM16A activation in Calu-3 cells. (A) Representative traces of change in Cl- current induced by 10
μM Eact with or without 10 μM MONNA pretreatment. (B) Data were fitted to the Hill equation and expressed as means of E actinduced Cl- current (mean ± S.E.M, n=3). ***P<0.001. Dawurung et al. 2020.143

highest TMEM16A inhibitory effects (Table 3.5), with ABDCM showing higher inhibitory
activity; therefore the potency of ABDCM was determined and it inhibited TMEM16A in a
concentration-dependent manner giving an IC50 value of 8.05±0.96 µg/mL, with complete
inhibition observed at the concentration of 20 µg/mL. (Fig. 3.8)
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Table 3.5 Primary screening of compounds and crude extracts (ABDCM and ABAQ) from N.
mitis for TMEM16A inhibitory activity in human airway epithelial (Calu-3) Cells
Compound (10µM)
/Extract (10µg/mL)
2
6
7
10
11
15
16
18
19
20
ABDCM
ABAQ

% TMEM16A
Inhibition
~42%
~1%
~3%
~24%
~28%
<1%
~19%
~4%
~10%
~44%
~86%
~76%

Figure 3.8 ABDCM dose-dependently inhibited TMEM16A in Calu-3 cells. (A) Representative trace of change in Cl- current.
ABDCM at indicated concentration were applied 20 min prior to TMEM16A activation by E act (10 μM). (B) Dose-response
relationship of TMEM16A inhibition by ABDCM. Data were fitted to the Hill equation and expressed as means of E act-induced
Cl- current (mean ± S.E.M, n=3). Dawurung et al. 2020.143

3.1.3.2 The mechanism of action of compound 10 (Dolineone)
The above studies revealed that dolineone (10) showed the highest inhibitory activity on the
CFTR Cl- channel; therefore we investigated its possible mechanism of action on this chloride
channel, where the apical IClˉ current was measured in basolateral permeabilized T84 cells. This
was aimed at determining whether the CFTR chloride channel inhibitory activity of compound
10 was through cAMP alteration. The results showed a concentration-dependent inhibition of
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CFTR-mediated apical IClˉ stimulated by various cAMP agonist, including forskolin (adenylate
cyclase activator), forskolin plus IBMX (phosphodiesterase inhibitor) and CPT-cAMP (a cellpermeable cAMP) by compound 10, with IC50 values of 2.12±0.39 µM, 1.9±0.18 µM and
1.49±0.23 µM, respectively. These findings showed that the CFTR inhibitory effect by
compound 10 does not involve cAMP alteration (Fig. 3.9). Secondly, we sought to know if the
CFTR inhibitory activity of compound 10 was through the activation of protein phosphatase
and/or MRP4, as CFTR Cl- current can be suppressed by negative regulators including protein
phosphatase (PP) and multidrug-resistance protein 4 (MRP4).

[Compound 10] (μM)

[Compound 10] (μM)

A
[Compound 10] (μM)

B
[Compound 10] (μM)
Figure 3.9 Effect of compound 10 on CFTR-mediated apical IClˉ in T84 cells. (A) The representative trace of apical IClˉ
stimulated by forskolin (20 µM), forskolin plus IBMX (100 µM) and CPT-cAMP (100 µM). (B) Data were fitted to the Hill
equation and expressed as means of %agonist-stimulated IClˉ ± S.E.M. (n=3). Dawurung et al. 2020.143
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These results showed that compound 10 inhibited CFTR-mediated apical IClˉ after treatment with
the protein phosphatase inhibitor (Na3VO4) or MRP4 inhibitor (MK571) in a concentrationdependent manner with IC50 values of 1.93±0.04 µM and 2.4±0.08 µM, respectively. Thus the
effect of dolineon on CFTR inhibition was not significantly affected by pre-treatment with a
protein phosphatase inhibitor or a MRP4 inhibitor. These results showed that the inhibitory
activity of dolineon on CFTR chloride channel activity does not involve activation of protein
phosphatase and/or MRP4 (Fig. 3.10). Furthermore, the pathogenesis of secretory diarrheas
involves a pivotal role by the intestinal Ca2+-activated Cl- channel (CaCC).156
A

B

Figure 3.10 No involvement of protein phosphatase and MRP4 in the inhibition of CFTR chloride channel activity by compound
10 (A) Representative trace of apical IClˉ stimulation after pretreatment with Na3VO4 (protein phosphatase inhibitor; 1 mM) and
MK571 (MRP4 inhibitor; 20 µM). (B) Data were fitted to the Hill equation and expressed as means of %forskolin-stimulated IClˉ
± S.E.M. (n=3). Dawurung et al. 2020.143

Therefore, compound 10 was investigated for possible inhibitory action on intestinal CaCC,
where the apical Cl- current measurement was performed in T84 cell monolayers. The results
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indicated that dolineon showed inhibitory activity against intestinal CaCC current in a
concentration-dependent manner with an IC50 value of 4.38±0.38 µM, with the highest inhibition
observed at 100 µM (Fig. 3.11).
A

B

Figure 3.11 Effect of compound 10 on intestinal CaCC activity. (A) Representative trace of apical IClˉ. T84 cell monolayers were
permeabilized with amphotericin B at basolateral membrane, and 5 µM of CFTRinh-172 was applied to apical solution 15 min
prior to addition of ATP (100 µM). Compound 10 was then added to both apical and basolateral solution at indicated
concentration. (B) Data were fitted to the Hill equation and expressed as means of ATP-induced IClˉ ± S.E.M. (n=3). Dawurung et
al. 2020.143

3.1.3.3 Cholera toxin challenge (CT) anti-diarrheal activity of compound 10 (Dolineone)
To test the potential of dolineon in the treatment of secretory diarrhea, its anti-diarrheal activity
was evaluated on in vitro models of chloride secretion in T84 cell monolayers and on an in vivo
closed loop model of fluid secretion induced by cholera toxin (CT).157 The results showed that
compound 10 inhibited CT-induced chloride secretion with >70% of inhibition of fluid secretion
at 100 µM in T84 cells giving an IC50 value of 1.16 µM (Fig. 3.12A).
In the mouse closed loop model, the intestinal fluid secretion was assess by the weight/length
ratios of loops, the intestinal loops were instilled with CT (1 µg/loop) with or without dolineon at
a dose of 16.9 µg/loop. Interestingly, at this dose dolineon showed inhibition of CT-induced fluid
secretion by ~70% (Fig. 3.12B). This is an indication that dolineon could serve as a lead
compound in the development of future CFTR inhibitors with therapeutic potential for the
management of diarrhea.
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A

B

Figure 3.12 Anti-diarrheal applications of compound 10 (A) Effect of compound 10 on CT-induced chloride secretion in T84
cells. (B) Effect of compound 10 on CT-induced intestinal fluid secretion in mouse closed-loop. Ileal loops were instilled with
phosphate-buffered saline (PBS) or PBS containing cholera toxin (1 µg/loop) with or without intraluminal (i.l.) administration of
compound 10 (16.9 µg/loop). Loop weight/length ratios were evaluated 6 h after CT challenges. ***, P < 0.001 when compared
with control ###, P < 0.001 when compared with the CT-treated group (one-way ANOVA) (n = 5). Dawurung et al. 2020.143

3.1.3.4 Castor oil induced diarrhea test by compounds from N. mitis
Further investigation of the potential of compounds 2, 6, 7 and 10, was carried out by the author,
in a castor oil induced (CO) model in albino rats. This was to help identify the
compound/compounds responsible for the inhibition of CO induced diarrhea shown by the crude
extract of N. mitis (ABAQ) discussed earlier in Chapter 2 of this thesis. These compounds were
tested based on their availability as they all had higher yields than most of the other compounds
that we isolated from ABDCM and compounds 2, 6, 7 were also isolated from the chloroform
soluble part of ABAQ extract.
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Compounds 7 and 10 showed dose dependent responses of 65.07% and 50.07% inhibition of
defaecation respectively, at 20 mg/kg. This implies that these compounds possess antidiarrheal
activity by slowing intestinal motility and reducing fluid secretion into the GIT just like the
control drug loperamide. These compounds gave lower percentage of diarrhea reduction
compared to loperamide (85.01%), this may be due to lack of optimal absorption and
bioavailability, since they are not formulated drugs yet. Compounds 2 and 6 did not give a dose
dependent response, but it is interesting to note that at 5 mg/kg, compound 6 gave a significant
(p≤0.05) inhibition of defaecation of 74.96% when compared to the control drug. Compound 2
showed a lower percentage of inhibition at all dose levels (Table 3.6).
Table 3.6 Percentage inhibition of defecation of rats treated with compounds 2, 6, 7 and 10
Treatments
Castor oil + Water 10 ml/kg
Castor oil + 5 mg/kg (2)
Castor oil + 10 mg/kg (2)
Castor oil + 20 mg/kg (2)
Castor oil + Loperamide 10 mg/kg

Mean defeacation
in 6 hrs
6.67±1.67
6.00±2.31
4.67±0.33
5.67±1.20
1.00±0.58a

Castor oil + Water 10 ml/kg
Castor oil + 5 mg/kg (6)
Castor oil + 10 mg/kg (6)
Castor oil + 20 mg/kg (6)
Castor oil + Loperamide 10 mg/kg

6.67±1.67
1.67±0.88 a
4.00±1.53
3.00±0.58
1.00±0.58a

Percentage inhibition
of defeacation
10.04
29.99
14.99
85.01
74.96
40.03
55.02
85.01

Castor oil + Water 10 ml/kg
Castor oil + 5 mg/kg (7)
Castor oil + 10 mg/kg (7)
Castor oil + 20 mg/kg (7)
Castor oil + Loperamide 10 mg/kg

6.67±1.67
4.67±0.88
4.00±1.53
2.33±0.88
1.00±0.58a

29.99
40.03
65.07
85.01

Castor oil + Water 10 ml/kg
Castor oil + 5 mg/kg (10)
Castor oil + 20 mg/kg (10)
Castor oil + Loperamide 10 mg/kg

6.67±1.67
4.00±0.58
3.33±0.88
1.00±0.58a

40.03
50.07
85.01

Values are expressed as mean±SEM (n=3). a= p≤0.05 significantly different when compared with distilled water group

3.1.3.5 Effects of compounds from N. mitis on the isolated rabbit jejunum
The isolated rabbit jejunum exhibits spontaneous rhythmic contraction which enables the testing
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of substances that have the ability to contract or relax soft tissues.The contraction/relaxation
effects are brought about by different mechanisms such as stimulation of receptors, opening of
ion channels or the synthesis of nitric oxide.158-161 Pronounced relaxation of contraction of the
jejunum was observed with compound 2 in a concentration dependent manner, giving a complete
relaxation at 194.7 µM. This relaxation is clearly an indication that compound 2 is able to
produce strong inhibition of gastric motility which is required in the management of diarrhea,
since the relaxation of the GIT leads to reduced intestinal transit which could result in fluid
retention and possible reabsoption from the GIT, hence decreasing the fecal output and its
frequency111,74 (Fig. 3.13). Therefore compound 2 may contribute to the inhibition of CO
induced diarrhea by the crude extract of N. mitis reported in Chapter 2. Compounds 6, 7, and 10
(Fig. 3.14, 3.15, 3.16) showed some moderate activity in abolishing the rhythmic contraction of
the jejunum in a concentration dependent manner.
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Figure 3.14 Effect of compound 6 on isolated rabbit jejunum
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Figure 3.15 Effect of compound 7 on isolated rabbit jejunum
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Figure 3.16 Effect of compound 10 on isolated rabbit jejunum

These compounds may have the ability to slow GIT motility at higher concentrations. A study
carried out by Vongtau et al. in 2000, showed that the aqueous root extract of N. mitis inhibited
normal rhythmic activity in oxytocin induced contraction in isolated rat uterus and acetylcholine
induced contraction in isolated rat jejunum. This study suggests that the active principle
responsible for the activity as indicated from this study to be neodulin (2), may be the reason that
the roots of this plant are used in the treatment of dysmenorrhea and inflammatory conditions
traditionally.40 Furthermore, some flavonoids isolated from plants have been reported to inhibit
gastric motility in a dose dependent manner.74
3.1.3.6 Antibacterial and antifungal activities of extracts and compounds from N. mitis
Bacterial and fungal organisms play a role in causing many episodes of diarrhea therefore
antimicrobial agents have been utilized in the management of diarrhea. Most of the compounds
isolated from N. mitis were tested against a wide range of bacteria and some fungi (Table 3.7).
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Table 3.7 Anti-microbial activity of crude extracts and compounds of N. mitis
Compound/Ext
ract
(32 µg/mL)
ABAQ
ABOH
ABDCM
1
2
3
5
6
7
8
9
10
11
12
13
15
16
17
18
19
20

Bacteria and Fungi inhibition (%)
Sa
13.23
13.36
-1.67
20.49
21.24
12.69
12.19
18.32
-2.15
-27.23
5.83
2.13
24.37
6.41
-39.35
6.28
18.69
17.5
20.65
-32.18
-21.45

Ec
-1.72
-5.95
-7.99
17.67
-4.03
11.86
4.42
-0.57
7.81
22.68
2.84
-4.34
15.36
10.4
14.59
23.46
10.26
4.32
15.38
16.07
25.09

Kp
20.84
14.18
4.52
21.52
11.2
13.03
9.57
18.15
20.13
-2.21
8.15
9.49
21.67
16.5
-2.33
18.17
16.97
10.76
18.02
-2.63
3.91

Pa
22.16
19.03
10.7
10.6
18.22
10.59
10.97
10.46
13.06
11.94
5.59
16.46
11.79
13.23
1.29
13.71
14.9
0.92
12.98
4.64
8.8

Ab
-1.98
-3.79
-13.91
34.04
-11.73
4.22
6.31
-28.33
32.8
-18.29
13.8
-5.88
24.88
22.59
-12.82
10.66
31.75
33.49
4.51
-14.19
-3.66

Ca
5.09
10.84
13.35
2.11
7.03
3.84
1.0
8.43
8.07
15.29
-0.58
11.11
2.0
1.9
11.45
2.78
6.66
3.77
4.33
4.16
15.07

Cn
-38.93
-56.91
-51.29
0.0
-23.13
1.98
12.59
-32.61
7.21
-15.4
-33.76
-31.75
20.38
3.56
-12.25
11.34
89.76
-11.04
0.32
-5.2
0.1

Abbreviations Sa- Staphylococcus aureus; Ec- Escherichia coli; Kp- Klebsiella pneumoniae; Pa- Pseudomonas aeruginosa; AbAcinetobacter baumannii; Ca- Candida albicans; Cn- Cryptococcus neoformans var. grubii.

None of the crude extracts or compounds isolated from N. mitis were active against the range of
bacteria used in this study. However, compound 16 (rotenone) showed significant inhibition of
Cryptococcus neoformans var. grubii at 89.76% at the concentration of 32 µg/mL. Castro et al.
in 2010 reported rotenone in synergy with staurosporine showed antifungal activity against
Neurospora crassa, Aspergillus fumigatus and Candida albicans.162 Its significant antifungal
activity without synergy in this study is quite interesting, although it was also found to be
cytotoxic (Table 3.8). This study also reveals that neither the crude extracts nor the pure
compounds from N. mitis may be effective in the management of diarrhea caused by the bacteria
and fungi tested.
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3.1.3.7 Cytotoxicity of extracts and compounds from N. mitis
We reported (Dawurung et al. 2020)143 that most of the isolated compounds were assayed for
cytotoxicity against KB (mouth epidermal carcinoma cells), Vero (kidney epithelial cells of an
African green monkey) and BHK21 (baby hamster kidney fibroblast) cell lines. The aqueous
(ABAQ) and DCM (ABDCM) extracts showed significant activities against KB cells with IC50
values of 1.0±0.2 and 0.35±0.04 µg/mL, respectively. They were also cytotoxic against Vero
cells with IC50 values of 5.8±1.1 and 2.7±0.6 µg/mL, respectively. Compounds 16 and 17 were
identified as responsible for the cytotoxicity observed in the crude DCM extract, as they also
showed high potencies against KB cells with IC50 values of 0.006±0.003, and 0.09±0.003 µM,
respectively. This is similar to the activity reported for these compounds against MCF-7 breast
cancer cells and A-549 lung cancer cells.27 However, these compounds were also found to be
highly toxic against Vero cells with IC50 values of 0.17±0.02 µM and 0.02±0.02 µM,
respectively (Table 3.8). Compound 17 was the most toxic, consistent with its insecticidal
properties.26 Compounds 2, 7, 10 and 20 showed low cytotoxicity. Importantly, compound 10
being identified as a lead CFTR inhibitor showed low toxicity on non-cancerous cell lines giving
IC50 values of >29.6 µM and 57.30 µM against Vero and BHK21 cells, respectively, and
therefore consistent with earlier reports.163
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Table 3.8 Cytotoxicity of crude extracts and isolated compounds from N. mitis
Compounds(µM)/
CrudeExtracts
(µg/mL)

Cytotoxicity

17
18
20

KB
1.0±0.2
SR - 5.8
0.35±0.04
SR = 7.71
>31.0
>32.5
> 17.2
>32.3
>31.0
>31.0
>28.5
>29.6
>28.4
>28.2
> 31.8
0.065±0.003
SR = 2.62
0.09±0.003
>30.9
42.87±9.46

Ellipticine

0.95±0.34

ABAQ Extract
ABDCM Extract
1
2
3
6
7
8
9
10
11
12
15
16

(IC50)
VERO
5.8±1.1

BHK21
-

2.7±0.6

5.25±1.28

>31.0
>32.5
> 17.2
>32.3
>31.0
>31.0
>28.5
>29.6
>28.4
>28.2
> 31.8
0.17±0.02

41.68±8.56
7.89±1.05
>100
57.30±6.77
-

0.02±0.02
>30.9
89.49±8.47
SR = 133
1.02±0.29

>12.50
82.68±7.75
-

Safety Ratio- (SR); not determined- (-)

3.1.4.0 Other biological activities of N. mitis
3.1.4.1 AA and AG inhibitory activity of N. mitis
Following the screening of all crude extracts for α-glucosidase inhibitory activity, (Table 3.9) the
crude DCM (ABDCM) and ethanol (ABEOH) extracts from N. mitis showed significant
inhibitory activities of 117.8 ± 27.2% and 101.2 ± 1.6% respectively, at 5 mg/mL higher than
acarbose (71.3%) at 0.1 M concentration. The aqueous extract (ABAQ) gave the lowest
inhibitory activity of 45.4%. This shows that the ethanol and DCM extracts have higher potency
than the aqueous extract.
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Table 3.9 AG inhibitory activity of N. mitis crude extracts
Extract (500 µg/mL)
in 50% DMSO
ABAQ
ABDCM
ABEOH
Acarbose 0.1M

% Inhibition
45.4 ± 12.6
117.8 ± 27.2
101.2 ± 1.6
71.3 ± 3.8

DMSO 50%

0

Both AA and AG are targets for potential glucosidase inhibitors, therefore the IC50 of the most
active extracts were tested against both AA and AG (Table 3.10). The results showed lower IC50
values for both ABDCM (26.8 ± 1.0 µg/mL) and ABEOH (6.2 ± 0.3 µg/mL) against AG when
compared to that of acarbose (438.5 ± 4.90 µg /mL). There was a similar inhibitory activity by
ABDCM and ABEOH found against AA with IC50 values of 0.55 ± 0.01 mg/mL and 0.74 ± 0.02
mg/mL by ABDCM and ABEOH, respectively, and that of acarbose with IC50 value of 0.44 ±
0.10 mg/mL. This gives an indication that the extracts show inhibitory activities against both AA
than AG.
Table 3.10 IC50 values of N. mitis crude extracts against AG and AA
Crude extracts
in 50% DMSO
ABDCM
ABEOH
Acarbose 0.1M

AG
IC50 (µg/mL)
26.8 ± 1.0
6.2 ± 0.3
438.5 ± 4.90

AA
IC50 (mg /mL)
0.55 ± 0.01
0.74 ± 0.02
0.44 ± 0.10

Some of the compounds isolated from ABDCM were screened for AA inhibitory activity at 250
µg/mL in DMSO. Compounds 10 and 19 showed interesting % inhibition of 54.2 ± 8.9 and 83.9
± 1.0, respectively (Table 3.11), and the IC50 values of 10 and 19 against AG were 0.66 mM and
0.28 mM, respectively (Table 3.12). Compound 19 showed a higher IC50 value than acarbose
which had an IC50 value of 0.91 mM. These IC50 values indicate compounds 10 and 19 are
relative weak inhibitions since useful compounds would have IC50 values in the 1.0 - 0.1 µM
range. Compound 10 appears to have both antidiarrheal activity (from our previous studies) and
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AG inhibitory activity, this combination of bioactivity in one compound is worthy of further
investigation, because the current drugs used in the management of type II diabetes (acarbose
and miglitol) both trigger diarrhea in patients as a side effect.114
Table 3.11 Screening for AG inhibitory activity of compounds from N. mitis
Samples (250 µg/mL)
in 50% DMSO
3

% Inhibition
14.8 ± 0.8

8

17.7 ± 0.3

10

54.2 ± 8.9

11

31.5 ± 2.1

16

19.9 ± 11.4

19

83.9 ± 1.0

20

29.3 ± 3.1

Acarbose 0.1M

86.5 ± 0.4

DMSO 50%

0

Table 3.12 IC50 values of the most active compounds
Compounds
in 50% DMSO
10
19
Acarbose

AG
IC50 (mM)
0.66
0.28
0.91

AA
IC50 (mM)
ND
ND
0.68

ND: not determined

3.1.4.2 The anti-tuberculosis, anti-trypanosoma and anti-malaria activity of the extract and
compounds from N. mitis.
The DCM crude extract and compounds from N. mitis were screened for activity against
Mycobacterium tuberculosis, Trypanosoma brucei rhodesience, and Plasmodium falciparum
(Table 3.13). The extract showed good activity against T. brucei rhodesience with an IC50 value
of 3.04 ± 0.27 µg/mL. It also showed good activity on the two strains of P. falciparum namely
TM4/8.2 and K1CB1 with IC50 values of 2.99±0.59 µg/mL and 2.67±1.05 µg/mL, respectively.
However, this extract was also found to be toxic (Table 3.8). Compounds 7, 10 and 11 showed
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activity against T. brucei with IC50 values of 17.01 ± 1.83 µM, 18.65 ± 3.20 µM and 4.87±0.49
µM, respectively. Compounds 16 and 17 were also active against T. brucei with IC50 values of
7.51 ± 0.17 µM and 8.63 ± 1.14 µM, respectively, however they were also cytotoxic against
VERO and KB cells (Table 3.8). The highest activity was displayed by compound 11 which
showed a safety ratio (SR) of > 5.83. The Safety ratio (SR) reveals the safety or toxicity of a
given compound; safe compounds will have very high SR to show they have low toxicity or are
non-toxic. The SR value is calculated from the cytotoxicity on VERO cells divided by the IC50
of the target activity. A moderate activity against M. tuberculosis was shown by compound 11.
The highlight of these results was the activity of compound 20 which showed excellent activity
against P. falciparum strains, with IC50 values of 0.75±0.12 µM and 0.61±0.2 µM against
TM4/8.2 and K1CB1, respectively. Both strains showed a high SR of 108 (TM4/8.2) and 133
(K1CB1), and 20 was non-toxic against VERO and KB cells (Table 3.8). It is interesting to note
that compound 20 was more potent against K1CB1 when compared with the standard drugs;
cycloquanil and pyrimethamine that had IC50 values of 10.7±1.62 µM and 23.21±2.24 µM,
respectively. N. mitis extract is traditionaly used as an antimalarial agent due to its activity
against the mosquito vector and its larva.139,142 The activity of N. mitis against P. falciparum, the
causative agent of malaria is reported here for the first time. A report by Amoa et al. in 2013
showed that 22% of compounds isolated from African plants with anti-malaria activity were
flavonoids,164 this is in line with our finding as 20 is a flavonoid isolated from an African plant.
Compound 20 stands out as a promising lead compound against K1CB1 for the development of a
new antimalarial drug and we highly recommend further studies. From the limits of our search,
the activity of N. mitis against T. brucei and M. tuberculosis are reported here for the first time.
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Table 3.13 Inhibitory activity of extract and compounds from N. mitis against M. tuberculosis, T.
brucei rhodesience, and P. falciparum
Compounds
(µM)/Crude Extracts
(µg/mL)

Mt
H37Rv
(MIC µM)

Tbr
(IC50 µM)

Pf (IC50 µM)

ABDCM

>20

3.04 ± 0.27

1
2
3
6
7
9
10
11

>62.1
>64.9
>34.4
>64.7
>62.0
>56.9
>59.9
56.8

12
15
16
17
18
20

>56.4
>56.8
>52.3
>55.2
>61.7
>20

17.01 ± 1.83
18.65 ± 3.20
4.87±0.49
SR > 5.83
7.51 ± 0.17
8.63 ± 1.14
23.54 ± 1.59

Isoniazid
Rifampin
Cycloquanil
Pyrimethamine
Pentamidine

0.02
0.08
-

0.007±0.00004

TM4/8.2

K1CB1

2.99±0.59
SR -0.9
>31.0
>32.5
>17.2
>32.3
>31.0
>28.5
>29.6
>28.4

2.67±1.05
SR -1.01
>31.0
>32.5
>17.2
>32.3
>31.0
>28.5
>29.6
>28.4

>28.2
>28.4
>26.2
>27.6
>30.9
0.75±0.12
SR -108
0.076±0.016
0.095±0.02
-

>28.2
>28.4
>26.2
>27.6
>30.9
0.61±0.2
SR -133
10.7±1.62
23.21±2.24
-

Abreviation; Mt- Mycobacterium tuberculosis; Tbr- Trypanosoma brucei rhodesience; Pf- Plasmodium falciparum

3.2 Conclusions
The isolation of compounds from N. mitis led to the characterization of one new compound (8)
and 19 known compounds, and through the aid of crystallography, the absolute configurations of
compounds 11 and 20 were determined. The presence of compounds 2, 6, 7, and 10 in the
extracts of N. mitis may account for its anti-secretory activity and there by its antidiarrheal
activity as acclaimed by TM practitioners. The most active CFTR inhibitor, compound 10 (IC50 =
0.81 ± 0.19 µM) was found to be relatively safe with an IC50 value of >29.6 µM against Vero
cells and 57.30±6.77 µM against BHK21 cells. Therefore this compound can serve as a potential
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lead candidate for drug development towards the treatment of secretory diarrhea. Compound 2
showed a remarkable ability to relax the rhythmic contraction of isolated jejunum, indicating its
ability to reduced GIT motility and ultimately diarrhea, although it remains unclear why
compound 2 gave lower inhibitory activity against CO induced diarrhea in rats, poor absorption
or bioavailability may be a factor. However, the dose dependent inhibitory activity on CO
induced diarrhea in rats exhibited by compound 7, may explain the inhibition of CO induced
diarrhea in rats by the crude aqueous extract (ABAQ) as described in Chapter 2 of this thesis,
being that 7 was also isolated from the chloroform portion of the crude aqueous extract (ABAQ).
Therefore, the results from four independent models in our collective studies, including; cAMPdependent Cl− channel, TMEM16A Cl- channel, CO induced diarrhea and the isolated tissue
technique (organ bath) brought to light the anti-secretory and anti-motility potential of N. mitis
thereby giving credence to its traditional usage in diarrhea therapy, and therefore validates its
anti-diarrheal activity.
Neither the crude extracts nor the pure compounds from N. mitis showed inhibitory activity
against the bacteria tested in this study; therefore diarrhea that may result from these microbes
may not be managed by N. mitis.
Searching for new bioactivities from N. mitis was also productive, as the crude extracts and
compounds 10 and 19 inhibited AA and AG, showing their potential in the treatment of diabetes
type II. The ability for compound 10 to have both anti-diarrheal and antidiabetic potential should
stimulate further research, and the current drugs used in the management of type II diabetes
cause diarrhea as a side effect. The DCM crude extract and compounds 7, 10, 11, 16 and 17
were active against trypanosome, however, the crude extract and compounds 16 and 17 were
found to be toxic. Compound 11 could serve as a lead compound in the development of a new
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anti-trypanosome drug since it showed good inhibitory activity and it is relatively safe.
Compound 20 showed excellent inhibitory activity against both strains of Plasmodia (TM4/8.2
and K1CB1), 20 is definitely a lead compound to consider for anti-malaria drug development,
and especially as it is also not cytotoxic (Table 3.8) with high a safety ratio. With the increase
rates in drug resistance by causative agents of disease, there is no better time to search for new
bioactivities to reveal lead compounds for the development and enhancement of new drugs.
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CHAPTER 4
Phytochemical and biological activity studies of Hydnora abyssinica A. Braun
(Hydnoraceae)
4.0 Introduction
Hydnora abyssinica is a known medicinal plant among TM practitioners and rural dwellers in
some African countries, in South Africa and Mozambique, H abyssinica is traded by traditional
medicine vendors,34,165 while in Nigeria, in Kanke Local Government Area (LGA), where the
plant was first sighted, the TM practitioners and indigenous people usually harvest the plant
during its season for personal and commercial purpose, it is said to be sold in the Kabwir local
market of Kanke LGA to TM traders from Kano State.21,33 While this plant is rare and not
popular among botanists and plant scientists, it is common to the harvesters, TM vendors and the
communities who use natural resources.34 It is used for the treatment of bacterial infections,
cholera, dysentery and tonsillitis in Sudan, while in Kenya, it is useful for the removal of
retained placenta in animals and to treat dysentery, stomach and throat aches. It is primarily used
in South Africa, Malawi and Mozambique to treat diarrhea, internal wounds, severe bacterial
infections such as UTI (urinary tract infection), helminthiasis, piles, acne, stomach cramps, and
menstrual problems and to stop bleeding. The TM practitioners in Nigeria utilize it for the
effective management of diarrhea.21,34,165-170, In our preliminary studies reported in Chapter 2 of
this thesis, the aqueous root extract from H. abyssinica showed significant inhibition of castor oil
induced diarrhea in albino rats, revealing its ability to treat the symptoms of diarrhea as
acclaimed by TM practitioners.30 The antibacterial, antifungal and cytotoxicity of the crude
extracts and chemical constituents of this plant were carried out in in-vitro studies, these studies
revealed that H. abyssinica can be a good natural source of bioactive compounds such as
catechins, protocatechuic acid and vanillin, and these compounds showed no cytotoxicity.166,171
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The immunosuppressive activity of the phenolic compounds from this plant was also studied,
and the compound catechin had the most potent immunosuppressive activity among the
compounds tested.169 H. abyssinica has also been studied for its cytotoxicity, antibacterial,166
antioxidant,172 molluscidal173 and antidiarrheal activities.30
In this study, we isolated the phytochemical constituents from H. abyssinica, and the constituents
together with the crude extracts from this plant were evaluated for their biological activities
against CFTR, and for their antidiarrheal activities. They were also tested against bacteria, fungi,
Trypanosoma brucei, Mycobacterium tuberculosis and Plasmodium falciparum, and for their αamylase (AA) and α-glucosidase (AG) inhibitory activities.
4.1 Results and discussion
4.1.0 Organic solvent extraction of plant material from the roots of H. abyssinica
Following a successive extraction of H. abyssinica dried pulverized roots with DCM and
ethanol, the DCM and ethanol extracts were obtained, and their colour, appearances and
percentage yield are recoded in Table 4.1. The DCM extract was coded KDCM while the ethanol
extract was coded KEOH. The higher yield of 10.3% obtained from the ethanol extract (KEOH)
compared to the yield of 1.0% obtained from the DCM extract (KDCM) could be attributed to
the fact that polar and semi-polar constituents from plant materials are likely to be dissolved
more in ethanol giving a higher percentage yield of KEOH.174
Table 4.1 Physical appearance and percentage yield based on dry mass of DCM and ethanol
extracts from H. abyssinica
Extract
KDCM

Colour/appearance
Brick red solid

Dry plant
material (g)
1000

Amount of
extract (g)
10.0

Percentage
yield (%)
1.0

KEOH

Crystal like dark brown solid

970

100.0

10.3
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4.1.1 Isolation of pure compounds from the crude KEOH extract
The crude extract KEOH from H. abyssinica was selected for the isolation procedure based on its
preliminary bioactivity and TLC profile; the compelling preliminary bioactivities of this extract
are discussed in the Results and Discussion section of this chapter. It was subjected to
purification by CC using silica gel and Sephadex-LH20 to obtained two known compounds; (+)catechin (26),169,175 and salidroside (27)176 (Fig. 4.1). Attemps to purify the other fractions by CC,
PTLC or Sephadex LH20 were unsuccessful in obtaining further pure compounds, and due to
time constrainsts attempts to separate fractions by HPLC could not be initiated.

Figure 4.1 Compounds isolated from the roots of H. abyssinica

Previously, the phytochemical studies on the roots of H. abyssinica revealed the presence of
catechin (26), cirsiliol (28), trans 3,5-dihydroxy-4,7-dimethoxydihydroflavonol (29), vanillin
(30), protocatechuic acid (31), stigmasterol (32), myristic acid (33), palmitric acid (34) and oleic
acid (35).166 While, catechin (26), tyrosol and ethyl 3,4,-dihydroxybenzoate, were isolated from
the whole plant only.169 (Fig. 4.2) Based on this current search, salidroside (27) is isolated from
this plant for the first time.
4.1.2 Biological activities of crude extracts and compounds from H. abyssinica
4.1.2.0 CFTR inhibitory activity
All the extracts (KAQ, KDCM and KEOH) and compounds 26 and 27 from H. abyssinica were
found to be inactive against CFTR. From our previous studies recorded in Chapter 2 of this
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thesis, the aqueous extract (KAQ) showed its ability to reduced defecation by 82% at 400 mg/Kg
in a CO induced diarrhea.30 This may be an indication that the antidiarrheal potential of H.
abyssinica may be mediated through mechanisms other than CFTR inhibition.

Figure 4.2 Previously isolated compounds from the roots H. abyssinica

The antidiarrheal activity of compound 26 was evaluated on its ability to reduce intestinal
motility and to inhibit castor oil induced diarrhea, since KAQ significantly reduced both
intestinal motility and defaecation induced by castor oil in rats. From TLC analysis compound 26
appears to be the most abundant constituent in the roots of H. abyssinica, hence we isolated it in
sufficient quantity for both animal experiments.
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4.1.2.1 Gastrointestinal transit of activated charcoal in rats treated with compound 26
There was no significant reduction in the intestinal motility of rats treated with compound 26 at
all dose levels, when compared to the negative control (water) (Table 4.2). Compound 26 may
not be responsible for this same activity shown by KAQ, if it contributes to this activity, it may
be acting in synergy with other constituents in the KAQ that were not isolated in the separation
process.
Table 4.2 Percentage intestinal transit of charcoal meal in rats treated with compound 26
Treatment
Water 10 mL/kg
5 mg/kg (26)
10 mg/kg (26)
20 mg/kg (26)
Atropine 5 mg/kg

Total length of
intestine (cm)
97.33±1.37
94.00±3.66
88.33±4.99
100.33±2.73
93.00±0.89

Distance travelled by
charcoal mean (cm)
83.67±5.41
72.33±7.17
76.33±1.81
74.33±3.24
49.67±4.59

% intestinal
transit
86.17±8.09
76.37±6.04
86.96±3.90
74.03±2.69
53.58±7.06a

Values are expressed as mean±SEM (n=3). a= p≤0.05 significantly different compared to water.

4.1.2.2 Inhibition of castor oil induced diarrhea in albino rats by compound from H.
abyssinica
Oral administration of catechin (26) at 3 dose levels of 5 mg/kg, 10 mg/kg and 20 mg/kg, lead to
the reduction of defecation in albino rats, with the highest inhibition of 59.97% in the group
treated with 20 mg/kg, when compared to the negative control (water) which offered no
protection against castor oil induced diarrhea (Table 4.3). Compound 27 may be responsible in
part for the significant reduction of castor oil induced diarrhea shown by the crude KAQ
extract.30
Table 4.3 Percentage inhibition of defecation of rats treated with compound 26
Treatment
Castor oil + Water 10 mL/kg
Castor oil + 5 mg/kg (26)
Castor oil + 10 mg/kg (26)
Castor oil + 20 mg/kg (26)
Castor oil + Loperamide 10 mg/kg

Mean defaecation
in 6 hrs
6.67±1.67
3.67±1.20
4.00±1.53
2.67±0.33
1.00±0.58a

% inhibition of
defaecation
44.98
40.03
59.97
85.01

Values are expressed as mean±SEM (n=3). a= p≤0.05 significantly different compared to water.
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4.1.2.3 Effects of compound 26 on the isolated rabbit jejunum
Compound 26 did not abolish rhythmic contraction of the rabbit jejunum (Fig. 4.3). Therefore
compound 26 may not be responsible for the reduction of the intestinal motility showed by KAQ,
and perhaps other compounds not isolated in the separation process are responsible for this
action.
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Figure 4.3 Effect of Compound 26 on isolated rabbit jejunum

4.1.2.4 Antibacterial and antifungal activities of extracts and compounds from H.
abyssinica
The screening of crude extracts and the two phytochemical constituents from H. abyssinica
against some causative agents of diarrhea was carried out. None of the crude extracts or
compounds showed inhibition of any of the fungal or bacteria organisms tested in this study
(Table 4.4). Similarly, previous studies reported that the aqueous crude extract from this plant
which is used traditionally in the therapy of diarrhea did not inhibit the bacteria species
responsible for diarrhea, including, Escherichia species, Salmonella species, Shigella species, or
Yersinia species. This leads to the suggestion that the potency of this plant in the treatment of
diarrhea may be due to it physical properties, since it has high concentration of tannins known to
impart strong astringency and bitterness known to aid with the treatment of intestinal
ailments.32,166
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Table 4.4 Anti-microbial activity of crude extracts and compounds from H. abyssinica
Compound/
Extract
(32 g/mL)
KAQ
KEOH
KDCM
26
27

Bacteria and Fungi growth inhibition (%)
Sa
32.99
21.64
27.01
-11.2
2.4

Ec
11.24
12.12
4.68
27.94
5.21

Kp
21.68
9.04
20.46
18.0
11.86

Pa
18.88
16.33
22.35
6.55
6.07

Ab
5.63
-3.56
7.77
20.52
8.42

Ca
7.31
8.67
6.35
1.28
4.83

Cn
-37.03
-46.4
-26.94
-23.48
14.11

Abbreviations Sa- Staphylococcus aureus; Ec- Escherichia coli; Kp- Klebsiella pneumoniae; Pa- Pseudomonas aeruginosa;
Ab- Acinetobacter baumannii; Ca- Candida albicans; Cn- Cryptococcus neoformans var. grubii.

4.1.2.5 Cytotoxicity of crude extracts and compounds from H. abyssinica
The crude extracts and the two isolated compounds were assayed for cytotoxicity against the
mouth epidermal carcinoma cells (KB), the kidney epithelial cells of an African green monkey
(Vero) and baby hamster kidney fibroblast (BHK21) cell lines were used to ascertain their effects
on normal cells (Table 4.5). All the extracts and compounds were found to be non-toxic on Vero
and BHK21 cells. The result showed that both the KAQ and KEOH extracts had low toxicity on
KB cells with IC50 values of 73.5±1.1 µg/mL and 74.1±1.8 µg/mL, respectively, this is similar to
the previous report on the cytotoxicity of this plant.166 Compounds 26 and 27 had IC50 values of
>100 µM on BHK21 cells, this shows that the extracts and these compounds can be considered
as relatively safe.
4.1.3 Other biological activities of H. abyssinica
4.1.3.0 α-Glucosidase (AG) and α-amylase (AA) inhibitory activity of H. abyssinica
The crude extracts and the two pure compounds were screened for their inhibitory activities
against α-glucosidase. The extracts showed significant inhibitory activities, all more than 90%
higher than acarbose, which had a percentage inhibitory activity of 71.3 ± 3.8% (Table 4.6). The
IC50 values of all the crude extracts were further analysed against α-glucosidase and α-amylase,
the ethanol extract (KEOH) displayed the strongest activity with IC50 values of 0.2 ± 0.09 µg/mL
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Table 4.5 Cytotoxicity of crude extracts and isolated compounds from H. abyssinica
Compounds (µM)/
Crude
Extracts
(µg/mL)
KAQ Extract
KEOH Extract
26
27
Ellipticine

Cytotoxicity
(IC50)
KB
73.5±1.1
74.1±1.8
0.95±0.34

VERO
78.1±6.6
74.7±12.9
1.02±0.29

BHK21
>50
>100
>100
-

and 0.05 ± 0.02 µg/mL against AG and AA, respectively (Table 4.7). This is an indication that
the extracts may possess some level of anti-glycaemic effect. The pure compounds were also
screened at 250 µg/mL for their AG inhibitory activities, and compound 26 showed significant
inhibitory activity of 97.5 ± 0.6%, when compared to acarbose at 86.5 ± 0.4% (Table 4.8).
Compound 26 also had modest IC50 values of 0.36 mM and 2.26 mM against AG and AA,
respectively.
Table 4.6 AG inhibitory activity of H. abyssinica crude extracts
Extract (500 µg/mL)
in 50% DMSO
KAQ
KDCM
KEOH
Acarbose 0.1M

% Inhibition
93.5 ± 10.3
99.2 ± 1.8
99.2 ± 1.4
71.3 ± 3.8

DMSO 50%

0

Table 4.7 IC50 of H. abyssinica crude extracts against AG and AA
Crude extracts
in 50% DMSO
KAQ
KDCM
KEOH
Acarbose 0.1M

AG
IC50 (µg/mL)
0.7 ±0.06
3.4 ±1.20
0.2 ±0.09
438.5 ± 4.90

AA
IC50 (mg/mL)
0.31 ±0.014
0.59 ±0.05
0.06 ± 0.02
0.44 ± 0.10
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Table 4.8 AG inhibitory activity of the compounds from H. abyssinica
Extract (250 µg/mL)
in 50% DMSO
26
27

% Inhibition
97.5 ± 0.6
47.7 ± 1.8

Acarbose 0.1M

86.5 ± 0.4

DMSO 50%

0

These values are comparable to that of acarbose, which had IC50 values of 0.91 mM and 0.68
mM against AG and AA, respectively (Table 4.9). Catechin (26) was isolated from KEOH which
may have contributed to the significant inhibitory activity observed against AG and AA. It is
known for its bioactivities and health benefits, and studies have revealed its ability to treat
diabetes and its complications through the modification of oxidative stress.177-178
Table 4.9 IC50 values of the compounds from H. abyssinica against α-glucosidase (AG) and αamylase (AA)
Compounds
in 50% DMSO
26
27
Acarbose

AG
IC50 (mM)
0.36
1.38
0.91

AA
IC50 (mM)
2.26
ND
0.68

ND: not determined

4.1.3.1 The anti-tuberculosis, anti-trypanosoma and anti-malaria activity of the extract and
compounds from H. abyssinica
The extract KEOH and 26 and 27 were tested for their inhibitory activities against
Mycobacterium tuberculosis, Trypanosoma brucei rhodesiense, and Plasmodium falciparum
(Table 4.10). Although none of these compounds were active against these organisms, KEOH
showed a moderate activity against T. brucei rhodesiense, this may be as a result of synergistic
effects in the extract or due to the active compound/compounds responsible for this activity not
being isolated.
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Table 4.10 Inhibitory activities of isolated compounds from H. abyssinica against M.
tuberculosis, T. brucei rhodesiense, and P. falciparum
Compounds (µM)
Crude
Extracts
(µg/mL)

MTB
H37Rv
(MIC µM)

T.br
(IC50 µM)

P.f (IC50 µM)
TM4/8.2

K1CB1

KEOH
26
27

>20
>20
>20

18.14 ± 1.34
>100
>100

>50
>100
>100

>50
>100
>100

Isoniazid
Rifampin
Cycloguanil
Pyrimethamine
Pentamidine

0.02
0.08
-

-

0.076±0.016
0.095±0.02
-

10.7±1.62
23.21±2.24
-

0.007±0.00004

Abreviation; MTB - Mycobacterium tuberculosis; T.br- Trypanosoma brucei rhodesience; P.f- Plasmodium falciparum,
SR- Safety Ratio

4.2 Conclusions
The isolation of compounds from H. abyssinica led to the characterization of two known
compounds (26 and 27). The antidiarrheal activity of H. abyssinica can be attributed partly to the
presence of catechin (26), which reduced defecation induced by castor oil induced diarrhea in
rats giving credence to its traditional usage in diarrhea therapy. Catechin (26) also showed
significant activity against α-glucosidase (AG) and α-amylase and may be partly responsible for
the activity shown by the crude extracts, it was also determined to be relatively non-cytotoxic.
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CHAPTER 5
Phytochemical and biological activity studies of Senna surattensis (Burm. f.) H. Irwin and
Barneby (Fabaceae)
5.0 Introduction
Senna surattensis is an ornamental plant which is spread across many tropical and subtropical
countries including Nigeria, it is used as food and also known for its medicinal properties. S.
surattensis serves as an ingredient in herbal mixtures with other medicinal plants for synergistic
effects. The treatment of gonorrhoea and snake bites are carried out by using the roots of this
plant and the leaves are used for the treatment dysentery and diarrhea, while the flowers are used
as a purgative.179-180 From the many studies conducted on S. surattensis, it has shown a variety
of bioactivities, the crude extracts and constituents have shown antioxidant,181-183 antidiabetic,184185

antimicrobial,181,186

hepatoprotective,183,187

antidiarrheal,30

anti-hyperlipidimic

and

antihyperglycemic188 properties. In Chapter 2 of this thesis, we demonstrated that the crude
aqueous extract from S. surattensis showed significant antidiarrheal activity by reducing
defecation induced by castor oil in rats by 81%. This promising initial result has led to further
studies on the isolation of the phytochemical constituents from this plant. The crude extracts and
constituents from this plant were evaluated for their biological activities against CFTR,
Trypanosoma brucei, Mycobacterium tuberculosis and Plasmodium falciparum, and for their
antimicrobial, α-amylase (AA) and α-glucosidase (AGO) inhibitory activities.
5.1 Results and discussion
5.1.0 Organic solvent extraction of plant material from the leaves of S. surattensis
The dried, pulverized leaves from S. surattensis were successively extracted with DCM and
ethanol to obtain the DCM and ethanol extracts coded as CDCM and CEOH, respectively. The
appearance, colour and percentage yields of the extracts were recorded (Table 5.1).
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A higher yield of 11.6% were obtained from the ethanol extract (CEOH) where compare to the
2.7% yield from the DCM extract (CDCM), this is expected as polar and semi-polar constituents
of plant material are known to dissolve more in ethanol, making it possible to produce higher
yields.174
Table 5.1 Physical appearance and percentage yield based on dry mass of DCM and ethanol
extracts from S. surratensis
Extract
CDCM

Colour/appearance
Green solid

Dry plant
material (g)
405

Amount of
extract (g)
11.0

Percentage
yield (%)
2.7

CEOH

Green sticky solid

380

44.0

11.6

5.1.1 Isolation of pure compounds from crude CEOH extract
The crude CEOH extract was selected for isolation based on its TLC profile and its promising
preliminary bioactivity findings which are discussed in the Results and Discussion section of this
chapter.The isolation of compounds from CEOH gave the three known compounds, (+)-catechin
(26) (Fig. 4.1), kempherol (36)189 and quercetin (37)187 (Fig. 5.1).

Figure 5.1 Compounds isolated from the leaves of S. surattensis

In previous phytochemical studies on S. surrattensis, the leaves yielded three compounds;
quercetin (37), rutin (38), and quercetin 3-O-glucoside 7-O- rhamnoside (39)187,190 (Fig. 5.2), the
isolation of compounds from the pods gave; 5,7-dihydroxy-4’-methoxyflavonol-3-O-β-Dgalactopyranoside, chrysophanol, physcion, kaempferide and quercetin.191 From the bark,
chrysophanol and physcion were isolated.192
79

Figure 5.2 Previously isolated compounds from the leaves of S. surrattensis

The stem yielded; 8-hydroxy-6-methoxy-3-methylanthraquinone-1-O-α-L-rhamnopyranosyl(16)-β-D-glucopyranoside,chrysophanol, physcion, stearic acid, β-sitosterol and β-sitosterol-β-Dglucoside,193-194 while isolation of compounds from the seeds yielded; luteolin-7-O-β-Dglucopyranosyl-(1-4)-O-α-L-arabinopyranoside, γ-sitosterolin and digitolutein.195-196 This current
study led to the isolation of compounds 26, 36 and 37, these compounds were isolated from the
leaves of this plant for the first time. The differences in the chemical constituents from the
different parts of this plant may account for the variety of biological activities shown by this
plant, and the different location of plant collection and methods of isolation may also account for
the differences in compounds isolated from the same plant parts.
5.1.2 Biological activities of the crude extracts and isolated compounds from S. surrattensis
5.1.2.0 CFTR inhibitory activity
The crude extracts and compounds from S. surrattensis were screened for their inhibitory activity
against CFTR. Compound 36 was found to inhibit forskolin-stimulated Cl- secretion in T84 cells
in a dose-dependent manner, with an IC50 value of ~3.05 μM with near complete inhibition
observed at 20 μM (Fig. 5.3). Although none of the crude extracts were active against CFTR, the
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inhibitory activity shown by 36 could be due to the low level content of 36 in the crude extracts
not enough to enact an inhibitory activity,197 this is consistent with its very low percentage yield
of 0.01%. Furthermore, identifying a potential CFTR inhibitor from S. surrattensis highlights the
importance of isolation of pure compounds from crude extracts as active compounds could show
more targeted activity than their crude extracts.143

A

[Compound 36] (μM)

B

[Compound 36] (μM)
Figure 5.3 Effect of 36 on cAMP-induced Cl- secretion in T84 cells. (A) Representative ISC tracing in response to 20 μM
forskolin with indicated concentrations of 36 being added into apical solutions. (B) Data were fitted to the Hill’s equation.

5.1.2.1 Antidiarrheal activity of compound from S. surrattensis
Compound 26 (Fig. 3.1) was also isolated from S. surrattensis, and it showed significant
inhibitory activity against CO induced diarrhea as discussed in Chapter 4 (Table 4.3), therefore
26 may be partly responsible for the inhibition of CO induced diarrhea shown by CAQ as
discussed in Chapter 2 of this thesis (Table 2.5), This further explains the science behind its
traditional usage in the treatment of diarrhea by TM practitioners. Due to the insufficient
amounts of compounds 36 and 37 their in-vivo antidiarrheal evaluation was not carried out.
5.1.2.2 Antibacterial and antifungal activities of extracts and compounds from S.
surrattensis
The crude extracts and the compounds isolated from S. surrattensis were tested for their
inhibitory activity against some diarrhea causative bacteria and fungi (Table 5.2).
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Table 5.2 Anti-microbial activity of the crude extracts and pure compounds from S. surrattensis
Compound/
Extract
(32 ug/mL)
CAQ
CEOH
CDCM
34
35

Bacteria and Fungi inhibition (%)
Sa
20.46
15.39
13.82
12.73
10.17

Ec
-3.83
-0.78
-2.56
4.59
7.51

Kp
19.96
14.92
9.77
4.96
9.67

Pa
18.88
20.99
20.28
1.5
-2.4

Ab
-0.05
4.71
-9.49
14.38
19.92

Ca
3.7
14.38
20.53
8.59
2.21

Cn
-21.98
-72.55
-34.91
-6.54
-8.34

Abbreviations Sa- Staphylococcus aureus; Ec- Escherichia coli; Kp- Klebsiella pneumoniae; Pa- Pseudomonas aeruginosa;
Ab- Acinetobacter baumannii; Ca- Candida albicans; Cn- Cryptococcus neoformans var. grubii.

Neither the crude extracts nor the pure compounds showed significant inhibitory activity against
the microorganisms tested. Other studies have revealed the antimicrobial activity of S.
surrattensis, the crude extract from the seeds was active against a wide range of
microorganisms.181 The methanol extract from the flowers showed significant anti-microbial
activity against Aspergillus niger.186 In another studies, the crude flower extract significantly
inhibited a wide range of bacteria and fungi of clinical importance, including; Micrococcus spp.,
Proteus mirabilis, Escherichia coli, Staphylococcus aureus, Enterobacter aerogenes, Salmonella
typhi, Klebsiella pneumoniae, Bacillus subtilis, Shigella sonnei, Azospirillum lipoferum,
Pseudomona aeruginosa, Aspergillus niger and Candida albicans.198 The anti-microbial activity
of S. surrattensis may be attributed to its flowers rather than its leaves as we have not found any
literature reports on the anti-microbial activity of its leaves and our studies too did not result in
the inhibition of any of the microorganisms used in this study. Therefore the antidiarrheal
activity of S. surrattensis may be through another mechanism other than its antimicrobial
activity.
5.1.2.3 Cytotoxicity of crude extracts and compounds from S. surrattensis
Both crude extracts from S. surrattensis did no show cytotoxicity against KB or VERO cells with
IC50 values of >100 µg/mL. The CEOH extract also showed low cytotoxicity with an IC50 value
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of >50 µg/mL against BHK21cells (Table 5.3). The low cytotoxicity on these cells indicates that
these extracts are relatively safe. However, compounds 36 and 37 showed mild cytotoxicity on
BHK21 with IC50 values of 8.88±0.74 µM and 11.53±3.63 µM, respectively. In a previous study,
the crude extract of the seeds was non-cytotoxic on VERO cells and it was also described as antigenotoxic due to its inhibitory effects against H2O2-mediated DNA damage observed in VERO
cells.199
Another study also revealed the ability of the seed crude extract to protect liver cells against
paracetamol induced hepatotoxicity in an in-vivo model study, this is an indication that S.
surrattensis is not only relative safe, but it may also have the ability to protect the cells against
injury and damage.183
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Table 5.3 Cytotoxicity of crude extracts and isolated compounds from S. surrattensis
Compounds(µM)/
CrudeExtracts
(µg/mL)
CAQ Extract
CEOH Extract
36
37
Ellipticine

Cytotoxicity

(IC50)

KB
>100
>100
0.95±0.34

VERO
>100
>100
1.02±0.29

BHK21
>50
8.88±0.74
11.53±3.63
-

5.1.3 Other biological activities of S. surrattensis
5.1.3.0 AA and AG inhibitory activity of S. surrattensis
Following the screening of the crude extracts from S. surrattensis (CAQ, CDCM and CEOH) for
their AGI activities (Table 5.4), all the crude extracts showed significant higher percentage
inhibitory activities of 82.6%, 95.7 %, and 99.1% by CAQ, CDCM and CEOH, respectively,
when compared to the acarbose at 71.3%.
All extracts were further analysed for their IC50 values against both AG and AA, the extracts
Table 5.4 AG inhibitory activity of S. surrattensis crude extracts
Extract (10 µg/mL)
in 50% DMSO
CAQ
CDCM
CEOH
Acarbose 0.1M

% Inhibition
82.6 ± 3.3
95.7 ± 8.5
99.1 ± 8.9
71.3 ± 3.8

DMSO 50%

0

showed significant inhibitory activity against AG and AA compared to acarbose. CEOH gave the
highest inhibitory activity with IC50 values of 1.2 ± 0.1 µg/mL and 0.05 ± 0.02 mg/mL against
AG and AA, respectively. (Table 5.5) These IC50 values were lower than to the IC50 values shown
by acarbose, which were; 438.5 ± 4.9 µg/mL and 0.71 ± 0.01 mg/mL for AG and AA,
respectively.
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Table 5.5 IC50 of the most active S. surrattensis crude extracts against AGO and AA
Crude extracts
in 50% DMSO
CAQ
CDCM
CEOH
Acarbose 0.1M

AG
IC50 (µg /mL)
20.1 ± 0.3
44.9 ± 1.7
1.2 ± 0.1
438.5 ± 4.9

AA
IC50 (mg /mL)
ND
0.59 ± 0.05
0.05 ± 0.02
0.71 ± 0.01

ND: not determined

The significant inhibitory activity of the crude extracts against AG and AA, showed they have
potential use in the management of type II diabetes. This condition occurs when the body
gradually losses its capacity to produce sufficient insulin and the excessive glucose absorption
from the GI tract causes the body to degenerate and become resistant to the normal effects of
insulin.113,200 The digestive enzymes; AG and AA are responsible for the excessive breakdown of
starch or disaccharides and making glucose readily available for uptake by the GIT, therefore the
ability od CEOH to inhibit of these two enzymes significantly is an indication of its ability to act
as potential inhibitor of these enzymes which have been targeted for the effective management of
hyperglycemia and maintaining the blood glucose balance.200-202 This study is in line with a
previous study, which showed the antidiabetic activity of the ethanol crude extract of S.
surrattensis.185 The inhibitory activity of CEOH against AG and AA could be partly attributed to
the presence of catechin (26) which showed significant inhibitory activity as reported in Chapter
4 of this thesis (Table 4.8). Compounds 36 and 37 gave low percentage inhibitory activity of
4.3% and 7.5 %, therefore, their IC50 values against AG and AA were not determined (Table
5.6).
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Table 5.6 AG inhibitory activity of the compounds from S. surrattensis
Extract (250 µg/mL)
in 50% DMSO
36
37

% Inhibition
4.3
7.5

Acarbose 0.1M

86.5

DMSO 50%

0

5.1.3.1 The anti-tuberculosis, anti-trypanosoma and anti-malaria activity of the extract and
compounds from S. surrattensis
CEOH and its isolated compounds were tested against M. tuberculosis, T. brucei rhodesiense,
and P. falciparum, the crude extract showed moderate inhibitory activity against T. brucei
rhodesiense with an IC50 value of 22.89 ± 1.29 μM (Table 5.7).
Compounds 36 and 37 also showed moderate activity against T. brucei rhodesiense which were
higher than that of the crude extracts with IC50 values of 10.35 ± 0.38 µM (SR - 3.3) and 8.44 ±
0.16 µM (SR - 4.52), respectively. The low safety ratio (SR) obtained for these two compounds
is a result of their mild cytotoxicities (Table 5.3). The moderate activity against T. brucei
rhodesiense and the low safety ratio could be improved by a semi-synthetic pathway which could
lead to more potent synthetic analogues and the future development of a new drug against T.
brucei rhodesiense. The crude extracts and its compounds did not show any inhibitory activity
against M. tuberculosis or P. falciparum.
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Table 5.7 Inhibitory activities of isolated compounds against M. tuberculosis, T. brucei
rhodesiense, and P.falciparum
Compounds (µM)
Crude
Extracts
(µg/mL)

MTB
H37Rv
(MIC µM)

CEOH
36

>20
>20

37

>20

Isoniazid
Rifampin
Cycloguanil
Pyrimethamine
Pentamidine

0.02
0.08
-

P.f (IC50 µM)
T.br
(IC50 µM)

TM4/8.2

K1CB1

22.89 ± 1.29
10.35 ± 0.38
SR - 3.3
8.44 ± 0.16
SR - 4.52

>50
39.90±13.16

>50
86.06±12.39

75.00±8.93

50.58±14.26

-

0.076±0.016
0.095±0.02
-

10.7±1.62
23.21±2.24
-

0.007±0.00004

Abreviation; MTB - Mycobacterium tuberculosis; T.br- Trypanosoma brucei rhodesience; P.f- Plasmodium
falciparum, SR- Safety Ratio

5.2 Conclusions
The isolation of pure compounds from S. surrattensis led to the characterization of three known
compounds (26, 36 and 37). The inhibitory activity against against α-glucosidase (AG) and αamylase (AA) and the antidiarrheal activity shown by 26, means that it could serve as a lead in
the development of a drug for the management of type II diabetes. This study also led to the
identification of compound 36 as a CFTR inhibitor, and 26 also showed a significant reduction of
defecation in CO induced diarrheic rats just like the aqueous extract (CAQ).30 Therefore the
ability of S. surrattensis to show antidiarrheal activity in two independent models further gives
credence to its traditional use as antidiarrheal therapy as acclaimed by TM practitioners.
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CHAPTER 6
Conclusions and highlights
6.0 Conclusions
Medicinal plants have remained a source of natural product remedies for the sustainance of
human and animal health, espercially in rural communities in developing countries. In the
developed countries, there is an inreases interest in the utitilization of medicines from plants due
to their beneficial health effects. Natual products from medicinal plants used in traditional
medicine have inspired the development of drugs against many diseases. In developing countries,
medicinal plants have been useful remedies in the management of the symptoms of diarrhea,
TMPs and rural dwellers have uterlized the effectiveness of certain medicinal plants to treat the
symtoms of diarrhea. Neorautanenia mitis, Hydnora abyssinica, Senna surattensis and Vitellaria
paradoxa are medicinal plants known and claimed by TMPs as effective remedies for the
treatment of diarrhea in Nigeria. The crude extracts from these plants showed inhibition of CO
induced diarrhea in albino rats. N. mitis, H. abyssinica, S. surattensis gave interesting inhibitory
activities, therefore further evaluation of their phytochemical constituents were studied against
diarrhea and other biological targets. Multiple compounds including; dolineon (10), neodulin (2),
pachyrrhizine (6) and neotenone (7) with CFTR inhibitory activity were isolated from N. mitis,
neotenone (7) also showed inhibition against CO induced diarrhea while neodulin (2) showed
significant soft muscle relaxant activity. These activities which were obtained from three
independent models suggest and identify the compounds which are responsible for the
antidiarrheal activity of N. mitis as acclaimed by TMPs. Catechin was isolated from both H.
abyssinica and S. surattensis, and it showed inhibitory activity against CO induced diarrhea in
albino rats, catechin may have contributed to the same activity shown by the aqueous extracts of
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both H. abyssinica and S. surattensis. Compound 36 (1,4,5,7-tetrahydroxy-9H-xanthan-9-one)
was isolated from S. surattensis, it showed CFTR inhibitory activity, these activity provides
evidence and give credence for the traditional use of this plant. All these compounds have shown
low cytotoxicity and can serve as potential candidates in the development of anti-secretory drugs
to aid in the management of diarrheas of multiple aeteology.
The screening of known medicinal plants in order to identify new bioactivities is useful in drug
discovery, and the contituents from these plants were screened for their anti-tuberculosis, antitrypanosoma and anti-malaria, antimicrobial, anti α-amylase (AA) and anti α-glucosidase (AG)
properties. Rautandiol B was isolated form N. mitis and showed significant inhibitory activities
against two strains of Plasmodium falciparum (TM4/8.2 and K1CB1), it also gave a high safety
ratio and proved to be non-cytotoxic and a likely candidate for the development of new anti
malarial drug. Compound 11; (-)-2-isopentenyl-3-hydroxy-8-9-methylene dioxypterocarpan,
from N. mitis showed significant inhibitory activity against T. brucei rhodesiense. The crude
extracts from these plants and two compounds including dolineone (10) and rautandiol A (19)
from N. mitis together with catechin (26) from H. abyssinica and S. surattensis, showed modest
inhibitory activity against AG and they can be considered for further development as therapy for
type II diabetes. Identification of different bioactivities from these plants shows the importance
of screening medicinal plants for other activities from the ones they are known for.
6.1 Highlights of the research
 Traditional medical (TM) practitioners gave useful information towards isolation of bioactive
natural product compounds.143
 Known natural product compounds with different bioactivities with potential for new drug
discovery.143
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 Identified inhibitors of CFTR and TMEM16A as potential leads for antidiarrheal therapy.143
 The presence of multiple compounds with CFTR inhibitory activity in the extracts of N. mitis
may account for its anti-secretory activity and there by its antidiarrheal activity as acclaimed
by TM practitioners.143
 Identified known medicinal plants with newly discovered bioactivities.
 Identification of potential lead compounds for the development of drugs for malaria,
trypanosoma and diabetes type II.
6.2 Future work
1. Phytochemical studies on all of the aqueous extracts from these plants will give more
insight into the phytochemical constituents that are responsible for the biactivities
attributed to the crude aqueous extracts.
2. Further phytochemical studies on the crude ethanol extract of H. abyssinica using HPLC
techniques may result in the isolation of more compounds which were not isolated by
CC.
3. Enriching the crude extracts with other natural products may potentiate or enhance the
biocativities of the extracts for drug formulation.
4. The synthesis of analogues of the active compounds and further biological testing is
highly recommended.
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CHAPTER 7
Experimental
7.0 General experimental procedures
Compounds were isolated from the plant extracts using the chromatography techniques; CC over
normal phase silica gel or Sephadex (LH20) or by PTLC. Bands of separation on TLC and PTLC
were observed using a spectroline model florescence analysis cabinet (CM-10) under ultraviolet
short wave (254 nm). TLC analysis was also made by staining the developed plates with cerium
ammonium molybdate to reveal the separated metabolites. The structures of all isolated
compounds were elucidated using the following spectroscopic methods; IR, MS, NMR (1D and
2D), MP, CD and optical rotation. IR spectra were measured on a FTIR Shimadzu IRAffinity-1
with MIRacle, the specific rotations were measured on Jasco P-2000 polarimeter while the CD
and UV spectra were analysed on a Jasco J-810 spectropolarimeter. The MS were measured on a
LCMS-2020 Shimadzu for ESI and HRSIMS on a Thermo Scientific Electron Transfer
Dissociated (ETD) Orbitrap Fusion FSN 10314-1. The NMR data was recorded on Bruker
Avance with Cryoprobe (1H NMR 500 MHz, 13C 126 MHz) and Bruker Ascend (1H NMR 400
MHz, 13C 101 MHz) using deuterated chloroform (CDCl3) and d4-methanol (CD3OD) as solvents
with TMS as an internal standard solvent, with a residual chemical shifts of 7.26 and 3.31 in
CDCl3 and CD3OD, respectively. Melting points were measured on a Buchi M.560 apparatus and
optical rotations were measured on a Jasco P-2000 polarimeter. The short-circuit current and
chloride current (Isc , ICl-) were measured on using a DVC-1000 voltage-clamp (World Precision
Instruments, Sarasota, FL, U.S.A.) with Ag/AgCl electrodes and 1 M KCl agar bridges.
7.1.0 Plant Material
7.1.1 Selection and identification of plant materials
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The selection of the plants was made with the assistance of a TM practitioner, Mr Yilnya
Gosomji. All the plants were collected from Kabwir Village in Kanke Local Government Area of
Plateau State, Nigeria (Latitude 9o 29ʹ 18.2ʹʹ N and 9o 29ʹ 30.0ʹʹ E) in July 2016. The plants were
submitted to the Department of Plant Science and Technology Faculty of Natural Sciences
University of Jos, Nigeria for identification. The plants were identified by Mr Otuwose Agyeno
and samples were deposited in the University of Jos herbarium with voucher/reference numbers
allocated. Below are the details of the plants identified;
Neorautanenia mitis (A. Rich) Verdc. synonyms: Dolichos mitis A. Rich. Neorautanenia
pseudopanchyrhiza (Harms) Milne-Redh. family: Fabaceae common name: Abargora, voucher
number: UJH16000246. Hydnora johannis Becc., synonyms: Hydnora bogosensis Becc.,
Hydnora abyssinica A. Br. ex Decne., Hydnora gigantean Chiov., family: Hydnoraceae,
common name:Kaushen kasa, voucher number: UJH16000252. Senna surratensis (Burm. f.) H.
Irwin and Barneby, synonyms: Cassia fastigiata Vahl, Cassia glauca Lam., Senna speciosa
Roxb, family: Fabaceae, common names: Golden or Bush Senna, voucher number:
UJH16000248. Vitellaria paradoxa C.F. Gaertn, synonym: Butyrospermum paradoxum (Geartn.
f.) Hepper, family: Sapotaceae, common name: Shea butter tree, voucher number:
UJH16000245.
7.2.0 Biological activities
7.2.1 Short-circuit current (ISC) and apical Cl- current (ICl-) measurement (Performed by
Muanprasat, C. Mahidol University, Samutprakarn Thailand)
T84 and Calu-3 cells were obtained from American Type Culture Collection (Manassas, VA,
USA). As reported by Dawurung et al. 2020,143 the cells were maintained in Dulbecco’s
modified eagle media (DMEM) and Ham’s F-12 medium (1:1) supplemented with 10% fetal
bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin, at 37 °C under a humidified
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95% O2/5% CO2 atmosphere. T84 and Calu-3 cells at the density of 5×105 cells/insert were
seeded in snapwellTM insert, and cultured in a humidified incubator with replacement of the
cultured medium on alternate day. After transepithelial electrical resistance of the cells
monolayer reached 1000 Ω•cm2 as measured by an EVOM2 volt-ohm meter (World Precision
Instruments, Sarasota, Florida, USA), the cells were mounted in an Ussing chamber. For ISC
analysis, both hemichambers were filled with Kreb’s solution (pH 7.4) containing 20 mM NaCl,
25 mM NaHCO3, 3.3 mM KH2PO4, 0.8 mM K2HPO4, 1.2 mM MgCl2, 1.2 mM CaCl2 and 10
mM glucose. For apical ICl- analysis, basolateral-to-apical Cl- gradient buffers were applied. The
basolateral high Cl- buffer (pH 7.4) was composed of 130 mM NaCl, 2.7 mM KCl, 1.5 mM
KH2PO4, 1 mM CaCl2,0.5 mM MgCl2, 10 mM Na-HEPES (pH 7.4) and 10 mM glucose. In
apical low Cl- buffer (pH 7.4), 65 mM NaCl was substituted with 65 mM sodium gluconate, and
the CaCl2 concentration was increased to 2 mM. In addition, amphotericin B (250 µg/mL) was
added into the basolateral solution 20 min before ICl- measurement to capacitate basolateral
membrane permeabilization. The solutions were maintained at 37 ºC with bubbling of 95%
O2/5% CO2 for the ISC measurements, or 100% O2 for the ICl- measurements.150,156
7.2.2 Experimental animals
Young adult (12 weeks old) Wister albino rats of both sexes and the adult rabbit were obtained
from a commercial breeder farm. The rats were kept in metal cages lined with wood shavings
and allowed to adjust to the laboratory environment for a period of two weeks before the
commencement of the experiments. The rats were housed in spacious cages (6 rats per cage size
17 x 13 inches) prior to the experimental groupings. They were fed on pelletized rodent feed
from Dagom Farms of the National Veterinary Research Institute (NVRI) Vom, and water was
provided ad libitum.
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7.2.3 Ethics approval and consent to participate
Ethics approval for animal use was obtained from the Animal Use and Care Committee (AUCC)
of National Veterinary Research Institute (Approval number–ACE\02\78\19). No consent
approval was required for this study.
7.2.4 Castor oil induced diarrhea for pure compounds (Performed by Dawurung, C. J. NVRI
Vom Nigeria)
For each pure compound, nine rats of both sexes weighing between 90-146 g were used for the
experiments. The rats were fasted for 12 h before the commencement of the experiment, having
access to water only. The rats were randomly allocated into 3 groups of 3 rats each. Groups 1, 2
and 3 were given graded doses (5, 10, 20 mg/kg) of the pure compounds reconstituted in distilled
water. A total of nine rats divided in 2 groups of 3 rats each were used as control, the first group
was given distilled water (10 mL/kg), while the second was given loperamide (10 mg/kg). All
The rats were then housed singly in a perforated cage lined with white blotting paper. One hour
after the above treatment, all the rats in the groups were given 1 mL of castor oil orally. The rats
were observed for 5 h for watery (wet) or unformed faeces. The watery faeces from each rat were
counted hourly for up to 5 h. At the end of the experiment the group mean faeces was obtained
and the percentage of protection calculated using the formula.43,203
% 𝑃𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛 =

𝑀𝑒𝑎𝑛 𝑢𝑛𝑓𝑜𝑟𝑚𝑒𝑑 𝑓𝑒𝑐𝑒𝑠 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
× 100
𝑀𝑒𝑎𝑛 𝑢𝑛𝑓𝑜𝑟𝑚𝑒𝑑 𝑓𝑒𝑐𝑒𝑠 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

7.2.5 Gastrointestinal transit of charcoal for pure compounds (motility test) (Performed by
Dawurung, C. J. NVRI Vom Nigeria)
For each of the compounds, 9 rats of both sexes weighing between 90-146 g were used for the
experiments, which were conducted during the day time. The animals were fasted for 16 h before
the commencement of the experiment but allow access to water. They were randomly divided
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into five groups of three rats each. Groups 1, 2 and 3 were treated orally with graded doses of the
compounds (5, 10, 20 mg/kg) reconstituted in distilled water. Group 4 were treated with distilled
water, while Group 5 was treated with atropine sulphate. Groups 4 and 5 are the control groups.
Thirty minutes after extract and drug administrations, 1 mL of 5% activated charcoal suspension
in 10% aqueous solution of acacia powder was given orally to each rat. After 30 min of
administering the activated charcoal, the rats were humanely sacrificed and the abdomen opened
to access the intestine. The distance travelled by the charcoal meal from pylorus was measured
and expressed as a percentage of the total length of intestine from pylorus to the caecum to
calculate the percentage intestinal transit of activated charcoal.43,65
% 𝐼𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑎𝑙 𝑇𝑟𝑎𝑛𝑠𝑖𝑡 =

𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑 𝑏𝑦 𝐶ℎ𝑎𝑟𝑐𝑜𝑎𝑙 𝑚𝑒𝑎𝑙
× 100
𝑇𝑜𝑡𝑎𝑙 𝐿𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝐼𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒 𝑓𝑟𝑜𝑚 𝑃𝑦𝑙𝑜𝑟𝑢𝑠 𝑡𝑜 𝐶𝑎𝑒𝑐𝑢𝑚

7.2.6 Isolated rabbit jejunum test (Performed by Gotep, J. J. and Dawurung C. J. University of
Jos Nigeria)
The rabbit jejunum was used to determine the effects of the compounds on the tone of
gastrointestinal smooth muscles. The rabbit weighing 3.2 g was humanely sacrificed by cervical
dislocation and exsanguination. The abdomen was opened and the jejunum was identified by
following it back to the stomach. The intestine was cut at a point not less than 10 cm from the
stomach and not up to the caecum. The jejunum was cut into 2-3 cm pieces and placed in a petri
dish containing Tyrode solution. The tissue was tied at the two ends using a thread. It was tied to
a tissue hook mounted in a 25 mL Panlab automatic organ bath at the lower end and a force
transducer at the other end. A load of 1 g tension was applied on the tissue and it was aerated
using 95 % Oxygen and 5 % carbon dioxide. The tissue was allowed to stabilize for 30 minutes
thereafter, 0.5 mL acetylcholine 10-3 g/ mL was added into the organ bath and the response was
recorded. The tissue was then washed and the compounds were added cumulatively to obtain 30,
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60 and 90 µg/ mL final bath concentrations and the response recorded for each
concentration.159,204-205
7.2.7 Anti-acterial and anti-fungal assays (Performed by the community for open antimicrobial
drug discovery-COADD University of Queensland)
Samples were provided to the collaborator and stored frozen at -20 oC. Samples were prepared in
DMSO and water to a final testing concentration of 32 μg/mL or 20 μM (unless otherwise
indicated in the data sheet), in 384-well, non-binding surface plate (NBS) for each
bacterial/fungal strain, and in duplicate (n = 2), and keeping the final DMSO concentration to a
maximum of 1% DMSO. All the sample-preparation where done using liquid handling robots.
Compounds that showed solubility issues during stock solution preparation are detailed in the
data sheet. All bacteria were cultured in Cation-adjusted Mueller Hinton broth (CAMHB) at 37
o

C overnight. A sample of each culture was then diluted 40-fold in fresh broth and incubated at

37 oC for 1.5-3 h. The resultant mid-log phase cultures were diluted (CFU/mL measured by
OD600), then added to each well of the compound containing plates, giving a cell density of 5 o
105 CFU/mL and a total volume of 50 μL. All the plates were covered and incubated at 37

o

C

for 18 h without shaking. Inhibition of bacterial growth was determined measuring absorbance at
600 nm (OD600), using a Tecan M1000 Pro monochromator plate reader. The percentage of
growth inhibition was calculated for each well, using the negative control (media only) and
positive control (bacteria without inhibitors) on the same plate as references. The significance of
the inhibition values was determined by modified Z-scores, calculated using the median and
MAD of the samples (no controls) on the same plate. Samples with inhibition value above 80%
and Z-Score above 2.5 for either replicate (n = 2 on different plates) were classed as actives.
Samples with inhibition values between 50 - 80% and Z-Score above 2.5 for either replicate (n=2
on different plates) were classed as partial actives. Samples with inhibition values between 50 96

80% and Z-Score above 2.5 for either replicate (n = 2 on different plates) were classed as partial
actives. Fungi strains were cultured for 3 days on Yeast Extract-Peptone Dextrose (YPD) agar at
30 oC. A yeast suspension of 1 x 106 to 5 x 106 CFU/mL (as determined by OD530) was prepared
from five colonies. The suspension was subsequently diluted and added to each well of the
compound-containing plates giving a final cell density of fungi suspension of 2.5 x 103 CFU/mL
and a total volume of 50 μL. All plates were covered and incubated at 35 oC for 24 h without
shaking.
Table 7.1 Names and strains of tested microrganisms
Abreviation
Sa
Ec
Kp
Ab
Pa
Ca
Cn

Name
Staphylococcus aureus
Escherichia coli
Klebsiella pneumoniae
Acinetobacter baumannii
Pseudomonas aeruginosa
Candida albicans
Cryptococcus neoformans var. grubii

Description
MRSA
FDA control
MDR
Type strain
Type strain
CLSI reference
Type strain

Strain
ATCC 43300
ATCC 25922
ATCC 700603
ATCC 19606
ATCC 27853
ATCC 90028
H99;ATCC 208821

Organism
Bacteria
Bacteria
Bacteria
Bacteria
Bacteria
Fungi
Fungi

Type
G+ve
G-ve
G-ve
G-ve
G-ve
Yeast
Yeast

7.2.8 Cytotoxicity (Performed by Kamchonwongpaisan, S. National Center for Genetic
Engineering and Biotechnology, Pathum Thani, Thailand)
Three mammalian cells: KB cells, (mouth epidermal carcinoma cells), Vero cells (kidney
African green monkey epithelial cells) and BHK cells (baby hamster kidney fibroblasts) were
cultured at 37 °C in a 5% CO2 incubator. KB and BHK cells were maintained in DMEM
Dulbecco's Modified Eagle media supplemented with 10% fetal bovine serum (FBS), 3.7 g/L
sodium bicarbonate and 1% MEM non-essential amino acids. For BHK21 cell, the media was
also supplemented with 1% glutamax. Vero cell was maintained in in Minimal Essential Medium
with Earle’s salts (MEM/EBSS) supplemented with 10% FBS, 2.2 g/L sodium bicarbonate and 1
mM sodium pyruvate.
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For in vitro cytotoxicity assays, the crude extract/ pure compound stocks were dissolved DMSO
and then diluted with cell culture medium. 25 µL of working crude extracts/ pure compounds
were added to each well of a 96 wells-plate containing 125 µL growth media. Then, the cells
were plated at a density of 19,000 cells/well. Following 72 h incubation, 100 µL of 10%
trichloroacetic acid was added to each well and the plates incubated at 4 °C for 45 min. Fixed
cells were washed with distilled water, air-dried and stained with 0.057% (w/v) sulforhodamine
B in 1% acetic acid. The plate was incubated in the dark for 30 min. The wells were washed four
times with 1% acetic acids and air dried. Then, 200 µL of 10X Tris-buffer was added to each
well and shaken for 30 min at 400 rpm. The absorbance for each well was measured at 510 nm
wavelength in a microplate reader. The 50% inhibitory concentration (IC50) values of the crude
extracts/ pure compounds were determined.206-208
7.2.9 Antimalaria assay against P. falciparum - TM4/8.2 and K1CB1 (Performed by
Kamchonwongpaisan, S. National Center for Genetic Engineering and Biotechnology, Pathum
Thani, Thailand)
Plasmodium falciparum TM4/8.2 and K1CB1 strains were maintained in RPMI 1640 medium
supplemented with 8% human serum, 2.5 mM HEPES and 2 g/L sodium bicarbonate. Parasite
cultures were incubated at 37 °C in a 3% CO2 incubator. The crude extracts/pure compounds
were tested against TM4/8.2 and K1CB1 P. falciparum in vitro by the modified [3H]
hypoxanthine incorporation assay.209-210 Briefly, stock solutions of the crude extracts/ pure
compounds were prepared in DMSO. Various concentrations of the samples were incubated with
malaria parasites with a final volume of 225 µL, 1% parasitemia, 1.5% hematocrit, 0.1%
dimethylsulfoxide (DMSO) in 96-well plates. Plates were incubated for 16-18 h. Then, 25 µL
[3H]-hypoxanthine solution was added and incubated for 20 hours. The parasites were harvested
onto a UniFilter-96 GF/B plate (PerkinElmer, USA). The filters in the plates were air- dried,
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and then 25 µL of liquid scintillation fluid (Microscint, Packard) was added. The radioactivity
was then measured using a microplate scintillation counter (TopCount, Packard). The IC50 values
of the crude extracts/ pure compounds were determined.
7.2.10 Anti-trypanosomal assay (T. brucei rhodesiense) (Performed by Kamchonwongpaisan,
S. National Center for Genetic Engineering and Biotechnology, Pathum Thani, Thailand)
T. brucei rhodesiense (STIB-900) was maintained in Minimal Essential Medium (MEM) with
Earle’s salts supplemented with 3 g/L sodium bicarbonate, 4.5 g/L glucose, 25 mM HEPES, pH
7.3, 0.05 mM bathocuproinedisulfonic acid disodium salt, 1.5 mM L-cysteine, 1 mM
hypoxanthine, 0.16 mM thymidine, 1 mM sodium pyruvate, 0.2 mM 2-mercaptoethanol, 1%
MEM non-essential amino acid, and 15% heated fetal bovine serum, at 37 °C in a 5% CO2
incubator. To assay anti-Tbr activity, a modified reported protocol was used.206,208 Briefly, 2 x
104 T. brucei rhodesiense parasites in 175 μL culture media were incubated with 25 μL of
varying concentrations of each compound in a 96-well plate under the same culture conditions.
Following 72 h incubation, 20 µL Alamar Blue (a resazurin solution) was added in each well.
The mixture was further incubated for 3 h. The fluorescence signals were measured by a
spectrofluorometer at ex530/em585 nm. The results were read as concentration of each
compound that exhibit 50% growth inhibition (IC50) from the dose-response curve established
from the fluorescence signals at each concentration of compound.
7.2.11 Mycobacterium tuberculosis assay (Performed by Kamchonwongpaisan, S. National
Center for Genetic Engineering and Biotechnology, Pathum Thani, Thailand)
Mycobacterium tuberculosis H37Rv (ATCC 27294) were grown in Löwenstein–Jensen (LJ)
medium agars (Biomedia Thailand cat. no. BMT B24420) in a biosafety level 3 facility at the
Department of Microbiology, Faculty of Science, Mahidol University. Two–three loopfuls of
each M. tuberculosis strain from the LJ medium were scratched and put into a tube containing 10
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mL of Middlebrook 7H9 broth supplemented with 0.2% glycerol and 10% Middlebrook OADC.
Clumps of colonies were dispersed using a loop. The bacterial suspensions were left undisturbed
for 15 minutes before the upper parts were collected. Absorbance at OD600 was measured.
Finally, bacterial suspensions were prepared to OD600 at 0.005. Anti-tuberculous activities were
evaluated by the Microplate Alamar Blue Assay.211 The assay was performed in a 96-well
microplate. From stock 10 mg/mL in dimethyl sulfoxide, two-fold serial dilution of
compounds/crude extracts (0.312 - 20 µg/mL) were prepared in Middlebrook 7H9 broth
supplemented with 0.2% glycerol and 10% Middlebrook OADC in a 96-well plate to the volume
of 100 µL. Then 100 µL of M. tuberculosis (OD600 of 0.005) was added to each well. Bacterial
growth control and compounds/crude extracts control wells contained the medium with either
bacteria or the test sample, respectively, while the medium control wells were without both. All
were done in triplicate. The plate was incubated in a 37 °C incubator for 5 days. Then 20 µL of
alamar blue and 12.5 µL of 20% Tween80 were added to one well of each control and the plate
was further incubated for 24 h to test bacterial growth by observing color change. A blue color
in the well was interpreted as no bacterial growth while a pink color represented proper bacterial
growth. Therefore, if the well was still blue, the additional control wells were tested daily until
the color changed to pink. Then the reagents were added to the entire plate and incubated for 24
h. Minimum inhibitory concentration (MIC) was then read from the lowest concentration of
samples that prevented the change from blue to pink. Isoniazid and rifampin were employed as
controls.
7.2.12 Assay for α-glucosidase inhibition activity (AGI) (Performed by Phuong T.M. Nguyen
Institute of Biotechnology, Cau Giay Hannoi, Vietnam)
AGI values of extracts and pure phytochemicals were quantitatively determined in a 96-well
plastic plate according to the method described by Nguyen et al.212 The enzyme was incubated
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with the samples dissolved in DMSO for 5 min before adding the substrate. The inhibition was
measured spectrophotometrically in 20 mM sodium phosphate buffer pH 6.0 at 37 °C using 3.0
mM p-nitrophenyl α-D-glucopyranoside (Sigma) as the substrate and 0.25 units/mL of AG from
S. cerevisiae (Sigma). The absorbance at 405 nm was measured using a microplate reader
(BioTek ELx808 microplate reader, USA). Acarbose (1.0 mM) was used as the positive
control.
7.2.13 Assay for α-Amylase Inhibitory Activity (AAI) (Performed by Phuong T.M. Nguyen
Institute of Biotechnology, Cau Giay Hannoi, Vietnam)
AAI values were determined using a microplate-based starch–iodine assay. Assay reactions were
initiated by adding 40 L of starch (Sigma S-2630) solution (2.0 g/L) and 40 L of enzyme in
0.1M phosphate buffer at pH 7.0 to microplate wells. The enzyme was incubated with the
samples for 5 min before adding the substrate. To minimize evaporative loss during incubation, a
plastic mat was used to cover the microplate. After 30 min of incubation at 50 °C, 20 L of 1M
HCl was added to stop the enzymatic reaction, followed by the addition of 100 L of iodine
reagent (5 mM I2 and 5 mM KI). Following color development, the absorbance at 580 nm was
measured using a microplate reader (Bio-TEK ELx808 microplate reader, USA).213
7.2.14 Statistical analysis for CO induced diarrhea and motility test
The data were presented as mean ± SEM (n = 5). Difference between means of different
treatments was determined by Analysis of Variance (ANOVA) using the statistical package for
the social sciences (SPSS) version 23. P values less than 0.05 were considered as significant.
7.2.15 Statistical analysis for CFTR and TMEM16A
Results were presented as means ± S.E.M. Student’s t test or One-way ANOVA with Tukey’s
post test was performed to evaluate statistical difference between control and treatment groups,
where appropriate p value < 0.05 was considered as statistical significance.
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Experimental for Chapter 2
7.3.0 Aqueous solvent extraction of the four plants materials
Neorautanenia mitis
Tubers of N. mitis were cut into smaller pieces and sun dried for 3 days and further dried in a hot
air oven at 45 °C for 1 day. The dried material was then pulverized, and 1000 g of the powder
was extracted with 4 L of distilled water and kept in the refrigerator for 24 h, after which it was
filtered and the filtrate dried in a hot air oven at 50 °C for 2 days to obtain the dried aqueous
extract as a dark brown solid weighing 65.2 g with a percentage yield of 6.5%.203,214 The dried N.
mitis aqueous extract was labeled ABAQ, coined from the Hausa local name Abargora.
Hydnora abyssinica
The roots were cut into smaller pieces and dried in a hot air oven at 45 °C for 5 days then ground
into a powder. To 571 g of the pulverized roots was added 3 L of distilled water and kept in the
refrigerator and allowed to extract for a period of 24 h, after which it was filtered and the filtrate
dried in a hot air oven at 50 °C for 2 days to obtain the dried aqueous extract as brick red solid
weighing 64.0 g with a percentage yield of 11.2%.203,214 The dried aqueous extract of H.
abyssinica was labeled KAQ, coined from the common Hausa name, Kaushe.
Senna surrantensis
The leaves of the plant were dried in a hot air oven at 45 °C for 2 days, after which they were
pulverized. To 285 g of the plant powder was added 2 L of distilled water and kept in the
refrigerator and allowed to extract for a period of 24 h, after which it was filtered and the filtrate
dried in the hot air oven at 50 °C for 3 days to obtain the dried aqueous extract as dark green
solid weighing 17.0 g with a percentage yield of 6.0%.203,214 The dried aqueous extract of S.
surattensis was labeled CAQ, coined from the name Cassia synonym for the genus Senna.
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Vitellaria paradoxa
The stem bark was cut into smaller pieces, dried in a hot air oven at 45 °C for 4 days and then
pulverized. To a portion of 1000 g of powdered plant material, 4 L of distilled water was added
and the mixture was kept in the refrigerator for 24 h, after which it was filtered and the filtrate
dried in a hot air oven at 50 °C for 3 days to obtain the dried aqueous extract as light brown solid
weighing 35.0 g with a percentage yield of 3.5%.203,214 The dried aqueous extract was labeled
SBAQ, coined from the English common name Shea butter.
7.3.1 Qualitative preliminary phytochemical analysis (Performed by Dawurung, C.J. Abullahi
U. NVRI Vom Nigeria)
All of the aqueous extracts were subjected to a qualitative phytochemical analysis to indicate the
presence or absence of specific classes of secondary metabolites, using standard methods as
described below.215- 216
Test for tannins
A measure of 0.5 g of the extract was stirred with 1 mL of distilled water and filtered. Ferric
chloride solution was added to the filtrate. A blue-black, green or blue-green precipitate was
taken as evidence for the presence of tannins. 215- 216
Test for cardiac glycosides (Keller Killiani test)
About 0.1 g of extract was dissolved in 1 mL of glacial acetic acid containing one drop of ferric
chloride solution. A 1 mL of concentrated sulphuric acid was added gently by the side of the test
tube. A brown ring obtained at the interphase indicates the presence of deoxy sugar characteristic
of cardenolides. 215- 216
Test for steroids (Steroidal ring)
About 0.1 g of the extract was dissolved in 2 mL of chloroform; sulphuric acid was carefully
added to form a lower layer. A reddish brown color at the interphase is indicative of the presence
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of the steroidal ring system. 215- 216
Test for alkaloids
About 0.5 g of extract was stirred with 3 mL of 1% aqueous hydrochloric acid on a steam bath
and filtered; 1mL of the filtrate was treated with few drops of the following reagents:
1. Mayer’s reagent
2. Picric acid solution
3. Dragendorff’s reagent
Precipitation with either of these reagents was taken as preliminary evidence for the presence of
alkaloids. 215- 216
Test for flavonoids
About 2 g of powdered sample was detanned with acetone. The sample was placed on a hot
water bath for all traces of acetone to evaporate. Boiling distilled water was added to the
detanned sample. The mixture was filtered while hot. The filtrate was cooled and 5 mL of 20%
NaOH was added to equal volume of the filtrate. A yellow solution indicates the presence of
flavonoids. 215- 216
Test for anthraquinones
About 0.5 g of extract was taken into a dry test tube and 5 mL of chloroform was added and
shaken for 5 min. This was filtered and the filtrate shaken with equal volume of 100% aq NH3
solution. Pink, violet or red color in the ammoniacal layer (lower layer) indicates the presence of
free anthraquinones. 215- 216
Test for saponins
About 0.5 g of the extract was shaken with water in a test tube. Frothing which persists on
warming was taken as preliminary evidence for presence of saponins. 215- 216
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7.3.2 Experimental Animals
Young adult (12 weeks old) Wister albino rats of both sexes were obtained from the animal
house of the National Institute for trypanasomosis Vom, Nigeria. The rats were kept in metal
cages lined with wood shavings and allowed to adjust to the laboratory environment for a period
of two weeks before the commencement of the experiments. The rats were housed in spacious
cages (6 rats per cage size 17 x 13 inches) prior to the experimental groupings. They were fed on
pelletized rodent feed from Dagom Farms of the National Veterinary Research Institute (NVRI)
Vom, and water was provided ad libitum.
7.3.3 Ethics approval and consent to participate
Ethics approval for animal use was obtained from the Animal Use and Care Committee (AUCC)
of National Veterinary Research Institute (Approval number–NVRI/EC/20/010). No consent
approval was required for this study.
7.3.4 Acute toxicity studies (limit test) (Performed by Dawurung, C. J. NVRI Vom Nigeria)
The acute toxicity studies were carried out using the limit test in Wister albino rats, to determine
the median lethal dose (LD50) of the aqueous extracts, using a standard protocol described by the
Organization for Economic Co‑ operation and Development (OECD).114 Briefly, three albino
rats kept in separate cages were used for the testing of each extract. The first rat was given a
limited dose of 2000 mg/kg of the extract orally and observed for signs of toxicity and ultimate
death. If the first rat survived, the procedure was repeated with the second rat, and then the third
rat if the second rat survived.
7.3.5 Castor oil induced diarrhea for crude extracts (Performed by Dawurung, C. J. NVRI
Vom Nigeria)
For each of the aqueous extracts, 25 rats of both sexes weighing between 130-200 g were used
for the experiments, which were conducted during the day time. The rats were fasted for 12 h
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before the commencement of the experiment, having access to water only. The rats were
randomly allocated into five groups of five rats each. Groups 1, 2 and 3 were given graded doses
of the dried extract reconstituted in distilled water. The graded doses for the extracts were
determined based on the result obtained from the toxicity studies. Group 4 were given distilled
water, while Group 5 was given loperamide. Groups 4 and 5 are the control groups. The rats
were then housed singly in a perforated cage lined with white blotting paper. One h after the
above treatment, all the rats in the groups were given 1 mL of castor oil orally. The rats were
observed for 5 h for watery (wet) or unformed faeces. The watery faeces from each rat were
counted hourly for up to 5 h. At the end of the experiment the group mean faeces was obtained
and the percentage of protection calculated using the formula.43
% 𝑃𝑟𝑜𝑡𝑒𝑐𝑡𝑖𝑜𝑛 =

𝑀𝑒𝑎𝑛 𝑢𝑛𝑓𝑜𝑟𝑚𝑒𝑑 𝑓𝑒𝑐𝑒𝑠 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 − 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
× 100
𝑀𝑒𝑎𝑛 𝑢𝑛𝑓𝑜𝑟𝑚𝑒𝑑 𝑓𝑒𝑐𝑒𝑠 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑐𝑜𝑛𝑡𝑟𝑜𝑙

7.3.6 Gastrointestinal transit of charcoal for crude extracts (motility test) (Performed by
Dawurung, C. J.)
For each of the aqueous extracts, 25 rats of both sexes weighing between 130-200 g were used
for the experiments, which were conducted during the day time. The animals were fasted for 16 h
before the commencement of the experiment but allow access to water. They were randomly
divided into five groups of five rats each. Groups 1, 2 and 3 were treated orally with graded
doses of the dried aqueous extracts reconstituted in distilled water. The graded doses for the
extracts were determined based on the result obtained from the toxicity studies. Group 4 were
treated with distilled water, while Group 5 was treated with atropine sulphate. Groups 4 and 5 are
the control groups. Thirty minutes after extract and drug administrations, 1 mL of 5% activated
charcoal suspension in 10% aqueous solution of acacia powder was given orally to each rat.
After 30 min of administering the activated charcoal, the rats were humanely sacrificed and the
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abdomen opened to access the intestine. The distance travelled by the charcoal meal from
pylorus was measured and expressed as a percentage of the total length of intestine from pylorus
to the caecum to calculate the percentage intestinal transit of activated charcoal.43

% 𝐼𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑎𝑙 𝑇𝑟𝑎𝑛𝑠𝑖𝑡 =

𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒 𝑡𝑟𝑎𝑣𝑒𝑙𝑙𝑒𝑑 𝑏𝑦 𝐶ℎ𝑎𝑟𝑐𝑜𝑎𝑙 𝑚𝑒𝑎𝑙
× 100
𝑇𝑜𝑡𝑎𝑙 𝐿𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝐼𝑛𝑡𝑒𝑠𝑡𝑖𝑛𝑒 𝑓𝑟𝑜𝑚 𝑃𝑦𝑙𝑜𝑟𝑢𝑠 𝑡𝑜 𝐶𝑎𝑒𝑐𝑢𝑚
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Experimental for Chapter 3
7.4.0 Organic solvent extraction and isolation of compounds from N. mitis
As reported by Dawurung et al. 2020,143 the roots of N. mitis were washed with water and
shredded into small pieces and dried in an oven at 45 °C for 2 d. The dried root was pulverized
using a mortar and pestle. About 1000 g of the powder was successively extracted for 72 h with
dichloromethane (DCM, 4 L) and then ethanol (4 L). The extracts were filtered through a sieve
(150 µm), a cotton plug and then filter paper. The filtrates were dried under a constant stream of
air provided by a laboratory electric fan overnight, to obtain dark brown solids for both extracts.
The yields for the DCM and ethanol extracts were 15 g (1.5%) and 10 g (1.0%), respectively
(Fig. 7.1). Both extracts show similar TLC profiles.
A portion of the DCM extract (14 g) was separated by column chromatography (CC) over silica
gel using a gradient system from ethyl acetate (EtOAc)/hexanes (1:9) to 100% EtOAc to yield 40
fractions; these were combined based on their similarities by TLC and NMR analysis to afford
12 fractions (F1-F12). Fraction F2 (150 mg) was separated by CC over silica gel using a gradient
system from EtOAc/hexanes (1:9) to 100% EtOAc to give seven sub-fractions (F2f1-F2f7). Subfraction F2f5 was triturated with hexane, the hexane was decanted to leave a white solid
identified as compound 1 (9.2 mg). Fraction F3 (490. mg) was purified by CC over silica gel
using a gradient system from EtOAc/hexanes (1:9) to 100% EtOAc to give compound 2 (343
mg) as a white solid. Separation of fraction F4 (150 mg) by CC over silica gel and elution with a
gradient system of hexanes/DCM (95:5) gave ten sub-fractions (F4f1-F4f10). Evaporation of
sub-fraction F4f5 gave compound 3 (22 mg) as a white solid. Fraction F5 (90 mg) yielded five
sub-fractions (F5f1-F5f5), when chromatographed on silica gel by elution with hexanes/ DCM
(5:95). Evaporation of sub-fraction F5f3 gave compound 4 (1.9 mg) as a white solid. Fraction F6
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(250 mg) was separated by CC over silica gel by elution with hexanes/DCM (5:95) to give ten
sub-fractions (F6f1-F6f10), F6f3 was crystallized from DCM/hexanes (1:3) to give large white
crystals identified as compound 5 (82 mg). Fraction F7 (560 mg) was separated by CC over
silica gel using a gradient system of EtOAc/DCM (2:98) to give seven sub-fractions (F7f1-F7f7).
Evaporation of sub-fraction F7f4 gave compound 6 (250 mg) as a yellow solid, while,
evaporation of sub-fraction F7f5 gave compound 7 (227 mg) as white needles. Fraction F8
(380.0 mg) was separated by CC over silica gel elution with EtOAc/DCM (5:95) to give 15 subfractions (F8f1-F8f15). The purification of sub-fraction F8f2 (19 mg) by PTLC with elution with
EtOAc/DCM (5:95) yielded compounds 8 (4.9 mg) as a white solid, and 9 (3.9 mg) as a yellow
solid. Sub-fractions F8f3, F8f5, and F8f8 respectively provided compounds 10, (84.1 mg) as
brown solid and compounds 11 (15.4 mg) and 12 (15.0 mg) as white sticky solids. Compound 11
was identified by X-ray crystallography; single white crystals were grown from DCM/hexanes
(1:3). Sub-fractions F8f9 and F8f10 were combined based on their TLC and NMR spectrum
similarities and named F8f910 (15 mg) which was purified by prep. TLC with elution with
EtOAc/DCM (95:5) to yield compounds 13 (4.5 mg) and 14 (2.7 mg), both as white sticky
solids. Fraction 9 (160 mg) was separated by CC over silica gel with a gradient system of
EtOAc/CH2Cl2 (5:95) to afford ten sub-fractions (F9f1-F9f10), on the bases of their TLC
similarities, sub-fractions F9f5, F9f6 and F9f7 were combined, evaporated and the solid residue
was triturated with hexane to obtain a white powder identified as compound 15 (9.1 mg).
Fraction F10 (1.18 g) was purified by CC over silica gel elution with DCM/CH2Cl2 (5:95) to
afford 26 sub-fractions (F10f1-F10f26). Sub-fractions F10f16 to F10f21 were combined based
on their TLC and NMR similarities. The combined fraction (215 mg) was triturated with
methanol and the soluble portion (113 mg) was separated by CC over Sephadex (LH20) by
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elution with 100% methanol to yield four fractions (A-D). Fraction B was purified once more by
CC over Sephadex (LH20) by elution with 100% methanol to yield compound 16 (19.2 mg), as
yellow needles and compound 17 (9.4 mg) as a brown solid. Fraction F11 (90 mg) was separated
by CC over silica gel using a gradient system of EtOAc/DCM (10:90) to yield ten fractions
(F11f1-F11f10). Sub-fraction F10f6 was identified as compound 18 (21.3 mg) with a white
fluffy appearance. Fraction F12 (2.28 g) was evaporated, washed with methanol to obtain the
methanol soluble portion (1.18 g), which was separated by CC over Sephadex (LH20) by elution
with 100% methanol to obtain ten sub-fractions (F12f1-F12f10). Sub-fractions F12f7, F12f8 and
F12f9 were combined based on their TLC and NMR similarities. The combined portion was
again purified over Sephadex (LH20) by elution with 100% methanol to yield two fractions (A
and B). Fraction A (2.9 mg) a white solid was identified as compound 19 (2.9 mg), while
fraction B was further washed with DCM to obtain a white solid (15 mg) which was crystallized
from methanol, DCM, hexanes (1:1:2) and the white crystal were identified as compound 20 (15
mg)143 (Fig. 7.2).
7.4.1 Preparation of aqueous extract and isolation of chloroform soluble compounds
As reported by Dawurung et al. 2020,143 the aqueous root extract (ABAQ) of N. mitis was
prepared as described (Dawurung et al., 2019),30 and about 1 g of ABAQ was dissolved in
chloroform, filtered and evaporated in rotary evaporator to obtain a yield of 291.1 mg, which is
tagged ABAQ-Chlo. The whole amount of ABAQ-Chlo was chromatographed on CC over silica
gel using a gradient system from EtOAc/hexanes (2:8) to 100% EtOAc to give eight fractions
(F1-F8). Fraction F1 (11.7 mg) was identified as compound 2, while fraction F4 was confirmed
as compound 7 (11.1 mg). Compound 6 (5.8 mg) was purified from fraction F5, and fraction F6
resulted in compound 18 (7.1 mg)143 (Fig. 7.3).
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Figure 7.1 Successive extraction of the roots of N. mitis
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Figure 7.2 Isolation of compounds from the roots crude DCM extract of N. mitis
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Figure 7.2 Isolation of compounds from the roots crude DCM extract of N. mitis
(Continued)
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Figure 7.2 Isolation of compounds from the roots crude DCM extract of N. mitis
(Continued)
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Figure 7.2 Isolation of compounds from the roots crude DCM extract of N. mitis
(Continued)
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Figure 7.2 Isolation of compounds from the roots crude DCM extract of N. mitis
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Figure 7.3 Isolation of compounds from the roots crude aqueous extract of N. mitis
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7.4.2 Spectroscopic data of isolated compounds from N. mitis
Note;The complete supporting spectroscopic data for compounds 1, 3, 4, 11, 12, 13 and 15 are
provided here for the first time. In the case where the operating frequency of the NMR spectrum
was no given, these are indicated by *. Literature Mps, MS and specific rotations are given when
they are known. The experimental and literature 13C NMR data of compounds 2, 6, 7, 9, 10, 14,
16, 17, 18, 19 and 20 are tabulated in Tables, 7.21, 7.22 and 7.23 based on their structure
similarities.
Compound 1 (Neoduleen)
White solid, 13C NMR (126 MHz, CDCl3) δ155.4 (C-3), 151.8 (C-4a), 150.6 (C-10a), 147.9 (C11a), 145.9 (C-8), 144.8 (C-10), 144.7 (C-2ʹ), 121.6 (C-2), 119.0 (C-6a), 113.4 (C-1a), 111.9 (C1), 108.3 (C-7a), 106.6 (C-3ʹ), 101.5 (C-2ʹʹ), 99.9 (C-4), 97.5 (C-7), 94.1 (C-10), 65.3 (C-6). For
1

H NMR (500 MHz, CDCl3) spectroscopic data see Table 7.2.

Table 7.2 Experimental and literature 1H NMR data of compound 1
P

Neoduleen (1) 1H δ (CDCl3)
Expt. (500 MHz)

Lit. (MHz)134*

1

7.65 (s, 1H)

7.63 (s)

4

7.08 (s, 1H)

7.06 (s)

6

5.54 (s, 2H)

5.51 (s, 2H)

7

6.74 (s, IH)

6.75 (s)

8

--------

--------

10

7.05 (s, 1H)

7.51 (s)

2ʹ

7.53 (d, J = 2.1, 1H)

7.56 (d, J= 2.2)

3ʹ

6.73 (m, IH)

6.69 (d, J=2.2)

2ʹʹ

6.01 (s, 2H)

5.98 (s, 2H)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P = Position
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Compound 2 (Neodulin)26
White solid; IR (neat) vmax; 1625 and 1453 cm-1; MS (ESI +ve) m/z 309 ([M+H]+); Mp 210°C;
[α]25D -176° ( c 0.3 CHCl3); For 1H NMR (400 MHz, CDCl3) and 13C NMR (101 MHz, CDCl3)
spectroscopic data see Tables 7.3 and 7.21, respectively.
Table 7.3 Experimental and literature 1H NMR data of compound 2
P

Neodulin (2) 1H δ (CDCl3)
Expt. (400 MHz)

Lit. (360 MHz)26

1

7.71 (s, 1H)

7.72 (s)

4

7.09 (s, 1H)

7.09 (s)

6

4.27 (ddd, J=11.0, 5.0, 0.5)

4.28 (dd, J = 4.8, 10.8)

3.71 (t, J = 11.0, 1H)

3.71 (dd, J = 10.8, 10.4)

7

6.74 (s)

6.75 (s)

10

6.44 (s, 1H)

6.44 (s)

2ʹ

7.55 (d, J = 2.2, 1H)

7.56 (d, J = 2.2)

3ʹ

6.72 (dd, J = 2.2, 1.0, 1H)

6.72 (dd, J = 2.2, 1.0)

2ʹʹ

5.92 ( d, J = 1.4, 1H)

5.93 (d, J = 1.3)

5.89 (d, J = 1.4, 1H)

5.90 (d, J = 1.3)

6a

3.59 (dd, J = 7.2, 5.0, 1H)

3.59 (ddd, J = 7.0, 4.8, 10.4)

11a

5.66 (d, J = 7.2, 1H)

5.67 (d, J = 7.0)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Compound 3 (Ferulic Acid)
White solid, IR (neat) vmax; 3536, 2848, 1700, 1517, 1265 and 734 cm-1; Mp 69-71°C; MS (ESI
+ve) m/z 581 ([M+Na]+); HRMS (ESI +ve TOF) calcd for C36H62O4Na 581.4564 found 581.4563
[M+Na]+. For 1H NMR (400 MHz, CDCl3) and 13C NMR (101 MHz, CDCl3) spectroscopic data
see Table 7.4.
Table 7.4 Experimental and literature 1H NMR and 13C NMR data of compound 3
P

Ferulic acid Expt. (400 MHz, CDCl3)
1

H NMR

1
2

13

C NMR

Lit. Ferulic acid (500 MHz)144
1

H NMR

127.1
7.03 (d, J = 1.9, 1H)

114.7

13

C NMR

127.1
7.04 (d, J = 1.8, 1H)

114.7

3

146.8

146.8

4

147.9

147.9

5

6.91 (d, J = 8.1, 1H)

109.3

6.92 (d, J = 8.1, 1H)

109.3

6

7.07 (dd, J = 8.2, 1.9, 1H)

123.1

7.08 (dd, J = 8.1, 1.81H)

123.1

1ʹ

7.61 (d, J = 15.9, 1H)

144.6

7.62 (d, J = 15.9, 1H)

144.6

2ʹ

6.29 (d, J = 15.9, 1H)

115.7

6.29 (d, J = 15.9, 1H)

115.7

3ʹ

167.4

167.4

5ʹ

4.19 (t, J = 6.7, 2H)

64.6

4.20 (t, J = 6.7, 2H)

64.6

6ʹ

1.74 – 1.65 (m, 2H)

29.7

1.70 quint, J=6.8, 2H)

29.7

7ʹ

1.25 (s, 58H, H-7')

29.7-22.7 (-CH2)n

1.25 (s, 58H, H-7')

29.7-22.7 (-CH2)n

8ʹ

0.88 (t, J = 6.9 Hz, 3H)

14.1 (-CH3)

0.89 (t, J = 6.9, 3H)

14.1 (-CH3)

OCH3

3.93 (s, 3H)

55.9

3.94 (s, 3H)

55.9

OH

5.86 (s, 1H)

146.8

5.85 (s. IH)

-----

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz
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Compound 4 (Ambonane)
White solid; IR (neat) vmax; 2930, 1472 and 1268 cm-1; [α] 25D -192 (c 0.05 CHCl3) [Lit.133 [α]D 214 ( c 0.01 CHCl3)]; MS (ESI +ve) m/z 347 ([M+Na]+); HRMS (ESI +ve TOF) calcd for
C19H16O5Na 347.0891 found 347.0895 [M+Na]+;

13

C NMR (126 MHz, CDCl3) δ 155.7 (C-3),

153.5 (C-4a), 153.1 (C-9), 151.2 (C-10), 145.1 (2''), 145. (C-10a), 123.3 (C-7a), 122.3 (C-1),
121.7 (C-2), 118.1 (C-7), 116.4 (C-1a), 106.3 (C-3''), 104.8 (C-8), 99.7 (C-4), 79.7 (C-11a),
77.27, 77.01, 76.76, 66.9 (C-6), 60.7 (OCH3), 56.4 (OCH3), 40.1 (C-6a). For 1H NMR (400
MHz, CDCl3) spectroscopic data see Table 7.5.
Table 7.5 Experimental and literature 1H NMR and 13C NMR data of compound 4
P

Ambonane(4) 1H δ (CDCl3)
Expt. (400 MHz)

Lit. (MHz)133*

1

7.81 (s, 1H)

7.71 (s)

4

7.09 (s, 1H)

7.03 (s)

6

4.33–4.27 (m)

4.22 (m)

3.73 (t, J = 10.7 1H)

3.72 (m)

7

6.91 (dd, J = 8.2,0.6 1H)

6.84 (d)

8

6.48 (d, J = 8.2, 1H)

6.41 (d)

2ʹ

7.56 (d, J = 2.2, 1H)

7.50 (d, J = 2.5)

3ʹ

6.73 (dd, J = 2.2, 1.0 1H)

6.63 (dd, J = 2.5, 1.0)

6a

3.65 (dd, J = 6.2, 4.8 1H)

3.53 (m)

11a

5.72 (d, J = 6.9 1H)

5.69 (d)

OCH3

3.95 (s, 3H)

3. 91 (s)

3.85 (s, 3H)

3.81 (s)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz
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Compound 5 (Stigmasterol)145
White solid; IR (neat) vmax; 3412, 2960, 1458, 1060 and 970 cm-1, MP 150-152°C; [α]21D -43.2 (c
0.2 CHCl3); For 1H NMR (400 MHz, CDCl3) and

13

C NMR (101 MHz, CDCl3) spectroscopic

data see Table 7.6.
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Table 7.6 Experimental and literature 1H NMR and 13C NMR data of compound 5
Position

Stigmasterol (5) 1H δ (CDCl3)
1

H Expt. (400 MHz)

Stigmasterol (5) 1H δ (CDCl3)
13

C Expt.

1

H Lit. (600 MHz)145

13

C Lit.

1

37.6

37.6

2

32.1

32.1

3

3.51 (tdd, J = 4.5, 4.2, 3.8 1H)

4
5

72.1

3.51 (tdd, J = 4.5, 4.2, 3.8 1H)

42.4
5.31 (t, J = 6.1 1H)

141.1

72.1
42.4

5.31 (t, J = 6.1 1H)

141.1

6

121.8

121.8

7

31.8

31.8

8

31.8

31.8

9

50.2

50.2

10

36.6

36.6

11

21.5

21.5

12

39.9

39.9

13

42.4

42.4

14

56.8

56.8

15

24.4

24.4

16

29.3

29.3

17

56.2

56.2

18

40.6

40.6

19

0.91 (d, J = 6.2 3H)

21.7

0.91 (d, J = 6.2 3H)

21.7

20

4.98 (m, 1H)

138.7

4.98 (m, 1H)

138.7

21

5.14 (m, 1H)

129.6

5.14 (m, 1H)

129.6

22

46.1

46.1

23

25.4

25.4

24

0.83 (t, J = 7.1,3H)

25

12.1

0.83 (t, 3H, J = 7.1 Hz)

29.6

12.1
29.6

26

0.82 (d, J = 6.6 3H)

20.2

0.82 (d, J = 6.6 3H)

20.2

27

0.80 (d, J = 6.6 3H)

19.8

0.80 (d, J = 6.6 3H)

19.8

28

0.71 (s, 3H)

18.9

0.71 (s, 3H)

18.9

29

1.03 (s, 3H)

12.2

1.03 (s, 3H)

12.2

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are inHz
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Compound 6 (Pachyrrhizine)26
Yellow solid; IR (neat) vmax; 2918, 1750, 1500 and 1269 cm-1; MS (ESI +ve) m/z 337 ([M+H]+);
HRMS (ESI +ve TOF) calcd for C19H13O6 337.0723 found 337.0712 [M+H]+; Mp 204-205°C;
For 1H NMR (400 MHz, CDCl3) and 13C NMR (101 MHz, CDCl3) spectroscopic data see Tables
7.7 and 7.21, respectively.
Table 7.7 Experimental and literature 1H NMR data of compound 6
P

Pachyrrhizine (6) 1H δ (CDCl3)
Expt. (400 MHz)

Lit. (360 MHz)26

4

7.81 (s, 1H)

7.80 (s)

5

7.68 (s, 1H)

7.69 (s)

8

7.50 – 7.49 (m)

7.46 (brs)

3ʹ

6.64 (s, 1H)

6.64 (s)

6ʹ

6.90 (s, 1H)

6.91 (s)

2ʹʹ

7.69 (d, J=2.3, 1H)

7.70 (d, J = 2.2)

3ʹʹ

6.83 (dd, J = 2.3, 1.0,1H)

6.76 (dd, J = 2.2, 1.0)

2ʹʹʹ

5.97 (s, 2H)

5.98 (s)

OCH3

3.78 (s, 3H)

3.79 (s)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in
δ (ppm), and Coupling constants (J) are in Hz
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Compound 7 (Neotenone)26
White needles; IR (neat) vmax; 1682, 1474 and 1155 cm-1; mP 174-175°C, [α]26D -232.2 ( c 0.4
CHCl3); For 1H NMR (400 MHz, CDCl3) and 13C NMR (101 MHz, CDCl3) spectroscopic data
see Tables 7.8 and 7.21, respectively.
Table 7.8 Experimental and literature 1H NMR data of compound 7
P

Neotenone(7) 1H δ (CDCl3)
Expt. (500 MHz)

Lit. (360 MHz)26

4.51 (dd, J = 10.9, 5.5 , 1H)

4.50 (dd, J = 5.4, 10.8)

4.32 (dd, J = 11.6, 5.5, 1H)

4.31 (dd, J = 5.4, 11.4 )

3

4.58 (t, J = 11.3, 1H)

4.58 (dd, J = 10.8, 11.4)

5

8.26 (s, 1H)

8.25 (s)

8

7.08 (s, 1H)

7.08 (brs)

3ʹ

6.58 (s, 1H)

6.57 (s)

6ʹ

6.62 (s, 1H)

6.62 (s)

2ʹʹ

7.58(d, J = 2.0, 1H)

7.57 (d, J = 2.3)

3ʹʹ

6.77 (brs, 1H)

6.76 (dd, J = 2.3, 1.0)

2ʹʹʹ

5.92 (s, 2H)

5.90 (s)

2ʹ OCH3

3.73 (s, 3H)

3.72 (s)

2

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in
δ (ppm), and Coupling constants (J) are in Hz
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Compound 9 (12a-Hydroxydolineon) 26
Yellow solid; IR (neat) vmax; 3460, 2918, 1624 and 1174 cm-1; MP 155-156°C, [α]23D -173.2 (c
0.3 CHCl3); For 1H NMR (400 MHz, CDCl3) and

13

C NMR (101 MHz, CDCl3) spectroscopic

data see Tables 7.9 and 7.21, respectively.
Table 7.9 Experimental and literature 1H NMR data of compound 9
P

12a-Hydroxydolineon (9) 1H δ (CDCl3)
Expt. (400 MHZ)

Lit. (360 MHz)26

1

6.51 (s, 1H)

6.52 (s)

4

6.48 (s, 1H)

6.48 (s)

6

4.65 (dd, J = 11.8, 2.5,1H)

4.63 (dd, J = 12.0, 2.4)

4.50 (d, J = 11.8, 2.4,1H)

4.50 (dd, J = 12.9, 2.0 )

8

7.02 (s, 1H)

7.02 (s)

11

8.19 (s, 1H)

8.19 (s, 1H)

2ʹ

7.55 (d, J = 2.0, 1H)

7.54 (d, J = 2.2, 1H)

3ʹ

6.74 (d, J = 2.0, 1H)

6.74 (dd, J = 2.2, 1.0, 1H)

2ʹʹ

5.85 (d, J = 1.0, 1H)

5.86 (d, J = 1.2)

5.80 (d, J = 1.0, 1H)

5.80 (d, J = 1.2)

6a

4.62 (s, 1H)

4.62 (br, 1H)

OH

4.42 (s, 1H)

4.46 (s)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm),
and Coupling constants (J) are in Hz. P= Position
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Compound 10 (Dolinione)26
Brown solid; IR (neat) vmax; 2924, 1625, 1467 and 1033 cm-1; MS (ESI +ve) m/z 359 ([M+Na]+);
HRMS (ESI +ve TOF) calcd for C19H12O6Na 359.0529 found 359.0532 [M+Na]+; Mp 220°C;
[α]23D +139.7 ( c 0.2 CHCl3); For 1H NMR (400 MHz, CDCl3) and 13C NMR (101 MHz, CDCl3)
spectroscopic data see on Tables 7.10 and 7.21, respectively.
Table 7.10 Experimental and literature 1H NMR data of compound 10
P

Dolineon (10) 1H δ (CDCl3)
Expt. (400 MHz)

Lit. (360 MHz)26

1

6.73 (s, 1H)

6.72 (s) overlap

4

6.44 (s, 1H)

6.44 (s)

6

4.63 (dd, J = 12.0, 3.2, 1H)

4.63 (d, J = 12.0, 3.2)

4.19 (d, J = 12.0, 1H)

4.19 (dd, J = 12.0)

8

7.06 (s, 1H)

7.05 (br s)

11

8.21 (s, 1H)

8.21 (s)

2ʹ

7.54 (d, J = 2.3, 1H)

7.54 (d, J = 2.3)

3ʹ

6.74 (dd, J = 2.3, 1.0, 1H)

6.73 (dd, J = 2.3, 1.0)

2ʹʹ

5.86 (d, J = 1.4, 1H),

5.86 (d, J = 1.3)

5.80 (d, J = 1.4, 1H)

5.80 (d, J = 1.3)

6a

4.99 – 4.92 (m, 1H)

4.96 (ddd, J = 3.2, 1.0, 3.9)

12a

3.89 (d, J = 3.9, 1H)

3.89 (d, J = 3.9)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm),
and Coupling constants (J) are in Hz. P= Position
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Compound 11 (-)-2-isopentenyl-3-hydroxy-8-9-methylenedioxypterocarpan146
White sticky solid; IR (neat) vmax; 3364, 2921, 1603, 1476, 1116 and 834 cm-1; Mp 149-152°C
(Lit.146 146-147°C), [α]23 -339.5 (c 0.1 CHCl3) [Lit.146 [α]23D -261.9 (c 0.8 CHCl3),

13

C NMR

(126 MHz, CDCl3) δ 155.8 (C-3), 154.9 (C-4a), 154.2 (C-10a), 148.1 (C-9a), 141.7 (C-8a), 134.8
(C-3'), 131.8 (C-1), 121.9 (C-2'), 121.2 (C-3), 118.1 (C-7a), 112.2 (C-1a), 104.8 (C-7), 103.9 (C4), 101.3 (C-2''), 93.8 (C-10), 78.6 (C-11a), 77.28, 77.03, 76.77, 66.5 (C-6), 40.2 (C-6a), 29.2
(1'), 25.8 (C-5'), 17.9 (C-4'). For 1H NMR (500 MHz, CDCl3) spectroscopic data see Table 7.11.
Table 7.11 Experimental and literature 1H NMR data of compound 11
P

(-)-2-isopentenyl-3-hydroxy-8-9methylenedioxypterocarpan (11) 1H δ
(CDCl3)
Expt. (500 MHz)
Lit.146*

1

7.21 (s, 1H)

7.25 (s)

4

6.44 (s, 1H)

6.47 (s)

6

4.19 (dd, = 11.0, 5.0, 1H)

4.18

3.61 (t, J = 11.0, 1H)

3.62

7

6.71 (s, 1H)

6.73 (s)

10

6.39 (s, 1H)

6.42 (s)

1ʹ

3.32 (d, J = 7.2, 2H)

3.27-3.38 (d)

2ʹ

5.34 – 5.29 (m, 1H)

5.45-5.22 (m)

4ʹ

1.81 (S, 3H)

1.77 (s)

5ʹ

1.76 (S,3H)

1.71 (s)

2ʹʹ

5.88, 5.91, (d, J = 1.4, 2H)

5.92

6a

3.44 (s, 1H)

3.47 (s)

11a

5.45 (d, J = 6.9, 1H)

5.46

OH

5.37 (d, J = 4.4, 1H)

5.45

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ
(ppm), and Coupling constants (J) are in Hz. P= Position
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Compound 12 (Nepseudin)140
White sticky solid; IR (neat) vmax; 2919, 1687, 1465 and 1260 cm-1 [α]24D -102.2 (c 0.8 CHCl3),
[Lit.140 [α]20 0 (CHCL3)], MS (ESI +ve) m/z 377 ([M+Na]+); HRMS (ESI +ve TOF) calcd for
C20H18O6Na 377.1001 found 377.0992 [M+Na]+ ;

13

C NMR (101 MHz, CDCl3) δ 192.9 (C-4),

159.9 (C-8a), 159.3 (C-7), 153.7 (C-3'), 152.0 (C-2'), 146.0 (C2''), 142.3 (C-4'), 124.5 (C-5'),
122.7 (C-6), 121.5 (C-1'), 120.9 (C-5), 118.8 (C-4a), 107.4 (C-6'), 107.1 (C-3''), 99.7 (C-8), 71.6
(C-2), 60.7 (OCH3), 60.7 (OCH3), 56.0 (OCH3), 49.0 (C-3). For 1H NMR (400 MHz, CDCl3)
spectroscopic data see Table 7.12.
Table 7.12 Experimental and literature 1H NMR data of compound 12
P

Nepseudin (12) 1H δ (CDCl3)
Expt. (400MH)

Lit.140*

4.64 (dd, J= 11.9, 11, 1H)

4.50 (dd)

4.52 (dd, J= 11.0, 5.5, 1H)

4.50 (dd)

3

4.24 (dd, J=11.9,5.5, 1H)

~4.50 (dd)

5

8.27 (s, 1H)

8.23 (s)

8

7.06 (s, 1H)

7.07 (s)

5ʹ

6.84 (d, J = 8.5, 1H)

6.83 (d)

6ʹ

6.65 (d, J = 8.5, 1H)

6.75 (d)

2ʹʹ

7.59 (d, J=2.3, 1H)

7.56 (d)

3ʹʹ

6.77 (dd, J = 2.3, 1.0 1H)

6.70 (d)

2ʹ OCH3

3.85 (s, 3H)

3.87 (s)

3ʹ OCH3

3.86 (s, 3H)

3.88 (s)

4ʹ OCH3

3.87 (s, 3H)

3.90 (s)

2

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz, P=Position
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Compound 13 (Neorautenol)134,135
White sticky solid; IR (neat) vmax; 3397, 2925, 1622, 1492, 1134 and 958 cm-1; Mp 172-174 °C,
(Lit.134,147 93-95 °C) [α] 21D -127.2 (c 0.2 CHCl3) [Lit. 134,147 [α]D -273 (c 0.08 in CHCl3)], MS
(ESI +ve) m/z 345 ([M+Na]+); HRMS (ESI +ve TOF) calcd for C20H18O4Na 345.1109 found
345.1103 [M+Na]+ ;

13

C NMR (101 MHz, MeOD) δ 161.9 (C-10a), 159.8 (C-9), 157.8 (C-3),

155.7 (C-4a), 130.2 (C-3'), 129.8 (C-1), 125.9 (C-7), 122.7 (C-4'), 119.4 (C-7a), 117.5 (C-1a),
114.2 (C-2), 108.7 (C-8), 105.3 (C-4), 98.8 (C-10), 79.7 (C-2'), 77.6 (C-11a), 67.7 (C-6), 40.9
(C-6a), 28.4 (3''), 28.2 (2''). For 1H NMR (400 MHz, CD3OD) spectroscopic data see Table 7.13.
Table 7.13 Experimental and literature 1H NMR data of compound 13
P

Neorautenol (13) 1H δ (CD3OD)
Expt. (400MHz)

Lit.134,135*

1

7.11 (s, 1H)

7.16 (s)

4

6.26 (s, 1H)

6.42 (s)

6

4.22 (dd, J = 9.7, 3.6, 1H)

4.22 (m)

3.51 (dd, J = 7.2, 5.7, 1H)

3.62 (m)

6a

3.36 – 3.27 (m, 1H)

3.52(m)

7

7.07 (d, J = 8.0, 1H)

7.06 (d)

8

6.33 (dd, J = 8.0, 2.1, 1H)

6.36 (d)

10

6.29 (d, J = 2.1, 1H)

6.40 (d)

11a

5.42 (d, J =6.3, 1H)

5.49 (d)

3ʹ

5.61 (d, J = 9.8, 1H)

5.56 (d)

4ʹ

6.37 (d, J = 9.8, 1H)

6.33 (d)

5ʹ

1.39 (s, 3H)

1.41 (s, 3H)

2ʹʹ

1.40 (s, 3H)

1.43 (s, 3H)

3ʹʹ

3.36 – 3.27 (m, 1H)

3.52 (m)

OH

2.78 (s)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Compound 14 (Isoneorautenol)147,148
Sticky white; IR (neat) vmax; 3397, 2916, 1623, 1264 and 1156 cm-1; MS (ESI +ve) m/z 323
([M+H]+); HRMS (ESI +ve TOF) calcd for C20H19O4 323.1283 found 323.1284 [M+H]+ ; [α]21D 234.6 (c 0.1 CHCl3); For 1H NMR (500 MHz, CDCl3) and

13

C NMR (126 MHz, CDCl3)

spectroscopic data see on Tables 7.14 and 7.22, respectively.
Table 7.14 Experimental and literature 1H NMR data of compound 14
P

Isoneorautenol (14) 1H δ (CDCl3)
Expt. (400 MHz)

Lit. (300 MHz)148*

4.23 (dd, J = 11.0, 5.1, 1H)

4.21 (t, J = 10.8, 1H)

3.62 (t, J = 11.0, 1H)

3.41 (dd J = 10.8, 4.8, 1H)

3

3.49 (dd, J = 11.0, 5.1, 1H)

3.49 (m, 1H)

4

5.49 – 5.42 (m, 1H)

5.45 (d, J = 10, 1H)

5

7.39 (d, J = 8.3, 1H,)

7.37 (d, J = 8.4, 1H)

6

6.55 (dd, J = 8.3, 2.2 1H)

6.53 (dd, J = 8.4, 1.5, 1H)

8

6.41 (d, J = 2.2, 1H)

6.40 (d, J = 1.5, 1H)

2ʹ

6.84 (s, 1H)

6.84 (s, 1H)

5ʹ

6.33 (s, 1H)

6.33 (s. 1H)

3ʹʹ

6.36 (d, J = 9.8, 1H)

6.37 (d, J = 6.8, 1H)

4ʹʹ

6.25 (d, J = 9.8, 1H)

6.24 (d, J = 10, 1H)

1ʹʹʹ

1.57 (s, 3H)

1.42 (s, 3H)

2ʹʹʹ

1.41 (s, 3H)

1.40 (s, 3H)

OH

2.75 (s)

-------

2

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Compound 15 ((-)-2-Hydroxypterocarpin)146
White powder; IR (neat) vmax; 3495, 2919, 1512, 1456 and 1216 cm-1; Mp 223-225 °C (Lit.146
238-239 °C) [α]23 -107.4(c 0.3 CHCl3) [Lit.146 [α] 23D -227.7 (c 0.8 CHCl3)]; MS (ESI +ve) m/z
315 ([M+H]+); HRMS (ESI +ve TOF) calcd for C17H15O6 315.0882 found 315.0883 [M+H]+ ;
13

C NMR (101 MHz, Acetone d6) δ 154.4 (C-10a), 149.1 (C-4a), 147.9 (C-9), 141.6 (C-8), 143.3

(C-3), 141.3 (C-2), 118.6 (C-7a), 115.7 (C-1), 112.1 (C-1a), 104.9 (C-7), 101.2 (C-2''), 100.4 (C4), 93.1 (C-10), 78.5 (C-11a), 66.3 (C-6), 55.3 (OCH3). For 1H NMR (400 MHz, Acetone d6)
spectroscopic data see Table 7.15.
Table 7.15 Experimental and literature 1H NMR data of compound 15
1

P

(-)-2-hydroxypterocarpin (15)
(Acetone d6)
Expt. (400 MHz)
Lit.146*

1

6.89 (s, 1H)

7.01 (s)

4

6.40 (s, 1H )

6.44 (s)

6

4.27 – 4.23 (m)

4.22 (m)

3.65 – 3.58 (m)

3.65 (m)

7

6.90 (s, 1H)

6.70 (s)

10

6.47 (s, 1H)

6.42 (s)

2ʹʹ

5.92 (d, J = 1.0, 2H)

5.90 (d, 2H)

6a

3.71 – 3.47 (m, 1H)

3. 45 (m)

11a

5.47 (d, J = 6.9, 1H)

5.43

OCH3

3.82 (s, 3H)

3.87 (s)

OH

5.62 (s)

5.28 (s)

H δ

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm),
and Coupling constants (J) are in Hz. P= Position
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Compound 16 (Rotenone)149-150
Yellow needles; IR (neat) vmax; 2920, 1606, 1455, 1196 and 815 cm-1; MS (ESI +ve) m/z 395
([M+H]+); HRMS (ESI +ve TOF) calcd for C23H23O6 395.1495 found 395.1490 [M+H]+ ; Mp
159-162°C; [α]24D -236 (c 0.3 CHCl3); 1H NMR (500 MHz, CDCl3) and

13

C NMR (126 MHz,

CDCl3) spectroscopic data see on Tables 7.16 and 7.22, respectively.
Table 7.16 Experimental and literature 1H NMR data of compound 16
P

Rotenone (16) 1H δ (CDCl3)
Expt. 400MHz

Lit. (360 MHz)149,150

1

6.77 (s, 1H)

6.76 (s)

4

6.45 (s, 1H)

6.43 (s)

6

4.67 – 4.55 (m, 1H)

4.59 (m)

4.18 (d, J =12.0 Hz, 1H)

4.15 (m)

10

6.51 (d,J=8.6, 1H)

6.48 ( d)

11

7.84 (d, J = 8.5, 1H)

7.82 (d)

4ʹ

3.32 (dd,J= 15.7, 9.8 1H)

3.33 (m)

2.96 (dd, J =15.7, 1H)

2.94 (m)

5ʹ

5.24 (t, J = 8.9 1H)

5.24 (m)

7ʹ

5.07 (s, 1H)

5.05 (s)

4.94 (s, 1H)

4.94 (s)

8ʹ

1.77 (s, 3H)

1.77 (s)

6a

4.93 (d, J = 3.7, 1H)

4.96 (m)

12a

3.84 (s, 1H)

3.79 (s)

2 OCH3

3.81 (s)

3.88 (s)

3 OCH3

3.77 (s)

3.74 (s)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Compound 17 (12a- Hydroxyrotenone)26,149
Brown solid; IR (neat) vmax; 3468, 2923, 1604, 1455, 1203, 1088 and 814 cm-1; MP 152-154°C;
[α]20D -59.2 (c 0.5 CHCl3); For 1H NMR (500 MHz, CDCl3) and 13C NMR (126 MHz, CDCl3)
spectroscopic data see on Tables 7.17 and 7.22, respectively.
Table 7.17 Experimental and literature 1H NMR data of compound 17
P

12a- hydroxyrotenone (17) 1H δ (CDCl3)
Expt. (500 MHz)

Lit. (360 MHz)26,149

1

6.55 (s, 1H)

6.55 (s)

4

6.48 (s, 1H)

6.48 (s)

6

4.61 (d, J = 2.5,1H)

4.50 (m)

4.60 – 4.57 (m, 1H)

4.62 (m)

10

6.54 (d,J=8.6, 1H)

6.53 (d, J=8.5)

11

7.83 (d, J = 8.6, 1H)

7.70 (d, J=8.5)

4ʹ

2.94 (dd,J= 15.8, 8.2,1H)

2.94 (m)

3.29(dd, J = 15.8, 9.8, 1H)

3.29 (m)

5ʹ

5.24 (t, J = 9.0,1H)

5.20 (m)

7ʹ

5.06 (s, 1H)

5.07 (s)

4.94 (s, 1H)

4.94 (s)

8ʹ

1.76 (s, 3H)

1.76 (s, br)

6a

4.47 (d, J = 4.8, 1H)

4.58 (m)

2 OCH3

3.82 (s)

3.78 (s)

3 OCH3

3.72 (s)

3.70 (s)

OH

4.50 (s)

4.5 (br)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Compound 18 (Dehydroneotenone)26
White fluffy; IR (neat) vmax; 2933, 1623, 1472 and 1194 cm-1; MP 237-239°C; [α]26D -152.6 (c
0.1 CHCl3); For 1H NMR (400 MHz, CDCl3) and

13

C NMR (101 MHz, CDCl3) spectroscopic

data see on Tables 7.18 and 7.22, respectively.
Table 7.18 Experimental and literature 1H NMR data of compound 18
P

Dehydroneotenone (18) 1H δ (CDCl3)
Expt. (400 MHz)

Lit. (360 MHz)26

2

7.99 (s, 1H)

7.98 (s)

5

8.54 (s, 1H)

8.28 (s)

8

7.58 (s, 1H)

7.63 (brs)

3ʹ

6.64 (s, 1H)

6.64 (s)

6ʹ

6.86 (s, 1H)

6.70 (s)

2ʹʹ

7.73 (d, J = 2.3, 1H)

7.88 (d,J=2.0)

3ʹʹ

6.91 (dd, J = 2.3, 1.0, 1H)

6.93 (dd, J = 2.0, 1.0)

2ʹʹʹ

5.96 (s, 2H)

5.86 (s)

OCH3

3.74 (s, 3H)

3.78 (s)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Compound 19 (Rautandiol A)27
White solid; IR (neat) vmax; 3404, 2923, 1626, 1486, 1123 and 958 cm-1; MS (ESI +ve) m/z 363
([M+Na]+); HRMS (ESI +ve TOF) calcd for C20H20O5Na 363.1208 found 363.1218 [M+Na]+ ;
Mp 194-196°C, [α]21D -161.4 (c 0.1 MeOH); For 1H NMR (500 MHz, CD3OD) and

13

C NMR

(126 MHz, CD3OD) spectroscopic data see on Tables 7.19 and 7.23, respectively.
Table 7.19 Experimental and literature 1H NMR data of compound 19
P

Rautandiol A (19)1H δ (CD3OD)
Expt. (500 MHz)

Lit.27*

1

7.17 (s)

7.17 (s)

4

6.26 (s)

6.26 (s)

6

4.21 – 4.15 (m)

4.18 (dd, J = 9.6, 3.1)

3.57 – 3.44 (m)

3.51-3.46 (m)

7

7.06 (d, 8.1)

7.06 (d, J = 8.1)

8

6.32 (dd, J = 8.0, 2.2)

6.31 (dd, J = 8.1, 2.4)

10

6.24 (d, J = 2.2)

6.23 (d, J = 2.4)

6a

3.48 (m)

3.50-3.46 (m)

11a

5.43 (d, J = 6.5)

5.44 (d, J = 6.6)

1'

3.00 ( dd, J =16.6, 5.3)

3.00 (dd, J = 16.5, 5.3)

2.70 (ddd, J = 16.3, 7.7, 0.7)

2.69 (dd, J = 16.5, 7.8)

2'

3.75 (dd, 7.7, 5.3)

3.74 (dd, J = 7.8, 5.3)

5'

1.33 (s)

1.33 (s)

4'

1.24 (s)

1.24 (s)

OH

4.59 (s)

-------

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Compound 20 (Rautandiol B)27
White solid; IR (neat) vmax; 3517, 3202, 1617, 1484, 1153 and 833 cm-1; MS (ESI +ve) m/z 341
([M+H]+); HRMS (ESI +ve TOF) calcd for C20H21O5 341.1489 found 341.1304 [M+H]+ ; Mp
209- 213°C; [α]21D -208.5 (c 0.1 MeOH); For 1H NMR (500 MHz, CD3OD) and 13C NMR (126
MHz, CD3OD) spectroscopic data see on Tables 7.20 and 7.23, respectively.
Table 7.20 Experimental and literature 1H NMR data of compound 20
P

Rautandiol B (20) 1H δ (CD3OD)
Expt. (500 MHz)

Lit.27

1

7.25 (s)

7.24 (s)

4

6.26 (s)

6.26 (s)

6

4.20 ( dd, J = 10.0,3.8)

4.19 (dd, J = 10.0, 3.6)

3.54 – 3.45 (m)

3.50 (dd, J = 10.0, 10.0)

7

7.07 (d, J = 8.1)

7.06 (d, J = 8.1)

8

6.32 (dd, J = 8.0, 2.2)

6.31 (dd, J = 8.1, 2.2)

10

6.23 (s)

6.23 (d, J = 2.2)

6a

3.48 (m)

3.48-3.44 (m)

11a

5.45 (d, J = 6.5)

5.43 (d, J = 6.6)

1'

3.14 (d, J = 8.7)

3.13 (d, J = 8.9)

2'

4.60 (t)

4.66 (t, J = 9.0)

4'

1.22 (s)

1.21 (s)

6'

1.24 (s)

1.24 (s)

OH

--------

--------

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P= Position
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Table 7.21 Experimental and literature 13C NMR data of compounds 2, 6, 7, 9 and 10
P
1
2
3
4
5
6
7
8
9
10
11
12
1ʹ
2ʹ
3ʹ
4ʹ
5ʹ
6ʹ
7ʹ
8ʹ
2ʹʹ
3ʹʹ
2ʹʹʹ
1a
4a
6a
7a
8a
10a
11a
12a
OCH3

13

C δ 2 (CDCl3)
Expt.
Lit.26
122.8
122.9
122.4
122.4
155.7
155.7
99.9
99.9
------------66.9
67.0
104.7
104.7
141.8
141.8
148.2
148.2
93.8
93.8
----------------------------------------------------------------------------------------------------------------------------------145.1
145.1
106.2
106.3
101.3
101.3
116.5
116.5
153.5
153.5
40.6
40.6
117.9
117.9
------------154.2
154.2
79.2
79.2
---------------------------

13

C δ 6(CDCl3)
Expt.
Lit.26
------------160.1
173.2
123.9
124.0
142.4
142.4
119.6
119.6
124.8
124.8
156.2
156.2
99.5
99.5
--------------------------------------------122.9
------151.6
151.7
95.5
95.5
148.7
148.8
141.1
141.3
110.3
110.3
------------------------146.7
146.7
106.4
106.4
101.5
101.5
-----------116.2
116.2
------------------------157.8
156.2
---------------------------------------56.9
56.9

13

C δ 7 (CDCl3)
Expt.
Lit.26
-----------71.3
71.3
48.33
48.3
192.7
192.6
120.9
120.8
115.5
115.6
159.2
159.2
99.7
99.6
----------------------------------------------------122.6
122.6
152.7
152.8
95.4
95.4
147.8
147.8
141.3
141.4
109.8
109.8
------------------------146.0
146.0
107.1
107.0
101.3
101.3
-----------118.8
118.8
------------------------159.9
159.9
---------------------------------------56.5
56.5

13

C δ 9 (CDCl3)
Expt.
Lit.26
106.8
106.8
142.3
142.3
149.5
149.5
99.2
99.9
------------63.9
63.9
------------100.0
100.0
158.3
158.3
123.3
123.3
121.0
121.0
192.9
192.9
--------------------------------------------------------------------------------------------------------146.5
146.4
105.7
105.7
101.3
101.3
109.2
109.2
149.6
149.6
75.9
75.9
160.3
160.3
------------------------114.6
114.6
68.3
68.3
-------------

13

C δ 10 (CDCl3)
Expt. Lit.26
106.9 106.9
142.4 143.2
147.4 147.9
98.9
98.9
------- ------66.4
66.4
------- ------99.9
99.8
158.6 158.6
123.1 123.1
121.0 121.0
190.6 190.6
------- -------------- -------------- -------------- -------------- -------------- -------------- -------------- -------146.2 146.2
106.9 106.9
101.2 101.2
105.3 105.3
148.5 148.5
72.1
72.1
159.8 159.8
------- ------------- ------116.1 116.1
45.3
45.3
------- -------
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Table 7.22 Experimental and literature 13C NMR data of compounds 14, 16, 17 and 18
P
1
2
3
4
5
6
7
8
9
10
11
12
1ʹ
2ʹ
3ʹ
4ʹ
5ʹ
6ʹ
7ʹ
8ʹ
2ʹʹ
3ʹʹ
2ʹʹʹ
4ʹʹ
4a
4ʹʹʹ
5ʹʹʹ
8a
10a
11a
12a
OCH3

13

C δ 14 (CDCl3)
Expt.
Lit.148
------------66.5
66.5
39.4
39.4
78.3
76.5
132.3
132.2
109.7
109.8
160.2
160.2
103.6
103.7
156.7
157.2
112.6
112.4
------------------------119.0
119.4
122.1
122.0
114.8
114.9
154.5
156.6
99.4
99.4
156.9
154.4
--------------------------76.8
78.4
127.6
127.6
-------------121.9
122.1
-------------28.0
------27.8
26.9
-------------------------------------------------------------

13

C δ 16 (CDCl3)
Expt.
Lit.149-150
108.7
108.8
142.9
142.9
151.1
151.2
101.0
101.1
------------63.8
63.9
------------113.2
113.2
168.1
168.0
105.3
105.3
130.1
130.2
191.1
191.1
---------------------------------------31.1
31.1
87.9
88.0
144.0
142.9
112.7
112.6
17.1
17.1
---------------------------------------109.3
109.5
148.4
148.4
76.0
76.1
157.7
157.7
--------------------------111.7
111.8
67.6
67.6
55.9
55.9
56.4
56.4

13

C δ 17 (CDCl3)
Expt.
Lit.26,149
110.4
110.1
157.9
157.4
167.4
166.8
100.9
100.6
------------66.3
65.9
------------112.9
112.9
149.5
149.0
104.9
104.4
130.0
129.4
188.9
188.3
----------------------------------------------31.3
30.9
87.9
87.3
143.1
142.1
112.6
112.5
17.1
16.7
---------------------------------------------104.8
104.5
143.9
143.4
72.2
71.8
147.4
147.0
------------------------------113.4
113.1
44.6
44.1
55.9
55.9
56.3
56.4

13

C δ 18 (CDCl3)
Expt.
Lit.26
-----------154.7
154.7
121.1
121.1
176.6
176.6
119.0
119.0
126.0
126.0
157.3
157.2
99.8
99.8
------------------------------------------------112.9
112.8
153.0
153.0
95.5
95.5
148.5
148.4
141.3
141.2
111.3
113.3
------------------------147.4
147.4
107.1
107.0
101.4
101.4
------------121.2
121.1
--------------------------154.3
154.2
---------------------------------------56.9
56.9
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Table 7.23 Experimental and literature 13C NMR data of compounds 19 and 20
P
1
2
3
4
6
7
8
9
10
1a
4a
6a
7a
10a
11a
1'
2'
3'
4'
5'
6'

13

C δ 19 (CD3OD)
Expt.
Lit.27
131.8
133.3
113.9
115.4
154.1
155.6
103.8
105.3
66.3
67.7
124.6
126.0
107.3
108.7
160.5
159.9
97.3
98.8
112.9
114.4
154.9
156.4
39.6
41.1
118.1
119.5
158.4
162.0
78.5
79.9
30.1
31.6
77.0
70.6
69.2
78.4
19.6
21.0
24.5
26.0
---------

13

C δ 20 (CD3OD)
Expt.
Lit. 27
126.3
127.7
121.1
122.5
161.3
162.7
97.2
98.6
66.4
67.8
124.6
126.0
107.3
108.7
160.5
158.8
97.3
98.8
112.1
113.6
155.9
157.4
39.5
40.9
118.2
119.0
158.4
162.0
78.9
80.4
29.3
30.8
89.9
91.4
71.2
72.5
23.7
25.2
--------23.9
25.4

7.4.3 Biological activities
7.4.3.1 Mouse model of cholera toxin-induced intestinal fluid secretion (Performed by
Muanprasat, C. Mahidol University, Samutprakarn Thailand)
As reported by Dawurung et al. 2020,143 the ICR male mice (30-35 g) were obtained from
Nomura Siam International, Pathumwan, Bangkok, Thailand. Mice were maintained under a
controlled environment (temperature 25 ± 1 °C; humidity 30–70%; 12:12 h dark-light). Mice
were fasting for 24 h prior to the experiment. After that, mice were anesthetized by
intraperitoneal administration of thiopental (50 mg/kg). During the surgery, the body
temperatures of the mice were maintained at 37 °C using heating pads. Abdominal incision was
made and the ileal segment of the small intestine was ligated two-point in 2-3 cm length with
sterile silk thread. Ileal loops were instilled with 100 µL of phosphate-buffered saline (PBS) or
PBS containing cholera toxin (1 µg/loop) with or without intraluminal administration of
140

compound 10 (16.9 µg/loop). The abdomen was closed and mice were allowed to recover from
anaesthesia. After 6 h, both mice were euthanized for collection of lileal loops. The
weight/length ratios of ileal loops were measured and were used as an indicator of intestinal fluid
secretion. This study has been approved by the institutional animal care and use committee of the
Faculty of Science, Mahidol University.146
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Experimental for Chapter 4
7.5.0 Organic solvent extraction H. abyssinica
The roots of H. abyssinica were cut into small pieces and dried in a hot air oven at 45 oC for 5
days. The dried plant materials were pulverized using a pestle and mortar. Measured amounts of
1000 g were successively extracted with DCM and ethanol using a ratio of 1:4 plant
material:solvent, for 72 h. The extracts were filtered through a sieve with a pore size of 150 µm,
a cotton plug and then filter paper. Filtrates were dried under a constant stream of air provided by
a laboratory electric fan overnight, to obtain the dried crude DCM (KDCM - 10 g) and ethanol
(KEOH - 100 g) extracts and their appearances and yields were recorded205 (Fig. 7.4)

Figure 7.4 successive extractions of the roots of H. abyssinica
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7.5.1 Isolation of phytochemicals from H. abyssinica
A number of attempts were made to separate the components of the crude ethanol extract using
CC over silica gel and LH20 (100% MeOH), however these efforts failed to give pure samples of
phytochemical components, consequently, about 50 g of the crude ethanol extract (KEOH) from
H. abyssinica was partitioned with solvents from low polarity (hexanes) to high polarity (nbutanol). The extract was dissolved in a mixture of distilled water and MeOH (10:90) and
extracted with 200 mL of hexanes in a separating funnel and allowed to settle before the hexanes
portion was collected. This process was repeated three times (200 mL x 3) to obtain the hexane
fraction (4.7 g) after evaporation of the volatiles under reduced pressure. In a similar way, the
aqueous MeOH solution was then extracted with DCM (200 mL x 3) to obtain the DCM fraction
(8.7 g). The same extraction procedure was repeated using ethyl acetate (200 mL x 3), acetone
(200 mL x 3), and n-butanol (200 ml x 3) in that order, to obtain the ethyl acetate (833.3 mg),
acetone (3.9 g) and n-butanol (1.8 g) fractions (Fig. 7.5). About 2 g of the DCM fraction was
separated by CC over silica gel with MeOH/DCM (10:90) to obtain 9 fractions (F1-F9). Fraction
F5 was evaporated and identified as compound 26 (197.0 mg), which was off white solid and
fraction F6 as compound 27 (45.8 mg) as brown solid (Fig. 7.6).

143

Figure 7.5 Parttioning of KEOH extract of H. abyssinica
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Figure 7.6 Isolation of compounds from the roots of H. abyssinica
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7.5.2 Spectroscopic data of isolated compounds from H. abyssinica
Compound 26 (catachin)169,175
Off white solid; IR (neat) vmax; 3253, 1617, 1521, 1286 and 1029 cm-1; Mp 100.8-102.5 oC, (Lit173-175 oC)174 [α]D24 +15.4 (c 0.4 MeOH), (Lit- [α]24D +14.7 (c 0.69 in acetone),175 MS (ESI
+ve) m/z 289 ([M-H]-); HRMS (ESI +ve TOF) calcd for C15H13O6 289.0719 found 289.0712 [MH] -; 13C NMR (126 MHz, CD3OD) δ 156.5(C-7), 156.2 (C-5), 155.5 (C-8a), 144.9 (C-3′), 144.8
(C-4′), 130.8 (C-1′), 118.6 (C-6′), 114.7(C-2′), 113.9 (C-8b), 99.40 (C-6), 94.9(C-8), 81.46 (C-2),
67.42 (C-3), 27.13(C-4). For 1H NMR (500 MHz, CD3OD) spectroscopic data see Table 7.24.
Table 7.24 Experimental and literature 1H NMR data of compound 26
P
2
2ʹ
3
4
5ʹ
6
6ʹ
8

Catechin 1H δ (CD3OD)
Expt. (500 MHz)
4.61 – 4.53 (m, 1H)
6.86 (d, J = 2.0, 1H)
3.99 (td, J = 8.0, 5.5, 1H)
2.87 (dd, J = 16.1, 5.4, 1H)
2.52 (dd, J = 16.1, 8.2, 1H)
6.78 (d, J = 8.1, 1H)
5.87 (d, J = 2.3, 1H)
6.74 (dd, J = 8.3, 2.0, 1H)
5.95 (d, J = 2.3, 1H)

Lit. (300 MHz)169,175
4.55 (d, J = 7.5, 1H)
6.86 (d, J = 1.7, 1H)
3.98 (dt, J = 7.6, 5.3, 1H)
2.87 (dd, J = 5.5, 2H)
6.75 ( d, J = 8.1, 1H)
5.8 (d, J= 2.2, 1H)
6.72 (d, J=1.8, 1H)
5.9 ( d, J = 2.2, 1H)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P = Position
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Compound 27 (salidroside)176
Brown solid; IR (neat) vmax; 3221, 1607, 1520, 1285 and 1079 cm-1; Mp 128-130 oC, (Lit-161162 oC)176 13C NMR (101 MHz, CD3OD) δ 155.4 (C-3), 129.5 (C-6), 129.4 (C-1,2), 114.7 (C4,5), 102.9 (C-4′), (C-8′) 76.5 (C-7′), 73.7 (C-5′), 70.7 (C-9′), 70.2 (C-6′), 61.4 (C-2′), 34.9 (C1′). For 1H NMR (400 MHz, CD3OD) spectroscopic data see Table 7.25.
Table 7.25 Experimental and literature 1H NMR data of compound 27
P
1, 5
2, 4
1ʹ
2ʹ
4ʹ
5ʹ
6ʹ
7ʹ
8ʹ
9ʹ

salidroside 1H δ (CD3OD)
Expt. (400 MHz)
7.08 (d, J = 8.5 Hz, 2H)
6.71 (d, J = 8.5 Hz, 2H)
2.89 – 2.82 (m, 2H)
3.85 (dd, J = 11.9, 1.9 Hz, 1H)
3.77 – 3.65 (m, 1H)
4.31 (d, J = 7.8 Hz, 1H)
3.20 (dd, J = 8.9, 7.9 Hz, 1H)
3.28 – 3.27 (m, 1H)
3.37 (m, 1H)
3.35 (m, 1H)
4.04 – 4.01 (m, 1H)
3.79 – 3.71 (m, 1H)

Lit. (400 MHz, DMSO-d6)176
7.04 (d, J = 8.3 Hz, 2H)
6.67 (d, J = 8.3 Hz, 2H)
2.73 (t, 8.6 Hz, 2H)
3.44 (dd, 11.4, 5.4Hz, 1H)
3.76 (d, 11.4Hz, 1H)
4.17 (d, J = 8.5 Hz, 1H)
3.15 (t, J = 8.5 Hz, 1H)
3.07 (m, 1H)
3.06 (d, J = 8.5, 1H)
2.96 (t, J = 8.5, 1H)
3.87 (dd, J = 16.0, 8.6 Hz, 1H)
3.56 (dd, J = 16.0, 8.8 Hz, 1H)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P = Position
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Experimental for Chapter 5
7.6.0 Organic solvent extraction of S. surattensis
The leaves of S. surattensis were removed from the small stems and dried in a hot air oven at 45
o

C for 2 days. The dried plant materials were pulverized using a pestle and mortar. Measured

amounts of the different plant materials (405 g) were successively extracted with DCM and
ethanol using a ratio of 1:4 plant material:solvent, for 72 h. The extracts were filtered through a
sieve with a pore size of 150 µm, a cotton plug and then filter paper. Filtrates were dried under a
constant stream of air provided by a laboratory electric fan overnight, to obtain the dried crude
DCM and ethanol extracts and their appearances and yields were recorded205 (Fig. 7.7).

Figure 7.7 Successive extractions of the roots of S. surattensis
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7.6.1 Isolation of phytochemicals from S. surattensis
The phytochemical components of the ethanol extract (CEOH) from S. surattensis (10 g) were
separated by flash CC over silica gel with increasing gradient solvent polarity from MeOH/DCM
(1.5:85) to 100% MeOH. A total of 12 fractions were obtained (F1-F12). Fraction F2 (369.2 mg)
was purified by CC over Sephadex (LH-20) by elution with 100% MeOH to obtain 4 fractions
(F2F1-F2F4). F2F3 was evaporated and identified as compound 36 (11.0 mg) as yellow powder,
while fraction F2F4 was identified as compound 37 (18.4 mg) as yellow solid. Fractions F3-F4
(524.5 mg) were combined and purified by CC over Sephadex (LH-20) by elution with 100%
MeOH to obtain 4 sub-fractions (F34f1-F34f4). Sub-fraction F34F3 (214 mg) was further
purified by CC over Sephadex (LH-20) by elution with 100% MeOH to obtain 9 sub-fractions
(F34F3f1-F34F3f9). Sub-fractions F34F3f5-F34F3f6 were combined and evaporated and
identified as compound 26 (40.6 mg) (Fig. 7.8).
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Figure 7.8 Isolation of compounds from the leaves of S. surattensis
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7.6.2 Spectroscopic data of isolated compounds from S. surattensis
Compound 36 (Kempherol)189
Yellow powder; IR (neat) vmax; 3221, 1607, 1517 1286 and 1020 cm-1; Mp 274-276 oC,

13

C

NMR (101 MHz, CD3OD) δ 175.9 (C-4), 164.3 (C-5), 161.1(C-7), 159.2 (C-4ʹ), 156.9 (C-8a),
146.7 (C-3), 135.7 (C-2), 129.3 (C-2ʹ 6ʹ), 122.3 (C-1ʹ), 114.91 (C-3ʹ 5ʹ), 103.1 (C-8b), 97.8 (C6), 93.1 (C-8). For 1H NMR (400 MHz, CD3OD) spectroscopic data see Table 7.26.
Table 7.26 Experimental and literature 1H NMR data of compound 36
P
2ʹ 6ʹ
3ʹ 5ʹ
8
6

Kempherol 1H δ (CD3OD)
Expt. (400 MHz)
8.10 (d, J = 9.0 Hz, 2H)
6.92 (d, J = 9.0 Hz, 2H)
6.41 (d, J = 2.1, 1H Hz)
6.20 (d, J = 2.1 Hz, 1H)

Lit. (600 MHz, DMSO-d6)189
8.04 (d, J = 9.0 Hz, 2H)
6.92 (d, J = 9.0 Hz, 2H)
6.44 (d, J = 1.8 Hz, 1H)
66.19 (d, J = 1.8 Hz, 1H)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P = Position
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Compound 37 (Quercetin)187
Yellow solid obtained with some impurities; IR (neat) vmax; 3234, 1606, 1517, 1285 and 1145
cm-1; Mp 292-296 oC, (Lit-Mp 310-312 oC),187 13C NMR (126 MHz, CD3OD) δ 175.9 (C-4),
164.3 (C-7), 161.1 (C-5), 156.8 (C-8a), 147.4 (C-2), 146.5 (C-3'), 144.8 (C-4'), 135.8 (C-3),
122.7 (C-1'), 120.2 (C-6'), 114.8 (C-2'), 114.5 (C-5'), 103.0 (C-8b), 97.8, (C-8) 93.0 (C-6). For 1H
NMR (400 MHz, CD3OD) spectroscopic data see Table 7.27.
Table 7.27 Experimental and literature 1H NMR data of compound 37
P
2ʹ
5ʹ
6
6ʹ
8

Quercetin 1H δ (CD3OD)
Expt. (400 MHz)
7.75 (dd, J = 2.1, 1H)
6.91 (d, J = 8.6, 1H,)
6.41 (d, J = 2.1 Hz, 1H)
7.65 (dd, J = 8.5, 2.1, 1H)
6.20 (d, J = 2.0 Hz, 1H, H-8)

Lit. (400 MHz, DMSO-d6)187
7.64 (d, J = 8.5, 1H)
6.85 (d, J = 8.5, 1H)
6.37 (d, J = 2.5, 1H)
7.49 (d, J = 8.5, 1H)
6.14 (d, J = 2.5, 1H)

Assignments are made on the basis of COSY, HSQC, HMBC and NOESY correlations, Chemical shift values are in δ (ppm), and
Coupling constants (J) are in Hz. P = Position
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Appendix A
1

H NMR spectra of compounds from N. mitis and crystal structure data

Figure A1 1H NMR spectrum of compound 1 (500 MHz, CDCl3)
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Figure A2 1H NMR spectrum of compound 2 (400 MHz, CDCl3)
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Figure A3 1H NMR spectrum of compound 3 (400 MHz, CDCl3)
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Figure A4 1H NMR spectrum of compound 4 (400 MHz, CDCl3)
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Figure A5 1H NMR spectrum of compound 6 (400 MHz, CDCl3)
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Figure A6 1H NMR spectrum of compound 7 (500 MHz, CDCl3)
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Figure A7 1H NMR spectrum of compound 8 (500 MHz, CDCl3)

177

Figure A8 1H NMR spectrum of compound 9 ((400 MHz, CDCl3)
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Figure A9 1H NMR spectrum of compound 10 (400 MHz, CDCl3)
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Figure A10 1H NMR spectrum of compound 11 (500 MHz, CDCl3)
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Figure A11 1H NMR spectrum of compound 12 (500 MHz, CDCl3)
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Figure A12 1H NMR spectrum of compound 13 (400 MHz, CDCl3)
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Figure A13 1H NMR spectrum of compound 14 (500 MHz, CDCl3)
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Figure A14 1H NMR spectrum of compound 15 (400 MHz, CDCl3)
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Figure A15 1H NMR spectrum of compound 16 (500 MHz, CDCl3)
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Figure A16 1H NMR spectrum compound 17 (500 MHz, CDCl3)
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Figure A17 1H NMR spectrum compound 18 (400 MHz, CDCl3)

187

Figure A18 1H NMR spectrum of compound 19 (500 MHz, MeOD)
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Figure A19 1H NMR spectrum of compound 20 (500 MHz, MeOD)
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Figure A20.13CNMR spectrum of compound 8 (126 MHz, CDCl3)
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Figure A21 DEPT spectrum of compound 8 (500 MHz, CDCl3)
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Figure A22 HMBC spectrum of compound 8 (500 MHz, CDCl3)
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Figure A23 HSQC spectrum of compound 8 (500 MHz, CDCl3)
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Figure A24 COSY spectrum of compound 8 (500 MHz, CDCl3)
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Crystal structure data
The crystal data of 11 and 20 have been deposited with the Cambridge Crystallographic Data
Centre and assigned supplementary publication numbers, CCDC 1973442 for 11 and CCDC
1972703 for 20. These data can be accessed from Cambridge Crystallographic Data Centre via;
www.ccdc.cam.ac.uk/data_request/cif.

Crystal structure of compound 11
(-)-2-isopentenyl-3-hydroxy-8-9-methylenedioxypterocarpan

Crystal structure of compound 20
Rautandiol B
195

Table A1 Crystal data and structure refinement for compound 11
Identification code
exp_80 CD2
Empirical formula
C21H20O5
Formula weight
352.37
Temperature/K
149.99(10)
Crystal system
Monoclinic
Space group
P21
a/Å
4.49030(10)
b/Å
28.1187(4)
c/Å
13.8306(3)
α/°
90
β/°
91.272(2)
γ/°
90
3
Volume/Å
1745.84(6)
Z
4
ρcalcg/cm3
1.341
-1
μ/mm
0.095
F(000)
744.0
3
Crystal size/mm
0.41 × 0.22 × 0.09
Radiation
MoKα (λ = 0.71073)
2Θ range for data collection/° 4.132 to 61.38
Index ranges
-6 ≤ h ≤ 6, -40 ≤ k ≤ 40, -19 ≤ l ≤ 19
Reflections collected
53882
Independent reflections
10507 [Rint = 0.0428, Rsigma = 0.0359]
Data/restraints/parameters
10507/1/475
2
Goodness-of-fit on F
1.021
Final R indexes [I>=2σ (I)] R1 = 0.0398, wR2 = 0.0935
Final R indexes [all data]
R1 = 0.0519, wR2 = 0.0992
-3
Largest diff. peak/hole / e Å 0.24/-0.17
Flack parameter
-0.2(3)
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Table A2 crystal data and structure refinement for compound 20
Code; pyn1808SNQ
C20H20O5
F(000) = 360
Mr = 340.38
Dx = 1.401 Mg m−3
Monoclinic, P21
Cu Kα radiation, λ = 1.54184 Å
Hall symbol: P 2yb
Cell parameters from 14561 reflections
a = 10.9525 (1) Å
θ = 5–74°
b = 6.5457 (1) Å
μ = 0.83 mm−1
c = 11.3823 (1) Å
T = 150 K
β = 98.6335 (8)°
Prism, colourless
V = 806.77 (2) Å3
0.31 × 0.12 × 0.10 mm
Z=2
Data collection
Super Nova, Dual, Cu at zero, EosS2
Absorption correction: multi-scan
diffractometer
Crys Alis PRO 1.171.39.46 (Rigaku Oxford
Radiation source: micro-focus sealed X- Diffraction, 2018) Empirical absorption correction
ray tube,
Super Nova (Cu) X-ray Source
using spherical harmonics, implemented in SCALE3
Mirror monochromator
ABSPACK scaling algorithm.
ω scans
Tmin = 0.70, Tmax = 0.92
19610 measured reflections
3089 independent reflections
3064 reflections with I > 2.0σ(I)
Rint = 0.031
θmax = 73.7°, θmin = 3.9°
h = −13→13
k = −7→8
l = −14→14
Refinement
Refinement on F2
Least-squares matrix: full
R[F2 > 2σ(F2)] = 0.035
wR(F2) = 0.094
S = 1.00
3089 reflections
233 parameters
1 restraint
Primary atom site location: structureinvariant direct
methods
Hydrogen site location: difference Fourier
map

H atoms treated by a mixture of independent and
constrained refinement
Method = Modified Sheldrick w = 1/[σ2(F2) + (
0.08P)2 + 0.06P] ,
where P = (max(Fo 2,0) + 2Fc 2)/3
(Δ/σ)max = 0.0004
Δρmax = 0.22 e Å−3
Δρmin = −0.23 e Å−3
Absolute structure: Flack (1983), 1307 Friedel-pairs
Absolute structure parameter: 0.19 (13)
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Appendix B
1

H NMR spectra for compounds isolated from H. abyssinica, and S. surattensis

Figure B1 1H NMR spectrum of compound 26 (500 MHz, CD3OD)
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Figure B2 1H NMR spectrum of compound 27 (400 MHz, CD3OD)
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Figure B3 1H NMR spectrum of compound 36 (400 MHz, CD3OD)
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Figure B4 1H NMR spectrum of compound 37 (400 MHz, CD3OD)
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Figure B5 NOESY spectrum of compound 27 (400 MHz, CD3OD)
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